

BMJ Best Practice

Coronavirus disease 2019 (COVID-19)

The right clinical information, right where it's needed



Last updated: Apr 17, 2020

Table of Contents

Summary	3
Basics	4
Definition	4
Epidemiology	4
Aetiology	5
Pathophysiology	7
Classification	8
Prevention	10
Primary prevention	10
Screening	12
Secondary prevention	13
Diagnosis	14
Case history	14
Step-by-step diagnostic approach	14
Risk factors	21
History & examination factors	22
Diagnostic tests	26
Differential diagnosis	30
Diagnostic criteria	32
Treatment	36
Step-by-step treatment approach	36
Treatment details overview	44
Treatment options	46
Emerging	62
Follow up	65
Recommendations	65
Complications	67
Prognosis	70
Guidelines	73
Diagnostic guidelines	73
Treatment guidelines	75
Online resources	80
References	83
Images	112
Disclaimer	114

Summary

- ◇ The World Health Organization declared the COVID-19 outbreak a pandemic on 11 March 2020. The situation is evolving rapidly. Clinical trials and investigations to learn more about the virus, its origin, and how it affects humans are ongoing.
-

Definition

Coronavirus disease 2019 (COVID-19) is a potentially severe acute respiratory infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).[1] The virus was identified as the cause of an outbreak of pneumonia of unknown cause in Wuhan City, Hubei Province, China, in December 2019.[2] The clinical presentation is that of a respiratory infection with a symptom severity ranging from a mild common cold-like illness, to a severe viral pneumonia leading to acute respiratory distress syndrome that is potentially fatal.

Epidemiology

The World Health Organization (WHO) was informed of 44 cases of pneumonia of unknown microbial aetiology associated with Wuhan City, Hubei Province, China on 31 December 2019. Most of the patients in the outbreak reported a link to a large seafood and live animal market (Huanan South China Seafood Market).[4] The WHO announced that a novel coronavirus had been detected in samples taken from these patients. Laboratory tests ruled out severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome (MERS)-CoV, influenza, avian influenza, and other common respiratory pathogens.[5] Since then, the outbreak has escalated rapidly, with the WHO first declaring a public health emergency of international concern on 30 January 2020 and then formally declaring it a pandemic on 11 March 2020.

Consult the resources below for updated information on daily case counts:

- [\[Johns Hopkins University: coronavirus COVID-19 global cases\]](#)
- [\[WHO: coronavirus disease \(COVID-19\) emergency dashboard\]](#)
- [\[WHO: coronavirus disease \(COVID-2019\) situation reports\]](#)
- [\[CDC: coronavirus disease 2019 \(COVID-19\) – cases in US\]](#)
- [\[CDC: COVIDView\]](#)

Data from the largest case series in China found that 87% of confirmed cases were aged 30 to 79 years, 1% were aged 9 years or younger, 1% were aged 10 to 19 years, and 3% were aged 80 years or older. Approximately 51% of patients were male and 49% were female.[6] Approximately 4% of cases were in healthcare workers, with 23 deaths reported.[7]

In the US, older patients (aged ≥ 65 years) accounted for 31% of all cases, 45% of hospitalisations, 53% of intensive care unit admissions, and 80% of deaths, with the highest incidence of severe outcomes in patients aged ≥ 85 years.[8]

Infection in children is reported much less commonly than among adults. A systematic review found that children account for only 1% to 5% of confirmed cases (depending on the country).[9] In the US, children accounted for only 1.7% of all cases.[10] All cases have been in family clusters or in children who have a history of close contact with an infected patient.[11] [12] [13] In a case series of 2143 paediatric patients in China, the median age of children was 7 years.[14]

Emerging evidence suggests that ambient temperature has no significant impact on the transmission of COVID-19; however, further research is required on how weather conditions influence transmission.[15]

Aetiology

Virology

- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a previously unknown betacoronavirus that was discovered in bronchoalveolar lavage samples taken from clusters of patients who presented with pneumonia of unknown cause in Wuhan City, Hubei Province, China, in December 2019.[2] Coronaviruses are a large family of enveloped RNA viruses, some of which cause illness in people (e.g., common cold, severe acute respiratory syndrome [SARS], Middle East respiratory syndrome [MERS]), and others that circulate among mammals and birds. Rarely, animal coronaviruses can spread to humans and subsequently spread between people, as was the case with SARS and MERS.
- SARS-CoV-2 belongs to the *Sarbecovirus* subgenus of the *Coronaviridae* family, and is the seventh coronavirus known to infect humans. The virus has been found to be similar to SARS-like coronaviruses from bats, but it is distinct from SARS-CoV and MERS-CoV.[16] [17] The full genome has been determined and published in GenBank. [GenBank]
- A preliminary study suggests that there are two major types (or strains) of the SARS-CoV-2 virus in China, designated L and S. The L type was found to be more prevalent during the early stages of the outbreak in Wuhan City and may be more aggressive (although this is speculative), but its frequency decreased after early January. The relevance of this finding is unknown at this stage and further research is required.[18]

[Fig-1]

Origin of virus

- A majority of patients in the initial stages of this outbreak reported a link to the Huanan South China Seafood Market, a live animal or 'wet' market, suggesting a zoonotic origin of the virus.[19] [20] [21]
- While the potential animal reservoir and intermediary host(s) are unknown at this point, studies suggest they may derive from a recombinant virus between the bat coronavirus and an origin-unknown coronavirus; however, this is yet to be confirmed.[16] [17] [22] [23] Pangolins have been suggested as an intermediate host as they have been found to be a natural reservoir of SARS-CoV-2-like coronaviruses.[24] [25]

Transmission dynamics

- Person-to-person spread has been confirmed in community and healthcare settings, with local transmission occurring in many countries around the world.
- An initial assessment of the transmission dynamics in the first 425 confirmed cases found that 55% of cases before 1 January 2020 were linked to the Huanan South China Seafood Market, whereas only 8.6% of cases after this date were linked to the market. This confirms that person-to-person spread occurred among close contacts since the middle of December 2019, including infections in healthcare workers.[21]
- It is uncertain how easily the virus spreads between people, but transmission in chains involving several links has been recognised. Available evidence indicates that human transmission occurs via close contact with respiratory droplets produced when a person exhales, sneezes, or coughs; via direct contact with infected people; or via contact with fomites. Airborne transmission has not been reported; however, it may be possible during aerosol-generating procedures performed in clinical care.[19] [21] [26] [27]

- The virus has been found to be more stable on plastic and stainless steel (up to 72 hours) compared with copper (up to 4 hours) and cardboard (up to 24 hours).[28] This study also found that the virus was viable in aerosol particles for up to 3 hours; however, aerosols were generated using high-powered apparatus that do not reflect normal human cough conditions or a clinical setting where aerosol-generating procedures are performed. The World Health Organization has confirmed that there have been no reports of airborne transmission.[29] In healthcare settings, the virus is widely distributed in the air and on object surfaces (e.g., floors, rubbish bins, sickbed handrails, and computer mice) in both general wards and intensive care units, with a greater risk of contamination in the intensive care unit.[30]
- The contribution to transmission by the presence of the virus in other body fluids is unknown; however, the virus has been detected in blood, cerebrospinal fluid, urine, saliva, tears, and conjunctival secretions. Faecal-oral transmission may be possible (virus has been detected in the stool samples of almost half of the patients in one meta-analysis), although it has not been reported yet.[31] [32] [33] [34] [35] [36] [37] The presence of virus in these fluids or viral RNA shedding does not necessarily equate with infectivity.
- Nosocomial transmission in healthcare workers and patients has been reported in 41% of patients in one case series.[38] The majority of healthcare workers with COVID-19 reported contact in the healthcare setting. In a study of over 9000 cases reported in healthcare workers in the US, 55% had contact only in a healthcare setting, 27% only in a household, 13% only in the community, and 5% in more than one setting.[39]
- Widespread transmission has been reported in long-term care facilities and on cruise ships (19% of 3700 passengers and crew were infected aboard the Diamond Princess).[40] [41]
- Clusters of cases originating from family gatherings have been reported, emphasising the importance of social distancing even within families.[42] The rate of secondary transmission among household contacts of infected patients is approximately 30%.[43]

Presymptomatic transmission

- A small number of studies suggest that some people can be contagious during the incubation period, the time between exposure to the virus and the onset of symptoms. The incubation period is estimated to be between 1 and 14 days, with a median of 5 to 7 days (possibly longer in children). Approximately 97.5% of patients develop symptoms within 11.5 days of infection.[44] [45] [46] [47] [48]
- Presymptomatic transmission has been reported in 12.6% of cases in China.[49] A study in Singapore identified 6.4% of patients among seven clusters of cases in which presymptomatic transmission was likely to have occurred 1 to 3 days before symptom onset.[50]
- Presymptomatic transmission still requires the virus to be spread by infectious droplets or contact with fomites.

Asymptomatic transmission

- An asymptomatic case is a laboratory-confirmed case who does not develop symptoms. There is some evidence that spread from asymptomatic carriers is possible, although it is thought that transmission is greatest when people are symptomatic (especially around the time of symptom onset).[51] [52] [53] [54] [55] [56] [57]
- Estimating the prevalence of asymptomatic cases in the population is difficult. The best evidence so far comes from the Diamond Princess cruise ship, which was quarantined with all passengers and crew members repeatedly tested and closely monitored. A modelling study found that approximately 700 people with confirmed infection (18%) were asymptomatic.[58] However, a Japanese study of citizens evacuated from Wuhan City estimates the rate to be closer to 31%.[59] Data from a long-

term care facility in the US found that 30% of patients with positive test results were asymptomatic (or presymptomatic) on the day of testing.[60] Early data from an isolated village of 3000 people in Italy estimates the figure to be higher at 50% to 75%.[61] Other studies ranged from 4% to 80%.[62]

- A study in a New York obstetric population found that 88% of women who tested positive for SARS-CoV-2 at admission were asymptomatic at presentation.[63]
- The proportion of asymptomatic cases in children is thought to be significant, and children may play a role in community spread.[64]

Superspreading events

- Multiple superspreading events have been reported with COVID-19. These events are associated with explosive growth early in an outbreak and sustained transmission in later stages.[65]
- Superspreaders can pass the infection on to large numbers of contacts, including healthcare workers. This phenomenon is well documented for infections such as severe acute respiratory syndrome (SARS), Ebola virus infection, and MERS.[66] [67]
- Some of these individuals are also supershedders of virus, but the reasons underlying superspreader events are often more complex than just excess virus shedding and can include a variety of behavioural and environmental factors.[66]

Perinatal transmission

- It is unknown whether perinatal transmission (including transmission via breastfeeding) is possible. Retrospective reviews of pregnant women with COVID-19 found that there is no evidence for intrauterine infection in women with COVID-19.[68] [69] [70] However, vertical transmission cannot be ruled out. There have been case reports of infection in neonates born to mothers with COVID-19, and virus-specific antibodies have also been detected in neonatal serum samples.[71] [72] [73] [74] [75]

Pathophysiology

Reproductive number

- Preliminary reports suggested that the reproductive number (R_0), the number of people who acquire the infection from an infected person, was estimated to be 2.2 to 3.3.[21] [76] However, the R_0 may actually be lower in light of social distancing measures that have been instituted.
- The secondary attack rate for SARS-CoV-2 is estimated to be 0.45% for close contacts of US patients.[27]

Angiotensin-converting enzyme-2 receptor

- While the pathophysiology is currently unknown, it has been confirmed that the virus binds to the angiotensin-converting enzyme-2 (ACE2) receptor in humans, which suggests a similar pathogenesis to SARS.[17] [77] However, a unique structural feature of the spike glycoprotein receptor binding domain of SARS-CoV-2 (which is responsible for the entry of the virus into host cells) confers potentially higher binding affinity for ACE2 on host cells compared with SARS-CoV.[78] A furin-like cleavage site has been identified in the spike protein of the virus; this does not exist in other SARS-like coronaviruses.[79]
- Based on an analysis of single-cell RNA sequencing datasets derived from major human physiological systems, the organs considered more vulnerable to SARS-CoV-2 infection due to their ACE2 expression levels include the lungs, heart, oesophagus, kidneys, bladder, and ileum.[80]

- Mechanistic evidence from other coronaviruses suggests that SARS-CoV-2 may downregulate ACE2, leading to a toxic overaccumulation of angiotensin-II, which may induce acute respiratory distress syndrome and fulminant myocarditis.[81]

Viral load and shedding

- High viral loads have been detected in nasal and throat swabs soon after symptom onset, and it is thought that the viral shedding pattern may be similar to that of patients with influenza. An asymptomatic patient was found to have a similar viral load compared with symptomatic patients.[82] [83]
- Pharyngeal viral shedding is high during the first week of symptoms when symptoms are mild or prodromal, peaking on day 4. This suggests active virus replication in upper respiratory tract tissues.[84]
- The duration of viral shedding has been estimated to be between 8 and 20 days after symptoms resolve. Also, the virus has been detected in sputum and faeces for up to 39 days after pharyngeal swabs became negative. However, it is unclear whether the virus is capable of transmission later in the course of the disease or after negative pharyngeal swabs.[85] [86] [87] [88]
- Factors associated with prolonged viral shedding include male sex, older age, comorbid hypertension, delayed admission to hospital after symptom onset or severe illness on admission, and use of invasive mechanical ventilation or corticosteroids.[89]

Classification

World Health Organization: clinical classification of COVID-19[3]

Mild illness

- Patients with uncomplicated upper respiratory tract viral infection may have non-specific symptoms such as fever, fatigue, cough (with or without sputum production), anorexia, malaise, muscle pain, sore throat, dyspnoea, nasal congestion, or headache. Rarely, patients may also present with diarrhoea, nausea, and vomiting.
- Older and/or immunosuppressed patients may present with atypical symptoms.
- Symptoms due to physiological adaptations of pregnancy or adverse pregnancy events (e.g., dyspnoea, fever, gastrointestinal symptoms, fatigue) may overlap with COVID-19 symptoms.

Pneumonia

- Adults: pneumonia with no signs of severe pneumonia (see below) and no need for supplemental oxygen.
- Children: pneumonia with cough or difficulty breathing plus fast breathing (i.e., <2 months of age: ≥ 60 breaths/minute; 2-11 months of age: ≥ 50 breaths/minute; 1-5 years of age: ≥ 40 breaths/minute) and no signs of severe pneumonia (see below).

Severe pneumonia in adults and adolescents

- Fever or suspected respiratory infection plus one of the following:
 - Respiratory rate >30 breaths/minute
 - Severe respiratory distress

- SpO₂ ≤93% on room air.

Severe pneumonia in children

- Cough or difficulty breathing plus at least one of the following:
 - Central cyanosis or SpO₂ <90%
 - Severe respiratory distress (e.g., grunting, very severe chest indrawing)
 - Signs of pneumonia with a general danger sign (i.e., inability to breastfeed or drink, lethargy or unconsciousness, or convulsions).
- Other signs of pneumonia may be present in children including chest indrawing or fast breathing (i.e., <2 months of age: ≥60 breaths/minute; 2-11 months of age: ≥50 breaths/minute; 1-5 years years of age: ≥40 breaths/minute).
- While the diagnosis is made on clinical grounds, chest imaging may identify or exclude some pulmonary complications.

Primary prevention

General prevention measures

- The only way to prevent infection is to avoid exposure to the virus and people should be advised to:^[105] ^[106]
 - Wash hands often with soap and water for at least 20 seconds or an alcohol-based hand sanitiser (that contains at least 60% alcohol), especially after being in a public place, blowing their nose, or coughing/sneezing. Avoid touching the eyes, nose, and mouth with unwashed hands
 - Avoid close contact with people (i.e., maintain a distance of at least 1 metre [3 feet]) including shaking hands, particularly those who are sick, have a fever, or are coughing or sneezing. It is important to note that recommended distances differ between countries (for example, 2 metres is recommended in the US and UK) and you should consult local guidance
 - Practice respiratory hygiene (i.e., cover mouth and nose when coughing or sneezing, discard tissue immediately in a closed bin, and wash hands)
 - Seek medical care early if they have a fever, cough, and difficulty breathing, and share their previous travel and contact history (travellers or suspected/confirmed cases) with their healthcare provider
 - Stay at home if they are sick, even with mild symptoms, until they recover (except to get medical care)
 - Clean and disinfect frequently touched surfaces daily (e.g., light switches, door knobs, countertops, handles, phones).
- [\[BMJ Learning: Covid-19 - handwashing technique and PPE videos\]](#)
- [\[WHO: coronavirus disease \(COVID-19\) advice for the public\]](#)

Face masks

- Recommendations on the use of face masks in community settings vary between countries.^[107] It is mandatory to wear a mask in public in certain countries, and masks may be worn in some countries according to local cultural habits. Consult local guidance for more information.
- The World Health Organization recommends that medical masks should be reserved for healthcare workers. People with symptoms should also wear a medical mask, self-isolate, and seek medical advice as soon as possible. Masks are also recommended for those caring for a sick person at home when in the same room. There is currently no evidence that wearing a mask (medical or other types) in the community setting can prevent infection with respiratory viruses, including COVID-19, in a healthy person.^[108]
- The Centers for Disease Control and Prevention recommends that homemade cloth face coverings can be worn in public settings where social distancing measures are difficult to maintain (e.g., pharmacies, supermarkets), especially in areas where there is significant community transmission.^[109] However, there is no evidence to support this.^[110]
- Use of a mask alone is insufficient to provide adequate protection, and they should be used in conjunction with other infection prevention and control measures such as frequent hand hygiene and social distancing. It is important to wash your hands with soap and water (or an alcohol-based sanitiser) prior to putting on a face mask, and to remove it correctly. Used masks should be disposed of properly.^[108] ^[111]
- Standard surgical masks are as effective as respirator masks for preventing infection of healthcare workers in outbreaks of viral respiratory illnesses such as influenza, but it is unknown whether this applies to COVID-19.^[112] A small study found that surgical and cotton masks are ineffective at preventing viral spread to the environment from the cough of patients with COVID-19.^[113]

- [\[BMJ: facemasks for the prevention of infection in healthcare and community settings\]](#)
- [\[BMJ: analysis - face masks for the public during the covid-19 crisis\]](#)
- [\[WHO: coronavirus disease \(COVID-19\) advice for the public - when and how to use masks\]](#)

Screening and quarantine

- People travelling from areas with a high risk of infection may be screened using questionnaires about their travel, contact with ill persons, symptoms of infection, and/or measurement of their temperature. Combined screening of airline passengers on exit from an affected area and on arrival elsewhere has been relatively ineffective when used for other infections such as Ebola virus infection, and has been modelled to miss up to 50% of cases of COVID-19, particularly those with no symptoms during the incubation period.[\[114\]](#) Symptom-based screening processes have been reported to be ineffective in detecting SARS-CoV-2 infection in a small number of patients who were later found to have evidence of SARS-CoV-2 in a throat swab.[\[115\]](#)
- Enforced quarantine is being used to isolate easily identifiable cohorts of people at potential risk of recent exposure (e.g., groups evacuated by aeroplane from affected areas, people returning to their home countries before border closures, or groups on cruise ships with infected people on board).[\[116\]](#) The psychosocial effects of enforced quarantine may have long-lasting repercussions.[\[117\]](#) [\[118\]](#) Despite limited evidence, a Cochrane review found quarantine to be important in reducing the number of people infected and deaths, especially when started earlier and when used in combination with other prevention and control measures.[\[119\]](#)

Social distancing

- Many countries have implemented mandatory social distancing measures in order to reduce and delay transmission (e.g., city lockdowns, stay-at-home orders, curfews, non-essential business closures, bans on gatherings, school and university closures, travel restrictions and bans, remote working, quarantine of exposed people/travellers).
- Although the evidence for social distancing for COVID-19 is limited, it is emerging, and the best available evidence appears to support social distancing measures to reduce the transmission and delay spread. The timing and duration of these measures appears to be critical.[\[120\]](#) [\[121\]](#)
- Researchers in Singapore found that social distancing measures (isolation of infected individuals and family quarantine, school closures, and workplace distancing) significantly decreased the number of infections in simulation models.[\[122\]](#)
- [\[Public Health England: guidance on social distancing for everyone in the UK\]](#)

Shielding extremely vulnerable people

- Shielding is a measure used to protect vulnerable people (including children) who are at very high risk of severe illness from COVID-19 because they have an underlying health condition. Shielding involves minimising all interactions between those who are extremely vulnerable and other people to protect them from coming into contact with the virus.
- Extremely vulnerable groups include:[\[123\]](#)
 - Solid organ transplant recipients
 - People with specific cancers
 - People with severe respiratory conditions (e.g., cystic fibrosis, severe asthma, or COPD)
 - People with rare diseases or inborn errors of metabolism that increase the risk of infections (e.g., sickle cell anaemia, severe combined immunodeficiency)
 - People on immunosuppression therapies sufficient to significantly increase the risk of infection
 - Women who are pregnant with significant heart disease (congenital or acquired).
- These groups are advised to stay at home at all times, and avoid any face-to-face contact for a period of at least 12 weeks (this time period is subject to change). Visits from people who provide essential

support should continue provided these people do not have symptoms and follow hand hygiene measures.

- Consult local health authorities for more guidance as recommendations, procedures, and resources differ between countries.
- [\[Public Health England: guidance on shielding and protecting people defined on medical grounds as extremely vulnerable from COVID-19\]](#)

Vaccine

- There is currently no vaccine available. Vaccines are in development, but it may take at least 12 months before one is available. An mRNA vaccine (mRNA-1273) has been shipped to the National Institute of Allergy and Infectious Diseases for phase 1 clinical trials in the US.[\[124\]](#) The vaccine includes a short segment of genetic code copied from the virus. The trial started in humans on 16 March 2020. The vaccine is being fast-tracked and has skipped the animal testing stage. Clinical trials in humans have also started on an experimental adenoviral vector vaccine in China.[\[125\]](#) Other vaccines are currently in development or clinical trials around the world.[\[126\]](#)

Smoking cessation

- Past or current smokers have double the risk for severe disease, and smoking cessation should be encouraged.[\[102\]](#)

Screening

Management of contacts

People who may have been exposed to individuals with suspected COVID-19 (including healthcare workers) should be advised to monitor their health for 14 days from the last day of possible contact. A contact is a person who is involved in any of the following from 2 days before, and up to 14 days after, the onset of symptoms in the patient:[\[211\]](#)

- Face-to-face contact with a COVID-19 patient within 1 metre (3 feet) for more than 15 minutes
- Providing direct care for patients with COVID-19 without using proper personal protective equipment
- Staying in the same close environment (e.g., workplace, classroom, household, gathering) as a COVID-19 patient for any amount of time
- Travelling in close proximity within 1 metre (3 feet) with a COVID-19 patient in any kind of conveyance
- Other situations as indicated by local risk assessments.

If a contact develops symptoms, they should notify the receiving facility, wear a medical mask while travelling to seek care, avoid taking public transport (e.g., call an ambulance or use a private vehicle), perform respiratory and hand hygiene, sit as far away from others as possible in transit, and clean any contaminated surfaces.

Screening of travellers

Exit and entry screening may be recommended in countries where borders are still open, particularly when repatriating nationals from affected areas. Travellers returning from affected areas should self-monitor for symptoms for 14 days and follow local protocols of the receiving country. Some countries may require travellers to enter mandatory quarantine in a designated location (e.g., a hotel). Travellers who develop symptoms are advised to contact their local healthcare provider, preferably by phone.[\[212\]](#) One study of 566 repatriated Japanese nationals from Wuhan City found that symptom-based screening performed poorly and missed presymptomatic and asymptomatic cases. This highlights the need for testing and follow-up.[\[213\]](#)

Drive-through screening centres

Drive-through screening centres have been set up in some countries for safer and more efficient screening. The testee does not leave their car throughout the entire process, which includes registration and questionnaire, examination, specimen collection, and instructions on what to do after. This method has the advantage of increased testing capacity and prevention of cross-infection between testees in the waiting space.^[214]

Secondary prevention

Early recognition of new cases is the cornerstone of prevention of transmission. Immediately isolate all suspected and confirmed cases and implement recommended infection prevention and control procedures according to local protocols, including standard precautions at all times, and contact, droplet, and airborne precautions while the patient is symptomatic.^[129] COVID-19 is a notifiable disease; report all suspected and confirmed cases to your local health authorities.

Detailed guidance on infection prevention and control measures are available from the World Health Organization and the Centers for Disease Control and Prevention:

- [\[WHO: infection prevention and control during health care when COVID-19 is suspected\]](#)
- [\[CDC: interim infection prevention and control recommendations for patients with suspected or confirmed coronavirus disease 2019 \(COVID-19\) in healthcare settings\]](#)

Case history

Case history #1

A 61-year-old man presents to hospital with fever, dry cough, and difficulty breathing. He also reports feeling very tired and unwell. He has a history of hypertension, which is controlled with enalapril. On examination, his pulse is 120 bpm and his temperature is 38.7°C (101.6°F). He is admitted to hospital in an isolation room and is started on oxygen, intravenous fluids, empirical antibiotics, and paracetamol. Chest x-ray shows bilateral lung infiltrates, and computed tomography of the chest reveals multiple bilateral lobular and subsegmental areas of ground-glass opacity. A nasopharyngeal swab is sent for real-time reverse transcriptase polymerase chain reaction testing, and the result comes back positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) the next day. The patient develops respiratory distress 7 days after admission and is transferred to the intensive care unit and started on mechanical ventilation.

Case history #2

A 26-year-old woman calls her doctor complaining of a sore throat and a persistent dry cough. She denies having a fever, and has not travelled in the last 14 days or knowingly been in contact with a confirmed case of COVID-19. She is advised to stay at home and self-isolate and to call her doctor if her symptoms get worse.

Step-by-step diagnostic approach

Early recognition and rapid diagnosis are essential to prevent transmission and provide supportive care in a timely manner. Have a high index of clinical suspicion for COVID-19 in all patients who present with fever and/or acute respiratory illness and who live in or report a travel history to an area with local transmission or close contact with a suspected or confirmed case in the 14 days prior to symptom onset. Evaluation should be performed according to pneumonia severity indexes and sepsis guidelines (if sepsis is suspected) in all patients with severe illness.

It is important that general practitioners avoid in-person assessment of patients with suspected COVID-19 in primary care when possible.^[127] Most patients can be managed remotely by telephone or video consultations.^[128] Algorithms for dealing with these patients are available:

- [\[BMJ: covid-19 in primary care \(UK\)\]](#)
- [\[BMJ: covid-19 - a remote assessment in primary care\]](#)

Infection prevention and control

Triage all patients on admission and immediately isolate all suspected and confirmed cases in an area separate from other patients. Suspected patients should be given a mask and kept at least 1 metre (3 feet) from other suspected patients. It is important to note that recommended distances differ between countries and you should consult local guidance. Implement appropriate infection prevention and control procedures. Screening questionnaires may be helpful. COVID-19 is a notifiable disease; report all suspected and confirmed cases to your local health authorities.

[[BMJ: covid-19 - PPE guidance](#)]

The World Health Organization (WHO) recommends the following basic principles:[[129](#)]

- Immediately isolate all suspected cases in an area that is separate from other patients
- Implement standard precautions at all times:
 - Practice hand and respiratory hygiene
 - Offer a medical mask to patients who can tolerate one
 - Wear personal protective equipment
 - Practice safe waste management, environmental cleaning, and sterilisation of patient care equipment and linen
- Implement additional contact and droplet precautions until the patient is asymptomatic:
 - Place patients in adequately ventilated single rooms; when single rooms are not available, place all suspected cases together in the same ward
 - Wear a medical mask, gloves, an appropriate gown, and eye/facial protection (e.g., goggles or a face shield)
 - Use single-use or disposable equipment
 - Consider limiting the number of healthcare workers, family members, and visitors in contact with the patient, ensuring optimal patient care and psychosocial support for the patient
 - Consider placing patients in negative pressure rooms, if available
- Implement airborne precautions when performing aerosol-generating procedures
- All specimens collected for laboratory investigations should be regarded as potentially infectious.

Some countries and organisations recommend airborne precautions for any situation involving the care of a COVID-19 patient.

It is important to disinfect inanimate surfaces in the surgery or hospital as patients may touch and contaminate surfaces such as door handles and desktops.[[130](#)]

Detailed guidance on infection prevention and control procedures are available from the WHO and the Centers for Disease Control and Prevention (CDC):

- [[WHO: infection prevention and control during health care when COVID-19 is suspected](#)]
- [[CDC: interim infection prevention and control recommendations for patients with suspected or confirmed coronavirus disease 2019 \(COVID-19\) in healthcare settings](#)]
- [[CDC: strategies to optimize the supply of PPE and equipment](#)]

History

Take a detailed history to ascertain the level of risk for COVID-19 and assess the possibility of other causes, including a travel history, smoking history, and presence of any underlying health conditions.

Diagnosis should be suspected in:[90]

- Patients with acute respiratory illness (i.e., fever and at least one sign/symptom of respiratory disease such as cough or shortness of breath) and a history of travel to or residence in a location reporting community transmission of COVID-19 disease during the 14 days prior to symptom onset.
- Patients with any acute respiratory illness if they have been in contact with a confirmed or probable COVID-19 case in the last 14 days prior to symptom onset.

See our Diagnostic criteria section for full case definitions.

Clinical presentation

The clinical presentation resembles viral pneumonia, and the severity of illness ranges from mild to severe. Approximately 80% of patients present with mild illness, 14% present with severe illness, and 5% present with critical illness.[6] Severe illness is associated with older age and the presence of underlying health conditions.[6] [91] Older patients and/or those with comorbidities may present with mild symptoms, but have a high risk of deterioration.[3] Atypical presentations may occur, especially in older patients or patients who are immunocompromised.

Approximately 5% of patients with a mild influenza-like illness (and no risk factors for COVID-19) who presented to a Los Angeles emergency department tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), although this study was limited by the brief sampling period at one medical centre.[131]

The most common symptoms are:[19] [20] [38] [132] [133] [134]

- Fever
- Cough
- Dyspnoea
- Myalgia
- Fatigue
- Anosmia/dysgeusia.

Less common symptoms include:

- Anorexia
- Sputum production
- Conjunctivitis
- Gastrointestinal symptoms
- Sore throat
- Confusion
- Dizziness
- Headache
- Rhinorrhoea or nasal congestion
- Chest pain
- Haemoptysis
- Cutaneous manifestations.

Approximately 90% of patients present with more than one symptom, and 15% of patients present with fever, cough, and dyspnoea.[20] Some patients may be minimally symptomatic or asymptomatic. Mild illness is defined as patients with an uncomplicated upper respiratory tract infection with non-specific

symptoms such as fever, cough (with or without sputum production), fatigue, anorexia, malaise, myalgia, sore throat, dyspnoea, nasal congestion, or headache. Patients may have gastrointestinal symptoms. The most common diagnosis in patients with severe COVID-19 is severe pneumonia.[3]

Initial impressions from cases in the US note that the clinical presentation may be broader than that observed in China and Italy, with chest pain, headaches, altered mental status, and gastrointestinal symptoms all observed on initial presentation. Severe hepatic and renal dysfunction that spares the lungs has also been observed.[135]

A retrospective case series of 62 patients in Zhejiang province found that the clinical features were less severe than those of the primary infected patients from Wuhan City, indicating that second-generation infection may result in milder infection. This phenomenon was also reported with Middle East respiratory syndrome.[136]

Co-infections have been reported. In a sample of approximately 1200 patients with respiratory symptoms, 21% of nasopharyngeal swab specimens that tested positive for SARS-CoV-2 also tested positive for other respiratory pathogens, most commonly rhinovirus/enterovirus, respiratory syncytial virus, and non-SARS-CoV-2 *Coronaviridae* .[137] Patients with influenza co-infection showed similar characteristics to those patients with COVID-19 only.[85] [138] [139]

Perform a physical examination. Avoid use of a stethoscope if possible due to risk of viral contamination. Patients may be febrile (with or without chills/rigors) and have obvious cough and/or difficulty breathing. Auscultation of the chest may reveal inspiratory crackles, rales, and/or bronchial breathing in patients with pneumonia or respiratory distress. Patients with respiratory distress may have tachycardia, tachypnoea, or cyanosis accompanying hypoxia.

Children

Signs and symptoms may be similar to other common viral respiratory infections and other childhood illnesses, so a high index of suspicion for COVID-19 is required in children.

Children are typically asymptomatic or present with mild symptoms (e.g., brief and rapidly resolving fever, mild cough, sore throat, congestion, rhinorrhoea).[10] [11] [12] [140] [141] [142] However, moderate to severe illness has also been reported in children.[143] Polypnoea has been reported in children with severe illness.[144] There are case reports of neonates and infants presenting with predominantly gastrointestinal symptoms.[145] [146]

In a case series of 2143 paediatric patients in China, over 90% of children were asymptomatic or had a mild or moderate illness; 16% were asymptomatic and had no radiological evidence of pneumonia.[14] However, it is important to note that children may have signs of pneumonia on chest imaging despite having minimal or no symptoms.[147]

Co-infections may be more common in children.[147] It is unknown whether children with underlying health conditions are more at risk of severe illness. Complications in children appear to be milder and more rare.

Pregnant women

Retrospective reviews of pregnant women with COVID-19 found that the clinical characteristics in pregnant women were similar to those reported for non-pregnant adults.[68] [72] It is important to note

that symptoms such as fever, dyspnoea, and fatigue may overlap with symptoms due to physiological adaptations of pregnancy or adverse pregnancy events.[3]

Initial investigations

Order the following investigations in all patients with severe illness:

- Pulse oximetry
- ABG (as indicated to detect hypercarbia or acidosis)
- FBC
- Comprehensive metabolic panel
- Coagulation screen
- Inflammatory markers (serum procalcitonin and C-reactive protein)
- Serum troponin
- Serum lactate dehydrogenase
- Serum creatine kinase.

The most common laboratory abnormalities in patients hospitalised with pneumonia include leukopenia, lymphopenia, leukocytosis, elevated liver transaminases, elevated lactate dehydrogenase, and elevated C-reactive protein. Other abnormalities include neutrophilia, thrombocytopenia, decreased haemoglobin, decreased albumin, and renal impairment.[19] [20] [38] [134] [148]

[VIDEO: Radial artery puncture animated demonstration]

Pulse oximetry

Pulse oximetry may reveal low oxygen saturation ($SpO_2 < 90\%$).

Clinicians should be aware that patients with COVID-19 can develop 'silent hypoxia': their oxygen saturations can drop to low levels and precipitate acute respiratory failure without the presence of obvious symptoms of respiratory distress. Only a small proportion of patients have other organ dysfunction, meaning that after the initial phase of acute deterioration, traditional methods of recognising further deterioration (e.g., National Early Warning Score 2 [NEWS2] scores) may not help predict those patients who go on to develop respiratory failure.[149]

While NEWS2 is still recommended for use in patients with COVID-19, the UK Royal College of Physicians now advises that any increase in oxygen requirements in these patients should trigger an escalation call to a competent clinical decision maker, and prompt an initial increase in observations to at least hourly until a clinical review happens.[150]

Blood and sputum cultures

Collect blood and sputum specimens for culture in all patients to rule out other causes of lower respiratory tract infection and sepsis, especially patients with an atypical epidemiological history. Specimens should be collected prior to starting empirical antimicrobials if possible.[3]

Molecular testing

Molecular testing is required to confirm the diagnosis. Diagnostic tests should be performed according to guidance issued by local health authorities and should adhere to appropriate biosafety practices. If testing is not available nationally, specimens should be shipped to an appropriate reference laboratory. Specimens for testing should be collected under appropriate infection prevention and control procedures.

Decisions about who to test should be based on clinical and epidemiological factors. The WHO recommends prioritising people with a likelihood of infection. Consider testing asymptomatic or mildly symptomatic contacts of confirmed COVID-19 cases. Symptomatic pregnant women should also be prioritised in order to enable access to specialised care.[3] Consult local health authorities for guidance as testing priorities will depend on local guidelines and available resources. See our Criteria section for CDC and Infectious Diseases Society of America recommendations on testing priorities.

Perform a nucleic acid amplification test, such as real-time reverse-transcription polymerase chain reaction (RT-PCR), for SARS-CoV-2 in appropriate patients with suspected infection, with confirmation by nucleic acid sequencing when necessary.[151]

- Collect upper respiratory specimens (nasopharyngeal and oropharyngeal swab or wash) in ambulatory patients and/or lower respiratory specimens (sputum and/or endotracheal aspirate or bronchoalveolar lavage) in patients with more severe respiratory disease. Consider the high risk of aerosolisation when collecting lower respiratory specimens.
- Also consider collecting additional clinical specimens (e.g., blood, stool, urine).

One or more negative results do not rule out the possibility of infection. If a negative result is obtained from a patient with a high index of suspicion for COVID-19, additional specimens should be collected and tested, especially if only upper respiratory tract specimens were collected initially.[151] Guidelines recommend that two consecutive negative tests (at least one day apart) are required to exclude COVID-19; however, there is a case report of a patient who returned two consecutive negative results and didn't test positive until 11 days after symptom onset and confirmation of typical chest computed tomography (CT) findings.[152]

Collect nasopharyngeal swabs for testing to rule out infection with other respiratory pathogens (e.g., influenza, atypical pathogens) according to local guidance. It is important to note that co-infections can occur, and a positive test for a non-COVID-19 pathogen does not rule out COVID-19.[3] [153]

Serological testing is not available as yet, but assays are in development and some assays have been approved, although they are mainly being used in research settings.[154] Serum samples can be stored to retrospectively define cases when validated serology tests become available. Early data indicate continuous high levels of immunoglobulin M (IgM) during the early/acute phase of infection, with IgM lasting more than 1 month (indicating prolonged virus replication in infected patients). IgG responded later than IgM.[155]

Chest x-ray

All imaging procedures should be performed according to local infection prevention and control procedures to prevent transmission. Chest imaging is considered safe in pregnant women.[156]

Order a chest x-ray in all patients with suspected pneumonia. Unilateral lung infiltrates are found in 25% of patients, and bilateral lung infiltrates are found in 75% of patients.[19] [20] [157]

Computed tomography

Consider ordering a computed tomography (CT) scan of the chest. CT imaging is the primary imaging modality in some countries, such as China. It may be helpful in making the diagnosis, guiding individual patient management decisions, aiding the diagnosis of complications, or giving clues to an alternative diagnosis. However, it is not diagnostic for COVID-19 and local guidance should be consulted on whether to perform a CT scan.

The British Society of Thoracic Imaging (BSTI) recommends CT imaging in patients with clinically suspected COVID-19 who are seriously ill if chest x-ray is uncertain or normal. Without the suspicion of COVID-19, the radiology is non-specific and could represent many other disease processes. The BSTI in collaboration with NHS England have produced a radiology decision support tool to help clinicians decide whether or not chest imaging should be ordered.[158]

[BSTI: radiology decision support tool for suspected COVID-19]

The American College of Radiology recommends reserving CT for hospitalised, symptomatic patients with specific clinical indications for CT, and emphasises that a normal chest CT does not mean that a patient does not have COVID-19 and that an abnormal chest CT is not specific for COVID-19 diagnosis.[159]

Abnormal chest CT findings have been reported in up to 97% of COVID-19 patients in one meta-analysis of 50,466 hospitalised patients.[133] Evidence of pneumonia on CT may precede a positive RT-PCR result for SARS-CoV-2 in some patients.[154] CT imaging abnormalities may be present in minimally symptomatic or asymptomatic patients.[54] [160] Some patients may present with a normal chest finding despite a positive RT-PCR.[161] Also, results of RT-PCR testing may be false-negative, so patients with typical CT findings should have repeat RT-PCR testing to confirm the diagnosis.[162]

Typical features

- Multiple bilateral lobular and subsegmental areas of ground-glass opacity or consolidation are seen in most patients, usually with a peripheral or posterior distribution, mainly in the lower lobes and less frequently in the right lower lobe. Consolidative opacities superimposed on ground-glass opacity may be found in a smaller number of cases, usually older patients.[19] [136] [163]
- Other classic findings include crazy-paving pattern, air bronchograms, and a reverse halo/perilobular pattern (i.e., organising pneumonia patterns).[158]
- A small comparative study found that patients with COVID-19 are more likely to have bilateral involvement with multiple mottling and ground-glass opacity compared with other types of pneumonia.[164]
- Older people are more likely to have extensive lung lobe involvement, interstitial changes, and pleural thickening compared with younger patients.[165]
- Small nodular ground-glass opacities and consolidation with surrounding halo signs are typical in children.[147] [166]

Atypical features

- Interlobular or septal thickening (smooth or irregular), thickening of the adjacent pleura, and subpleural involvement are atypical features. Some patients may rarely present with pleural effusion, pericardial effusion, bronchiectasis, cavitation, pneumothorax, lymphadenopathy, and round cystic changes. Atypical features appear to be more common in the later stages of disease, or on disease progression.[19] [136] [163]

Disease progression

- Abnormalities can rapidly evolve from focal unilateral to diffuse bilateral ground-glass opacities that progress to, or co-exist with, consolidations within 1 to 3 weeks.[160]
- The greatest severity of CT findings is usually visible around day 10 after symptom onset, and imaging signs associated with clinical improvement (e.g., resolution of consolidative opacities, reduction in number of lesions and involved lobes) usually occur after week 2 of the disease.[163]

Sensitivity of CT

- In a cohort of over 1000 patients in a hyperendemic area in China, chest CT had a higher sensitivity for diagnosis of COVID-19 compared with initial RT-PCR from swab samples (88% versus 59%). Improvement of abnormal CT findings also preceded change from RT-PCR positivity to negativity in this cohort during recovery. The sensitivity of chest CT was 97% in patients who ultimately had positive RT-PCR results. However, in this setting, 75% of patients with negative RT-PCR results also had positive chest CT findings. Of these patients, 48% were considered highly likely cases, while 33% were considered probable cases.[167]

Lung ultrasound

There is emerging evidence that lung ultrasound may be a useful aid in the diagnosis of COVID-19 as it has high sensitivity for detecting pleural thickening, subpleural consolidation, and ground-glass opacity. It has the advantages of portability, bedside evaluation, reduced healthcare worker exposure, and repeatability during follow-up. However, it also has limitations (e.g., it is unable to discern chronicity of a lesion) and other imaging modalities may be required. Characteristic ultrasound patterns have been reported in patients with COVID-19 and include B-lines, white lung, pleural line thickening, and consolidations with air bronchograms.[168] [169] [170] [171] [172] [173]

Risk factors

Strong

residence in/travel to location reporting community transmission during the 14 days prior to symptom onset

- Diagnosis should be suspected in patients with acute respiratory illness (i.e., fever and at least one sign/symptom of respiratory disease such as cough or shortness of breath) and a history of travel to or residence in a location reporting community transmission of COVID-19 disease during the 14 days prior to symptom onset.[90]

close contact with a confirmed case

- Diagnosis should be suspected in patients with any acute respiratory illness if they have been in contact with a confirmed or probable COVID-19 case in the last 14 days prior to symptom onset.[90]

older age and/or underlying health conditions

- People aged 65 years and older, those who live in a nursing home or long-term care facility, and those with a high-risk condition (e.g., chronic respiratory disease, cardiovascular disease, immunocompromised, severe obesity, diabetes, hypertension, renal or liver disease) are at higher risk for severe illness.[91] [92]
- The most prevalent comorbidities in patients with COVID-19 are hypertension, cardiovascular disease, diabetes, smoking, respiratory disease such as COPD, malignancy, and chronic kidney disease.[93]
- Obesity is also a common risk factor for COVID-19, including younger patients. These patients are at higher risk of severe disease and intensive care admission.[94] [95] [96]
- Initial data suggest that immunosuppressed patients are not at increased risk of severe illness from coronaviruses; however, further research is required in this patient group.[97]

malignancy

- Patients with cancer are thought to be at a higher risk of contracting COVID-19 because treatments such as radiotherapy and chemotherapy are immunosuppressive, and patients with cancer are often in hospital for treatment and monitoring and so may be at risk of nosocomial infection. A retrospective study of 1524 patients at a single institution in Wuhan City, China, found that the infection rate in patients with cancer was higher than the cumulative incidence of all diagnosed cases reported in the city over the same period of time (i.e., 0.79% versus 0.37%). However, fewer than half of these infected patients were undergoing active treatment, suggesting that recurrent hospital visits and admissions were a potential risk factor.[98]

smoking

- Smoking has been associated with more severe disease, adverse outcomes, and a poorer prognosis.[99] [100] [101] Past or current smokers with COVID-19 have double the risk for severe disease outcomes (18%) compared with people who have never smoked (9%) according to a preprint (not peer reviewed) meta-analysis of 9000 patients.[102] This may be due to increased airway expression of the angiotensin-converting enzyme-2 receptor in smokers.[103]

surgery

- Surgery may accelerate and exacerbate disease progression. A retrospective study of 34 patients in China who underwent elective surgeries during the incubation period of COVID-19 found that all patients developed pneumonia after surgery. Approximately 44% of these patients required admission to the intensive care unit, and 20% died. Further study is required.[104]

History & examination factors

Key diagnostic factors

fever (common)

- Reported in 83% to 98% of patients in case series.[19] [20] [38] [133] [134] [174] In one case series, 44% of patients had a fever on presentation, but it developed in 89% of patients after hospitalisation.[132]
- Children may not present with fever, or may have a brief and rapidly resolving fever.[11] [141] [142]
- Patients may present with chills/rigors.
- The course of fever is not fully understood yet, but it may be prolonged and intermittent.

cough (common)

- Reported in 57% to 82% of patients in case series.[19] [20] [38] [132] [133] [134] [174]
- Less common in children.[141]
- Cough is usually dry.

dyspnoea (common)

- Reported in 18% to 55% of patients in case series.[19] [20] [38] [132] [134] [174]
- Median time from onset of symptoms to development of dyspnoea is 5 to 8 days.[19] [20] [38]
- Polyphnoea has been reported in children with severe illness.[144]

anosmia/dysgeusia (common)

- There is evidence that patients with mild to moderate illness may develop anosmia/hyposmia or ageusia/dysgeusia as an early symptom and in the absence of other symptoms.[175] In one small cross-sectional survey in Italy, approximately 53% of hospitalised patients reported at least one taste or olfactory disorder (or both).[176] In a multicentre European study of 417 patients with mild to moderate illness, 86% of patients reported olfactory dysfunction (most patients reported anosmia without nasal obstruction or rhinorrhoea), and 88% of patients reported gustatory dysfunction. Symptoms may appear before, during, or after other COVID-19 symptoms. Prevalence of these symptoms in European patients is substantially higher than that reported in China.[177]
- King's College London has reported that loss of smell/taste has been flagged as a key symptom for COVID-19 in the UK through its symptom tracker app.[178]
- It is possible that these patients may be hidden carriers, but further research is required.[179]
- The American Academy of Otolaryngology - Head and Neck Surgery has proposed adding anosmia and dysgeusia to the list of screening items for potential infection and recommends that clinicians consider testing and self-isolation of these patients (in the absence of other respiratory diseases such as rhinosinusitis or allergic rhinitis).[180]

Other diagnostic factors

fatigue (common)

- Reported in 29% to 69% of patients in case series.[19] [38] [132] [134] [174]
- Patients may also report malaise.

myalgia (common)

- Reported in 11% to 44% of patients in case series.[19] [20] [38] [132] [133] [174]
- Arthralgia has also been reported.

anorexia (common)

- Reported in 40% of patients in case series.[38]

sputum production/expectoration (common)

- Reported in 26% to 33% of patients in case series.[19] [38] [132] [174]

sore throat (common)

- Reported in 5% to 17% of patients in case series, and usually presents early in the clinical course.[20] [38] [132] [174]
- Children may have pharyngeal erythema.[141]

conjunctivitis (uncommon)

- Ocular manifestations consistent with conjunctivitis (i.e., conjunctival hyperaemia, chemosis, epiphora, and increased secretions) have been reported in 32% of patients in one case series. Manifestations are more frequent in patients with severe illness.[181]

gastrointestinal symptoms (uncommon)

- Gastrointestinal symptoms (e.g., nausea, vomiting, diarrhoea, abdominal pain) have been reported commonly. Early case series in China found up to 11% of patients had gastrointestinal symptoms.[19] [20] [38] [132] [134] [174] [182] However, more recent studies report gastrointestinal symptoms in up to 50% of patients.[36] [183] [184] [185]

- A case-control study in New York found that 35% of patients had gastrointestinal symptoms, and patients with these symptoms were more likely to have an illness duration of more than 1 week. Gastrointestinal symptoms were associated with a 70% relative increased risk of testing positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in this study.[186]
- Some patients may present with predominantly gastrointestinal symptoms, especially children.[145] [146] [187]
- Patients may present with nausea or diarrhoea 1 to 2 days prior to onset of fever and breathing difficulties.[38]
- Haematochezia has been reported.[188]

confusion (uncommon)

- Reported in 9% of patients in case series.[20]

dizziness (uncommon)

- Reported in 9% to 12% of patients in case series.[38] [134]

headache (uncommon)

- Reported in 6% to 14% of patients in case series.[19] [20] [38] [132] [134] [174]

haemoptysis (uncommon)

- Reported in 1% to 5% of patients in case series.[19] [132]

rhinorrhoea or nasal congestion (uncommon)

- Reported in 4% to 5% of patients in case series.[20] [132]
- Nasal congestion has been reported in nearly 4% of patients in one case series.[189]

chest pain (uncommon)

- Reported in 2% to 5% of patients in case series.[19] [20]
- May indicate pneumonia.

cutaneous manifestations (uncommon)

- Cutaneous manifestations (e.g., erythematous or maculopapular or morbilliform rash, petechiae, urticaria, vesicles) have been reported in some patients; however, further data is required to better understand skin involvement.[190] [191] [192]

bronchial breath sounds (uncommon)

- May indicate pneumonia.

tachypnoea (uncommon)

- May be present in patients with acute respiratory distress.

tachycardia (uncommon)

- May be present in patients with acute respiratory distress.

cyanosis (uncommon)

- May be present in patients with acute respiratory distress.

crackles/rales on auscultation (uncommon)

- May be present in patients with acute respiratory distress.

Diagnostic tests

1st test to order

Test	Result
<p>pulse oximetry</p> <ul style="list-style-type: none"> Order in patients with severe illness. Recommended in patients with respiratory distress and cyanosis. Clinicians should be aware that patients with COVID-19 can develop 'silent hypoxia': their oxygen saturations can drop to low levels and precipitate acute respiratory failure without the presence of obvious symptoms of respiratory distress. Only a small proportion of patients have other organ dysfunction, meaning that after the initial phase of acute deterioration, traditional methods of recognising further deterioration (e.g., National Early Warning Score 2 [NEWS2] scores) may not help predict those patients who go on to develop respiratory failure.[149] 	<p>may show low oxygen saturation (SpO₂ <90%)</p>
<p>ABG</p> <ul style="list-style-type: none"> Order in patients with severe illness as indicated to detect hypercarbia or acidosis. Recommended in patients with respiratory distress and cyanosis who have low oxygen saturation (SpO₂ <90%). 	<p>may show low partial oxygen pressure</p>
<p>FBC</p> <ul style="list-style-type: none"> Order in patients with severe illness. The most common laboratory abnormalities in patients hospitalised with pneumonia include leukopenia, lymphopenia, and leukocytosis. Other abnormalities include neutrophilia, thrombocytopenia, and decreased haemoglobin.[19] [20] [38] [148] Lymphopenia and thrombocytopenia have been associated with increased risk of severe disease and may be useful as clinical indicators for monitoring disease progression.[193] [194] High neutrophil-to-lymphocyte ratio is a useful marker for indicating risk for severe illness and poor prognosis.[195] [196] 	<p>leukopenia; lymphopenia; leukocytosis</p>
<p>coagulation screen</p> <ul style="list-style-type: none"> Order in patients with severe illness. The most common abnormalities are elevated D-dimer and prolonged prothrombin time.[19] [20] [38] Non-survivors had significantly higher D-dimer levels and longer prothrombin time and activated partial thromboplastin time compared with survivors in one study.[197] 	<p>elevated D-dimer; prolonged prothrombin time</p>
<p>comprehensive metabolic panel</p> <ul style="list-style-type: none"> Order in patients with severe illness. The most common laboratory abnormalities in patients hospitalised with pneumonia include elevated liver transaminases. Other abnormalities include decreased albumin and renal impairment.[19] [20] Liver function abnormalities may be more common in patients with COVID-19 compared with other types of pneumonia.[164] 	<p>elevated liver transaminases; decreased albumin; renal impairment</p>
<p>serum procalcitonin</p> <ul style="list-style-type: none"> Order in patients with severe illness. 	<p>may be elevated</p>

Test	Result
<ul style="list-style-type: none"> • May be elevated in patients with secondary bacterial infection.[19] [20] May be more common in children.[147] 	
<p>serum C-reactive protein</p> <ul style="list-style-type: none"> • Order in patients with severe illness. • May be elevated in patients with secondary bacterial infection, or may indicate hyperinflammation.[19] [20] • Increases at the initial stage of disease in patients with severe illness; therefore, it may be useful in identifying patients who might become severely ill.[198] 	may be elevated
<p>serum ferritin level</p> <ul style="list-style-type: none"> • Order in patients with severe illness. • May indicate development of cytokine release syndrome.[199] 	may be elevated
<p>serum lactate dehydrogenase</p> <ul style="list-style-type: none"> • Order in patients with severe illness. • Elevated lactate dehydrogenase has been reported in 73% to 76% of patients.[19] [20] May be more common in patients with COVID-19 compared with other types of pneumonia.[164] • May indicate hyperinflammation. 	may be elevated
<p>serum creatine kinase</p> <ul style="list-style-type: none"> • Order in patients with severe illness. • Elevated creatine kinase has been reported in 13% to 33% of patients.[19] [20] • Indicates muscle or myocardium injury. 	may be elevated
<p>serum troponin level</p> <ul style="list-style-type: none"> • Order in patients with severe illness. • Elevated in patients with cardiac injury.[19] • Other cardiac markers may also be elevated and are associated with severe disease.[200] 	may be elevated
<p>blood and sputum cultures</p> <ul style="list-style-type: none"> • Collect blood and sputum specimens for culture in all patients to rule out other causes of lower respiratory tract infection and sepsis, especially patients with an atypical epidemiological history.[3] • Specimens should be collected prior to starting empirical antimicrobials if possible. 	negative for bacterial infection
<p>real-time reverse transcription polymerase chain reaction (RT-PCR)</p> <ul style="list-style-type: none"> • Molecular testing is required to confirm the diagnosis. Nucleic acid sequencing may be required to confirm the diagnosis.[151] Priorities for testing depend on local guidelines and available resources. • Collect upper respiratory specimens (nasopharyngeal and oropharyngeal swab or wash) in ambulatory patients and/or lower respiratory specimens (sputum and/or endotracheal aspirate or bronchoalveolar lavage) in patients with more severe respiratory disease. Also consider collecting additional clinical specimens (e.g., blood, stool, urine). Specimens should be collected under appropriate infection prevention and control procedures. Consider the high risk of aerosolisation when collecting lower respiratory specimens.[151] • There are little data available on the rates of false-positive and false-negative results for the various RT-PCR tests available; however, both have been reported. If a negative result is obtained from a patient 	positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral RNA; may be positive for influenza A and B viruses and other respiratory pathogens

Test	Result
<p>with a high index of suspicion for COVID-19, additional specimens should be collected and tested, especially if only upper respiratory tract specimens were collected initially.[151]</p> <ul style="list-style-type: none"> • Many tests are available under the US Food and Drug Administration’s emergency-use authorisation scheme. A test that uses saliva has just been approved.[201] • A point-of-care test that provides results within hours is available in some countries.[202] While rapid point-of-care tests are available, the World Health Organization does not recommend the use of these tests outside of research settings as they have not been validated as yet.[203] • Tests are available in many laboratories worldwide and testing should be done according to instructions from local health authorities and adhere to appropriate biosafety practices. If testing is not available nationally, specimens should be shipped to an appropriate reference laboratory. • Sensitivity and specificity of RT-PCR for diagnostic testing are unknown.[204] • Collect nasopharyngeal swabs to rule out influenza and other respiratory infections according to local guidance. It is important to note that co-infections can occur, and a positive test for a non-COVID-19 pathogen does not rule out COVID-19.[3] [153] 	
<p>chest x-ray</p> <ul style="list-style-type: none"> • Order in all patients with suspected pneumonia. • Unilateral lung infiltrates are found in 25% of patients, and bilateral lung infiltrates are found in 75% of patients.[19] [20] [157] 	<p>unilateral or bilateral lung infiltrates</p>
<p>computed tomography (CT) chest</p> <ul style="list-style-type: none"> • Consider a CT scan of the chest. Consult local guidance on whether to perform a CT scan. • The British Society of Thoracic Imaging (BSTI) recommends CT imaging in patients with clinically suspected COVID-19 who are seriously ill if chest x-ray is uncertain or normal. [BSTI: radiology decision support tool for suspected COVID-19] The American College of Radiology recommends reserving CT for hospitalised, symptomatic patients with specific clinical indications for CT, and emphasises that a normal chest CT does not mean that a patient does not have COVID-19 and that an abnormal chest CT is not specific for COVID-19 diagnosis.[159] • Abnormal chest CT findings have been reported in up to 97% of hospitalised patients.[133] Evidence of pneumonia on CT may precede a positive RT-PCR result for SARS-CoV-2 in some patients.[154] CT imaging abnormalities may be present in minimally symptomatic or asymptomatic patients.[54] [160] Some patients may present with a normal chest finding despite a positive RT-PCR.[161] Also, results of RT-PCR testing may be false-negative, so patients with typical CT findings should have repeat RT-PCR testing to confirm the diagnosis.[162] • Atypical features appear to be more common in the later stages of disease, or on disease progression.[19] [136] [163] • Older people are more likely to have extensive lung lobe involvement, interstitial changes, and pleural thickening compared with younger patients.[165] Small nodular ground-glass opacities and consolidation with surrounding halo signs are typical in children.[147] [166] • Abnormalities can rapidly evolve from focal unilateral to diffuse bilateral ground-glass opacities that progress to, or co-exist with, 	<p>typical features: multiple bilateral lobular and subsegmental areas of ground-glass opacity or consolidation (usually peripheral or posterior, mainly in the lower lobes, less frequently in right lower lobe), crazy-paving pattern, air bronchograms, reverse halo/perilobular pattern; atypical features: interlobular or septal thickening (smooth or irregular), thickening of the adjacent pleura, subpleural involvement, pleural effusion, pericardial effusion, bronchiectasis, cavitation, pneumothorax, lymphadenopathy, round cystic changes</p>

Test	Result
<p>consolidations within 1 to 3 weeks.[160] The greatest severity of CT findings is usually visible around day 10 after symptom onset, and imaging signs associated with clinical improvement (e.g., resolution of consolidative opacities, reduction in number of lesions and involved lobes) usually occur after week 2 of the disease.[163]</p> <ul style="list-style-type: none"> In a cohort of over 1000 patients in a hyperendemic area in China, chest CT had a higher sensitivity for diagnosis of COVID-19 compared with initial RT-PCR from swab samples (88% versus 59%). Improvement of abnormal CT findings also preceded change from RT-PCR positivity to negativity in this cohort during recovery. The sensitivity of chest CT was 97% in patients who ultimately had positive RT-PCR results. However, in this setting, 75% of patients with negative RT-PCR results also had positive chest CT findings. Of these patients, 48% were considered highly likely cases, while 33% were considered probable cases.[167] <p>[Fig-2]</p>	

Emerging tests

Test	Result
<p>serology</p> <ul style="list-style-type: none"> Serological testing is not available as yet, but assays are in development.[154] Serum samples can be stored to retrospectively define cases when validated serology tests become available. Early data indicate continuous high levels of IgM during the acute phase of infection, with IgM lasting more than 1 month (indicating prolonged virus replication in infected patients). IgG responded later than IgM.[155] Rapid antibody detection kits have been approved in Europe and the US for the qualitative detection of SARS-CoV-2 IgG/IgM antibodies in serum, plasma, or whole blood. While rapid point-of-care tests are available, the World Health Organization does not recommend the use of these tests outside of research settings as they have not been validated as yet.[203] 	<p>positive for SARS-CoV-2 virus antibodies</p>
<p>lung ultrasound</p> <ul style="list-style-type: none"> There is emerging evidence that lung ultrasound may be a useful aid in the diagnosis of COVID-19 as it has high sensitivity for detecting pleural thickening, subpleural consolidation, and ground-glass opacity. It has the advantages of portability, bedside evaluation, reduced healthcare worker exposure, and repeatability during follow-up. However, it also has limitations (e.g., it is unable to discern chronicity of a lesion) and other imaging modalities may be required.[168] [169] [170] [171] [172] 	<p>B-lines; white lung; pleural line thickening; consolidations with air bronchograms</p>

Differential diagnosis

Condition	Differentiating signs / symptoms	Differentiating tests
Middle East respiratory syndrome (MERS)	<ul style="list-style-type: none"> • Travel history to the Middle East or contact with a confirmed case of MERS. • Differentiating COVID-19 from MERS is not possible from signs and symptoms. • Initial data suggest that the clinical course of COVID-19 is less severe and the case fatality rate is lower compared with MERS. 	<ul style="list-style-type: none"> • Reverse-transcriptase polymerase chain reaction (RT-PCR): positive for MERS-CoV viral RNA.
Severe acute respiratory syndrome (SARS)	<ul style="list-style-type: none"> • There have been no cases of SARS reported since 2004. 	<ul style="list-style-type: none"> • RT-PCR: positive for severe acute respiratory syndrome coronavirus (SARS-CoV) viral RNA.
Community-acquired pneumonia	<ul style="list-style-type: none"> • Lack of residence in/travel history to an area with ongoing transmission, or lack of close contact with a suspected/confirmed case of COVID-19 in the 14 days prior to symptom onset. • Differentiating COVID-19 from community-acquired bacterial pneumonia is not usually possible from signs and symptoms. However, patients with bacterial pneumonia are more likely to have rapid development of symptoms and purulent sputum. They are less likely to have myalgia, anosmia, or pleuritic pain.[205] [206] 	<ul style="list-style-type: none"> • Blood or sputum culture or molecular testing: positive for causative organism. • RT-PCR: negative for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral RNA (co-infections are possible). • CT chest: centrilobular nodules, mucoid impactions.[207]
Pneumocystis jirovecii pneumonia	<ul style="list-style-type: none"> • Lack of residence in/travel history to an area with ongoing transmission, or lack of close contact with a suspected/confirmed case of COVID-19 in the 14 days prior to symptom onset. • Differentiating COVID-19 from pneumocystis jirovecii pneumonia is not usually possible from signs and symptoms. • Patients are usually immunocompromised (e.g., 	<ul style="list-style-type: none"> • Sputum culture: positive for <i>Pneumocystis</i>. • RT-PCR: negative for SARS-CoV-2 viral RNA (co-infections are possible). • CT chest: ground-glass opacity is usually more diffusely distributed with a tendency to spare the subpleural regions.[207]

Condition	Differentiating signs / Differentiating tests symptoms	
	<p>HIV positive) and duration of symptoms may be longer.</p>	
<p>Influenza infection</p>	<ul style="list-style-type: none"> • Lack of residence in/travel history to an area with ongoing transmission, or lack of close contact with a suspected/confirmed case of COVID-19 in the 14 days prior to symptom onset. • Differentiating COVID-19 from community-acquired respiratory tract infections is not possible from signs and symptoms. 	<ul style="list-style-type: none"> • RT-PCR: positive for influenza A or B viral RNA; negative for SARS-CoV-2 viral RNA (co-infections are possible).
<p>Common cold</p>	<ul style="list-style-type: none"> • Lack of residence in/travel history to an area with ongoing transmission, or lack of close contact with a suspected/confirmed case of COVID-19 in the 14 days prior to symptom onset. • Differentiating COVID-19 from community-acquired respiratory tract infections is not possible from signs and symptoms. 	<ul style="list-style-type: none"> • RT-PCR: positive for causative organism; negative for SARS-CoV-2 viral RNA (co-infections are possible).
<p>Avian influenza A (H7N9) virus infection</p>	<ul style="list-style-type: none"> • May be difficult to differentiate based on epidemiological history as avian influenza H7N9 is endemic in China. • Close contact with infected birds (e.g., farmer or visitor to a live market in endemic areas), or living in an area when avian influenza is endemic. 	<ul style="list-style-type: none"> • RT-PCR: positive for H7-specific viral RNA.
<p>Avian influenza A (H5N1) virus infection</p>	<ul style="list-style-type: none"> • Lack of residence in/travel history to an area with ongoing transmission, or lack of close contact with a suspected/confirmed case of COVID-19 in the 14 days prior to symptom onset. • Close contact with infected birds (e.g., farmer or visitor to a live market in endemic areas), or living in an area when avian influenza is endemic. 	<ul style="list-style-type: none"> • RT-PCR: positive for H5N1 viral RNA.

Condition	Differentiating signs / symptoms	Differentiating tests
<p>Other viral or bacterial respiratory infections</p>	<ul style="list-style-type: none"> • Lack of residence in/travel history to an area with ongoing transmission, or lack of close contact with a suspected/confirmed case of COVID-19 in the 14 days prior to symptom onset. • Differentiating COVID-19 from community-acquired respiratory tract infections is not possible from signs and symptoms. • Adenovirus and <i>Mycoplasma</i> should be considered in clusters of pneumonia patients, especially in closed settings such as military camps and schools. 	<ul style="list-style-type: none"> • Blood or sputum culture of molecular testing: positive for causative organism. • RT-PCR: negative for SARS-CoV-2 viral RNA (co-infections are possible).
<p>Pulmonary tuberculosis</p>	<ul style="list-style-type: none"> • Consider diagnosis in endemic areas, especially in patients who are immunocompromised. • History of symptoms is usually longer. • Presence of night sweats and weight loss may help to differentiate. 	<ul style="list-style-type: none"> • Chest x-ray: fibronodular opacities in upper lobes with or without cavitation; atypical pattern includes opacities in middle or lower lobes, or hilar or paratracheal lymphadenopathy, and/or pleural effusion. • Sputum acid-fast bacilli smear and sputum culture: positive. • Molecular testing: positive for <i>Mycoplasma tuberculosis</i>.
<p>Febrile neutropenia</p>	<ul style="list-style-type: none"> • Suspect neutropenic sepsis in patients with a history of recent systemic anticancer treatment who present with fever (with or without respiratory symptoms) as this can be rapid and life-threatening.[208] • Symptoms of COVID-19 and neutropenic sepsis may be difficult to differentiate at initial presentation. 	<ul style="list-style-type: none"> • CBC: neutropenia. • RT-PCR: negative for SARS-CoV-2 viral RNA.

Diagnostic criteria

World Health Organization: case definitions[90]

Suspect case

- A. Patients with acute respiratory illness (i.e., fever and at least one sign/symptom of respiratory disease such as cough or shortness of breath) AND a history of travel to or residence in a location reporting community transmission of COVID-19 during the 14 days prior to symptom onset; OR
- B. Patients with any acute respiratory illness AND having been in contact with a confirmed or probable COVID-19 case in the last 14 days prior to symptom onset; OR
- C. Patients with severe acute respiratory illness (i.e., fever and at least one sign/symptom of respiratory disease such as cough or shortness of breath) AND requiring hospitalisation AND in the absence of an alternative diagnosis that fully explains the clinical presentation.

Probable case

- A. Suspect case for whom testing for the COVID-19 virus is inconclusive (inconclusive being the result of the test reported by the laboratory); OR
- B. Suspect case for whom testing could not be performed for any reason.

Confirmed case

- Patients with laboratory confirmation of COVID-19 infection, irrespective of clinical signs and symptoms.

Definition of contact

- A contact is a person who experienced any one of the following exposures during the 2 days before and the 14 days after the onset of symptoms of a probable or confirmed case:
 - Face-to-face contact with a probable or confirmed case within 1 metre (3 feet) and for more than 15 minutes
 - Direct physical contact with a probable or confirmed case
 - Direct care for a patient with probable or confirmed COVID-19 disease without using proper personal protective equipment
 - Other situations as indicated by local risk assessments.
- Note: for confirmed asymptomatic cases, the period of contact is measured as the 2 days before through the 14 days after the date on which the sample was taken that led to confirmation.

[WHO: [global surveillance for COVID-19 caused by human infection with COVID-19 virus](#)]

Centers for Disease Control and Prevention: criteria to guide evaluation and laboratory testing for COVID-19^[209]

Clinicians should use their judgement to determine whether a patient has signs and symptoms compatible with COVID-19 and whether the patient should be tested. Most patients with confirmed COVID-19 have developed fever and/or symptoms of acute respiratory illness (e.g., cough, difficulty breathing).

Priorities for testing

- Priority 1
 - Hospitalised patients
 - Symptomatic healthcare workers
- Priority 2

- Patients in long-term care facilities with symptoms
- Patients 65 years of age and older with symptoms
- Patients with underlying conditions with symptoms
- First responders with symptoms
- Priority 3
 - Critical infrastructure workers with symptoms
 - Individuals who do not meet any of the above categories with symptoms
 - Healthcare workers and first responders
 - Individuals with mild symptoms in communities experiencing high COVID-19 hospitalisations
- Non-priority
 - Individuals without symptoms

Other considerations that may guide testing are epidemiologic factors such as the occurrence of local community transmission of COVID-19 infections in a jurisdiction. Clinicians are strongly encouraged to test for other causes of respiratory illness, including infections such as influenza.

[CDC: [evaluating and testing persons for coronavirus disease 2019 \(COVID-19\)](#)]

[CDC: [priorities for testing patients with suspected COVID-19 infection](#)]

Infectious Diseases Society of America (IDSA): COVID-19 prioritization of diagnostic testing^[210]

IDSA recommends a tiering system for prioritising patients given the current limited availability of near-patient or point-of-care testing. These recommendations will likely change as testing becomes more widely available.

Tier 1

- Critically ill patients in the intensive care unit with unexplained viral pneumonia or respiratory failure, regardless of travel history or close contact with a suspected or confirmed COVID-19 patient.
- Any person, including healthcare workers, with fever or signs/symptoms of a lower respiratory tract illness and close contact with a laboratory-confirmed COVID-19 patient within 14 days of symptom onset (including all residents of a long-term care facility that has a laboratory-confirmed COVID-19 case).
- Any person, including healthcare workers, with fever or signs/symptoms of a lower respiratory tract illness and a history of travel within 14 days of symptom onset to geographical regions where sustained community transmission has been identified.
- Individuals with fever or signs/symptoms of a lower respiratory tract illness who also are immunosuppressed (including patients with HIV), are older, or have underlying chronic health conditions.
- Individuals with fever or signs/symptoms of a lower respiratory tract illness who are critical to pandemic response including healthcare workers, public health officials, and other essential leaders.

Tier 2

- Hospitalised (non-intensive care unit) patients and long-term care facility residents with unexplained fever and signs/symptoms of a lower respiratory tract illness. The number of confirmed COVID-19 cases in the community should be considered.
- As testing becomes more widely available, routine testing of hospitalised patients may be important for infection prevention and management at discharge.

Tier 3

- Patients in outpatient settings who meet the criteria for influenza testing (e.g., older people and/or those with underlying health conditions). Testing in pregnant women and symptomatic children with similar risk factors for complications is encouraged. The number of confirmed COVID-19 cases in the community should be considered.

Tier 4

- Community surveillance as directed by public health and/or infectious diseases authorities.

[IDSA: COVID-19 prioritization of diagnostic testing]

Step-by-step treatment approach

No specific treatments are known to be effective for COVID-19 yet; therefore, the mainstay of management is early recognition and optimised supportive care to relieve symptoms and to support organ function in more severe illness. Patients should be managed in a hospital setting where possible; however, home care may be suitable for selected patients with mild illness unless there is concern about rapid deterioration or an inability to promptly return to hospital if necessary. Children are less likely to require hospitalisation.[10]

[BMJ talk medicine podcast: coping with Covid-19 - advice from a New York City intensivist]

Rationing of medical resources may be required during the pandemic if healthcare infrastructures are overwhelmed. This raises many ethical questions on how to best triage patients to save the most lives. Recommendations have been suggested, but there is no clear international guidance on this issue as yet.[215] [216] [217] [218] [219]

Infection prevention and control

Immediately isolate all suspected or confirmed cases in an area separate from other patients. Suspected cases should be given a mask and kept at least 1 metre (3 feet) from other suspected cases. It is important to note that recommended distances differ between countries and you should consult local guidance. Implement appropriate infection prevention and control procedures. COVID-19 is a notifiable disease; report all suspected and confirmed cases to your local health authorities.

[BMJ: covid-19 - PPE guidance]

Detailed guidance on infection prevention and control procedures are available from the World Health Organization (WHO) and the US Centers for Disease Control and Prevention (CDC):

- [WHO: infection prevention and control during health care when COVID-19 is suspected]
- [CDC: interim infection prevention and control recommendations for patients with suspected or confirmed coronavirus disease 2019 (COVID-19) in healthcare settings]
- [CDC: strategies to optimize the supply of PPE and equipment]

The WHO recommends that patients should remain in isolation for 2 weeks after symptoms disappear, and visitors should not be allowed until the end of this period.[220] Guidance on when to stop isolation depends on local circumstances and may differ between countries; consult local guidelines.

Severe COVID-19: location of care and admission

Promptly admit patients with pneumonia or acute respiratory distress to an appropriate healthcare facility and start supportive care depending on the clinical presentation. Patients with impending or established respiratory failure should be admitted to an intensive care unit. Approximately 14% of patients present with severe illness requiring oxygen therapy, and 5% present with critical illness requiring intensive care unit treatment.[6] The most common reasons for intensive care unit admission are hypoxaemic respiratory failure leading to mechanical ventilation and hypotension.[221] The median time from onset of symptoms to hospital admission is reported to be approximately 7 days.[19] [38]

Treatment and care planning

- Discuss the risks, benefits, and potential outcomes of treatment options with patients and their families, and allow them to express preferences about their management. Take their wishes and expectations into account when considering the ceiling of treatment. Use decision support tools if available. Put treatment escalation plans in place, and discuss any existing advance care plans or advance decisions to refuse treatment with patients who have pre-existing advanced comorbidities.[222]

Admission to critical care

- Assess all adults for frailty on admission to hospital, irrespective of age and COVID-19 status, using the Clinical Frailty Scale (CFS). [Clinical frailty scale]
- Involve critical care teams in discussions about admission to critical care for patients where:
 - The CFS score suggests the person is less frail (e.g., CFS <5), they are likely to benefit from critical care organ support, and the patient wants critical care treatment; or
 - The CFS score suggests the person is more frail (e.g., CFS ≥5), there is uncertainty regarding the benefit of critical care organ support, and critical care advice is needed to help the decision about treatment.
- Take into account the impact of underlying pathologies, comorbidities, and severity of acute illness.[223]

Severe COVID-19: supportive care

Oxygen

- Give supplemental oxygen at a rate of 5 L/minute to patients with severe acute respiratory infection and respiratory distress, hypoxaemia, shock, or SpO₂ <90%. [3] [224] Titrate flow rates to reach a target SpO₂ ≥94% during resuscitation. [3] Use a face mask with a reservoir bag (at 10-15 L/minute) if the patient is in critical condition.
- Once the patient is stable, the target SpO₂ is >90% in children and non-pregnant adults, and ≥92% to 95% in pregnant women. Nasal prongs or a nasal cannula are preferred in young children. [3] Some guidelines recommend that SpO₂ should be maintained no higher than 96%. [224]
- Some locations may recommend different targets in order to support prioritisation of oxygen flow for the most severely ill patients in hospital. For example, NHS England recommends a target of 92% to 95% (or 90% to 94% if clinically appropriate). [225]

Intravenous fluids

- Manage fluids conservatively in adults and children with severe acute respiratory infection when there is no evidence of shock as aggressive fluid resuscitation may worsen oxygenation. [3]

Antimicrobials

- Start empirical antimicrobials to cover other potential bacterial pathogens that may cause respiratory infection according to local protocols. Give within 1 hour of initial patient assessment for patients with suspected sepsis. Choice of empirical antimicrobials should be based on the clinical diagnosis, and local epidemiology and susceptibility data. Consider treatment with a neuraminidase inhibitor until influenza is ruled out. De-escalate empirical therapy based on microbiology results and clinical judgement. [3]

- Some patients with severe illness may require continued antimicrobial therapy once COVID-19 has been confirmed depending on the clinical circumstances.

Monitoring

- Monitor patients closely for signs of clinical deterioration, such as rapidly progressive respiratory failure and sepsis, and immediately start general supportive care interventions as indicated (e.g., haemodialysis, vasopressor therapy, fluid resuscitation, ventilation, antimicrobials) as appropriate.[3]

Prevention of complications

- Implement standard interventions to prevent complications associated with critical illness.[3] Complications such as acute respiratory distress syndrome (ARDS), sepsis, and septic shock should be managed according to usual protocols. See our Complications section for more information.

Palliative care

- Follow local palliative care guidelines for patients in the last days and hours of life.

Severe COVID-19: symptom management

Managing fever

- Guidelines recommend an antipyretic for the relief of fever.[3] [224] However, current evidence does not support routine antipyretic administration to treat fever in acute respiratory infections.[226] If used, these drugs should only be taken when necessary while symptoms are present.
- Some clinicians have suggested that non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen could worsen COVID-19 or have a negative impact on disease outcome based on anecdotal reports.[227] There is currently no strong evidence to support this. The European Medicines Agency, the US Food and Drug Administration, the Commission of Human Medicines, and the WHO do not recommend avoiding NSAIDs in COVID-19 when clinically indicated.[228] [229] [230] [231] However, the National Institute for Health and Care Excellence in the UK recommends paracetamol as the drug of choice until there is more information available.[222] [232]

Managing cough

- Advise patients to avoid lying on their back as this makes coughing ineffective. Use simple measures first (e.g., a teaspoon of honey in patients aged 1 year and older). Consider short-term use of an oral opioid in adults if the cough is distressing to the patient.[222]

Managing breathlessness

- Keep the room cool, and encourage relaxation, breathing techniques, and changing body positions. Identify and treat any reversible causes of breathlessness (e.g., pulmonary oedema). Consider a trial of oxygen, if available. Consider an opioid and benzodiazepine combination in patients with moderate to severe breathlessness or patients who are distressed.[222]

Managing anxiety, delirium, and agitation

- Identify and treat any reversible causes (e.g., offer reassurance, treat hypoxia). Consider a benzodiazepine for the management of anxiety or agitation. Consider haloperidol or a phenothiazine for the management of delirium.[222]

Severe COVID-19: high flow nasal oxygen/non-invasive ventilation

Provide advanced oxygen or non-invasive ventilation in patients who are deteriorating and failing to respond to standard oxygen therapy.[3] Follow local infection prevention and control procedures to prevent transmission to healthcare workers, especially when performing aerosol-generating procedures. Novel methods to protect clinicians without access to standard personal protective equipment during aerosol-generating procedures have been suggested (e.g., aerosol box, plastic drapes, helmet devices).[233] [234] [235]

Consider a trial of high-flow nasal oxygen or non-invasive ventilation (e.g., continuous positive airway pressure [CPAP] or bilevel positive airway pressure [BiPAP]) in patients with hypoxaemic respiratory failure.[3] [224] These procedures may avoid the need for intubation and mechanical ventilation; however, they have a higher risk of aerosol generation.[236]

There is ongoing debate about the optimal mode of respiratory support before mechanical ventilation, and you should check local guidelines for preferred options.[237] NHS England recommends CPAP as the preferred form of non-invasive ventilation, and doesn't advocate the use of high-flow nasal oxygen based on a lack of efficacy, oxygen use, and infection spread. High-flow oxygen delivery can place a strain on oxygen supplies with the risk of site supply failure. Early CPAP may provide a bridge to invasive mechanical ventilation. Use of BiPAP should be reserved for patients with hypercapnic acute or chronic ventilatory failure.[238]

Monitor patients closely for clinical deterioration that could result in the need for urgent intubation.[3] Patients with lower PaO₂/fraction of inspired oxygen (FiO₂) were more likely to experience failure with high-flow nasal oxygen and require ventilation in one study.[239]

Severe COVID-19: mechanical ventilation

Consider intubation and mechanical ventilation in patients who are acutely deteriorating despite advanced oxygen/non-invasive ventilatory support measures. Two-thirds of patients who required critical care in the UK had mechanical ventilation within 24 hours of admission.[240]

Endotracheal intubation should be performed by an experienced provider using airborne precautions. Young children, or adults who are obese or pregnant, may desaturate quickly during intubation and therefore require pre-oxygenation with 100% FiO₂ for 5 minutes.[3]

Patients who fit standard acute respiratory distress syndrome criteria should receive a lung-protective, low tidal volume/low inspiratory pressure ventilation strategy (lower targets are recommended in children). A higher positive end-expiratory pressure (PEEP) strategy is preferred over a lower PEEP strategy.[3] [224]

Italian clinicians have warned that protocol-driven ventilator use may be causing lung injury in some patients, and that ventilator settings should be based on physiological findings rather than using standard protocols. They note that many COVID-19 patients have an atypical presentation, showing a dissociation between well-preserved lung mechanics and the severity of hypoxaemia.[241] They have identified two disease phenotypes for COVID-19 pneumonia:

- Type L: low elastance; low ventilation-to-perfusion ratio; low lung weight; low lung recruitability (the near normal compliance may explain why some patients present without dyspnoea)
- Type H: high elastance; high right-to-left shunt; high lung weight; high lung recruitability.

Patients may initially present with the type L phenotype, which may remain unchanged for a period of time and then either improve or worsen, or it may transition to type H. Type H pattern fits the severe acute respiratory distress syndrome criteria, and only 20% to 30% of patients in the case series of 150 patients displayed this phenotype. Type L appeared to be more common (more than 50% of patients) in this series.[\[242\]](#)

High PEEP may have a detrimental effect on patients with normal compliance, and a lower PEEP strategy should be considered in these patients. NHS England recommends a low PEEP strategy in patients with normal compliance where recruitment may not be required.[\[243\]](#) You should consult an intensivist with experience in treating COVID-19 patients for more detailed guidance.

Consider prone ventilation in patients with persistent severe hypoxic failure.[\[3\]](#) [\[224\]](#) [\[244\]](#) Pregnant women may benefit from being placed in the lateral decubitus position.[\[3\]](#) A small cohort study of 12 patients in Wuhan City, China, with COVID-19-related acute respiratory distress syndrome suggests that spending periods of time in the prone position may improve lung recruitability.[\[245\]](#)

A trial of an inhaled pulmonary vasodilator may be considered in adults who have severe acute respiratory distress syndrome and hypoxaemia despite optimising ventilation. Lung recruitment manoeuvres are suggested, but staircase recruitment manoeuvres are not recommended.[\[224\]](#)

Severe COVID-19: extracorporeal membrane oxygenation

Some patients may require extracorporeal membrane oxygenation (ECMO) according to availability and expertise if the above methods fail.[\[3\]](#) [\[224\]](#) [\[244\]](#) [\[246\]](#) However, ECMO is not suitable for all patients, and only those who meet certain inclusion criteria may be considered for ECMO.[\[247\]](#) Preliminary data on the use of ECMO in patients with COVID-19 is not promising.[\[248\]](#)

Severe COVID-19: experimental therapies

Corticosteroids

- Corticosteroids are being used in some patients with COVID-19; however, they have been found to be ineffective and are not recommended.[\[19\]](#) [\[249\]](#) [\[250\]](#)
- The WHO (as well as other international pneumonia guidelines) does not routinely recommend systemic corticosteroids for the treatment of viral pneumonia or acute respiratory distress syndrome unless they are indicated for another reason.[\[3\]](#)
- Surviving Sepsis Campaign guidelines on the treatment of critically ill patients with COVID-19 suggest that adults with acute respiratory distress syndrome who are receiving mechanical ventilation should receive corticosteroids, although this recommendation is based on weak evidence.[\[224\]](#)
- The Infectious Diseases Society of America recommends against the use of corticosteroids in patients with COVID-19, except in the context of a clinical trial.[\[251\]](#)
- A meta-analysis of over 5000 patients found that corticosteroid treatment in patients with COVID-19 was associated with longer hospital stays and a higher rate of mortality.[\[252\]](#)
- A randomised controlled trial investigating the use of corticosteroids in patients with COVID-19 is in progress.[\[253\]](#)

Other experimental therapies

- Drug therapies (e.g., antivirals) are being used in patients with COVID-19; however, unlicensed or experimental treatments should only be administered in the context of ethically-approved clinical trials.^[3] See our Emerging section for more information about these treatments.

Mild COVID-19 with risk factors

Patients with mild illness who have risk factors for poor outcomes (i.e., age >60 years, presence of comorbidities) should also be prioritised for hospital admission.^[211] These patients should be managed in the same way as severe COVID-19 (above) depending on the clinical presentation.

Mild COVID-19 without risk factors

All laboratory-confirmed cases, regardless of severity, should be managed in a healthcare facility where possible. In situations where this is not possible, patients with mild illness and no risk factors (i.e., age >60 years, presence of comorbidities) can be isolated in non-traditional facilities (e.g., repurposed hotels or stadiums) or at home. This will depend on guidance from local health authorities and available resources. Forced quarantine orders are being used in some countries.^[211]

Home care can be considered when the patient can be cared for by family members and follow-up with a healthcare provider or public health personnel is possible. The decision requires careful clinical judgement and should be informed by an assessment of the patient's home environment.^[211]

Patients and household members should follow appropriate infection prevention and control measures while the patient is in home care. Detailed guidance is available from the WHO and CDC:

- [\[WHO: home care for patients with COVID-19 presenting with mild symptoms and management of their contacts\]](#)
- [\[CDC: interim guidance for implementing home care of people not requiring hospitalization for coronavirus disease 2019 \(COVID-19\)\]](#)

Recommend symptomatic therapies (as per the recommendations above) and advise patients to keep hydrated but not to take too much fluid as this can worsen oxygenation. Advise patients to improve air circulation by opening a window or door (fans can spread infection and should not be used).^[222]

Monitor patients closely and advise them to seek medical care if symptoms worsen as mild illness can rapidly progress to lower respiratory tract disease. Two negative test results (on samples collected at least 24 hours apart) are required before the patient can be released from home isolation. If testing is not possible, the patient should remain in isolation for an additional 2 weeks after symptoms resolve.^[211] Guidance on when to stop isolation depends on local circumstances and may differ between countries; consult local guidelines.

Pregnancy and breastfeeding

Pregnant women should be managed by a multidisciplinary team, including obstetric, perinatal, neonatal, and intensive care specialists, as well as mental health and psychosocial support. There is no evidence to suggest that pregnant women are more likely to contract COVID-19, or present with increased risk of severe illness or fetal compromise. Data on pregnant women with COVID-19 are limited; however, pregnant women can generally be treated with the same supportive therapies detailed above, taking into account the physiological changes that occur with pregnancy.^[3] ^[254]

Antenatal care

- Pregnant women have been placed in the vulnerable category in the UK and are advised to engage with strict social distancing measures, particularly if they are above 28 weeks' gestation.[255]
- Remote consultations and self-monitoring of blood pressure may be recommended in healthy women whenever possible to reduce the number of hospital visits.[255] [256]
- Routine antenatal care appointments should be delayed in patients with suspected or confirmed COVID-19 until after the recommended period of self-isolation. More urgent appointments require a senior decision on urgency and potential risks and benefits.[255]

Location of care

- Manage suspected and confirmed cases in a hospital setting with appropriate maternal and fetal monitoring whenever possible. Women with severe illness or complications may require admission to an intensive care unit. Consider home care in women with asymptomatic or mild illness, provided the patient has no signs of potentially severe illness (e.g., breathlessness, haemoptysis, new chest pain/pressure, anorexia, dehydration, confusion), no comorbidities, and no obstetric issues; the patient is able to care for herself; and monitoring and follow-up is possible.[156] [256] [257]
- The American College of Obstetricians and Gynecologists has published an algorithm to help decide whether hospital admission or home care is more appropriate. [ACOG: outpatient assessment and management for pregnant women with suspected or confirmed novel coronavirus (COVID-19)]

Delivery

- Choice of delivery and timing should be individualised based on gestational age, as well as maternal, fetal, and delivery conditions. Induction of labour and vaginal delivery is preferred in pregnant women with confirmed COVID-19 infection to avoid unnecessary surgical complications; however, an emergency caesarean delivery may be required if medically justified (e.g., in patients with complications such as sepsis or if there is fetal distress). A negative pressure isolation room is recommended in confirmed cases for labour, delivery, and neonatal care, if possible.[3] [156] [257]
- Corticosteroid therapy may be considered in women who are at risk of preterm birth from 24 to 37 weeks' gestation for fetal lung maturation, but caution is advised as this could potentially worsen the maternal clinical condition, and the decision should be made in conjunction with the multidisciplinary team.[3] [156] [257] [258]

Newborns and breastfeeding

- Babies born to mothers with suspected or confirmed infection should be considered a person under investigation and tested at 24 hours and 48 hours after birth.[259]
- The WHO recommends that mothers and infants should remain together when possible, and breastfeeding should be encouraged while applying appropriate infection prevention and control measures (e.g., performing hand hygiene before and after contact with the baby, wearing a mask while breastfeeding).[3] However, the CDC recommends that temporary separation of the mother and baby should be considered on a case-by-case basis using shared-decision making between the mother and the clinical team, at least until the mother's transmission-based precautions are discontinued. It recommends that mothers who intend to breastfeed should be encouraged to express their breast milk using a dedicated breast pump and using appropriate infection prevention and control measures in order to maintain milk supply. Expressed milk should be fed to the

newborn by a healthy carer.[260] Separation appears to be the best option for mothers who are severely or critically ill.[156] Consult local guidelines for specific recommendations.

- After discharge, advise mothers with COVID-19 to practice prevention measures (e.g., distance, hand hygiene, respiratory hygiene/mask) for newborn care until they are afebrile for 72 hours without use of antipyretics and at least 7 days have passed since symptoms first appeared. A newborn with documented infection requires close outpatient follow-up after discharge.[259]

Management of comorbidities

Data on the management of comorbidities in patients with COVID-19 is limited.[261] Tailor the management of critical illness to the patient's comorbidities (e.g., decide which chronic therapies should be continued and which therapies should be temporarily stopped, monitor for drug-drug interactions).[3]

Cardiovascular disease

- There is insufficient clinical or scientific evidence to determine how to manage hypertension in patients with COVID-19. There have been advocates for both the use and cessation of ACE inhibitors or angiotensin-II receptor antagonists in patients with hypertension due to theoretical concerns of increased expression of ACE2 in these patients.[262] [263] However, professional societies from all over the world recommend continuing these drugs unless clinically indicated.[264] Individualised treatment decisions should be made according to the haemodynamic status and clinical presentation of each patient. A small retrospective study of patients with COVID-19 and hypertension in China found that ACE inhibitors/angiotensin-II receptor antagonists may attenuate the inflammatory response in patients with severe illness and improve clinical outcomes; however, further research is required.[265]
- [\[BMJ: drugs and the renin-angiotensin system in covid-19\]](#)
- [\[Centre for Evidence-Based Medicine: angiotensin converting enzyme \(ACE\) inhibitors and angiotensin receptor blockers in COVID-19\]](#)

Asthma

- Advise patients to continue taking their regular prescribed medications in line with their asthma action plan to ensure their condition is as stable as possible. Advise patients to follow their asthma action plan in the event of an exacerbation. There is currently no evidence that inhaled/oral corticosteroids or biological agents for asthma increase the risk of getting COVID-19.[266] However, there is some evidence that inhaled corticosteroids may increase the risk of some respiratory infections in patients with asthma, and there is uncertainty over whether higher doses increase the risk of pneumonia.[267]

Cancer

- In patients who require systemic anticancer treatment, take into account: the level of immunosuppression associated with cancer types and individual treatments, as well as any other patient-specific factors; resource issues; and balancing the risk of not treating cancer optimally versus the risk of the patient being immunosuppressed and becoming severely ill from COVID-19.[208] Radiotherapy should be avoided if the evidence suggests there is little to no benefit or if alternative treatment is available, or should be deferred if clinically appropriate.[268] Clinicians should consider the severity of disease and post-transplant risks of COVID-19 when deciding on treatment plans for haematopoietic stem cell transplantation.[269]

Chronic kidney disease

- The impact of COVID-19 on chronic kidney disease has not been reported as yet; however, there are challenges for patients with suspected or confirmed COVID-19 infection who are on dialysis. Guidelines for patients on dialysis and for dialysis units have been developed.[270] [271] [272] [273] [274]

Inflammatory bowel disease

- There is a lack of data about COVID-19 in patients with inflammatory bowel disease; however, guidelines have been developed. Patients who are already on treatment should continue their current drug regimen if their disease is stable, and contact their healthcare provider to discuss suitable options during disease flares.[275] [276] [277] It has been suggested that patients should be screened for SARS-CoV-2 infection before starting therapy with corticosteroids (for flares) or biologics.[278] [279]
- Guidelines for the management of rheumatological, autoimmune, inflammatory, and metabolic bone disorders are available.[280]

Best Practice is currently producing a new topic on the management of co-existing conditions in the context of COVID-19. This will be launching soon.

Treatment details overview

Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups: [see disclaimer](#)

Initial		(summary)
suspected COVID-19		
	1st	isolation and infection prevention and control procedures
	plus	empirical antimicrobials
	plus	monitoring
	adjunct	supportive care
	adjunct	antipyretic
	adjunct	antitussive

Acute		(summary)	
confirmed COVID-19			
<ul style="list-style-type: none"> ■ severe illness; mild illness with risk factors 	1st	hospital admission	
	plus	infection prevention and control procedures	
	plus	treatment and care planning	
	plus	monitoring	
	adjunct	supportive care	
	adjunct	empirical antimicrobials	
	adjunct	antipyretic	
	adjunct	antitussive	
	adjunct	advanced oxygen/ventilatory support	
	adjunct	tailor management to comorbidities	
	adjunct	experimental therapies	
<ul style="list-style-type: none"> ■ mild illness with no risk factors 	1st	isolation in non-traditional facility or at home	
	plus	monitoring	
	plus	supportive care	
	adjunct	antipyretic	
	adjunct	antitussive	

Treatment options

Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups: [see disclaimer](#)

Initial

suspected COVID-19

- 1st isolation and infection prevention and control procedures**
- » Immediately isolate all suspected cases in an area separate from other patients, and implement appropriate infection prevention and control procedures. Suspected cases should be given a mask and kept at least 1 metre (3 feet) from other suspected cases. It is important to note that recommended distances differ between countries and you should consult local guidance.
 - » [\[BMJ: covid-19 - PPE guidance\]](#)
 - » Detailed guidance is available from the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC):
 - » [\[WHO: infection prevention and control during health care when COVID-19 is suspected\]](#)
 - » [\[CDC: interim infection prevention and control recommendations for patients with suspected or confirmed coronavirus disease 2019 \(COVID-19\) in healthcare settings\]](#)
 - » COVID-19 is a notifiable disease; report all suspected cases to your local health authorities.
 - » Pregnant women should be managed by a multidisciplinary team, including obstetric, perinatal, neonatal, and intensive care specialists, as well as mental health and psychosocial support.[\[3\]](#) [\[257\]](#)
- plus empirical antimicrobials**
- Treatment recommended for ALL patients in selected patient group
- » Start empirical antimicrobials to cover other potential bacterial pathogens that may cause respiratory infection according to local protocols. Give within 1 hour of initial patient assessment for patients with suspected sepsis. Choice of empirical antimicrobials should be based on the clinical diagnosis, and local epidemiology and susceptibility data.[\[3\]](#)
 - » Consider treatment with a neuraminidase inhibitor until influenza is ruled out.[\[3\]](#)
 - » De-escalate empirical therapy based on microbiology results and clinical judgement.
- plus monitoring**

Initial

Treatment recommended for ALL patients in selected patient group

» Monitor patients closely for signs of clinical deterioration, such as rapidly progressive respiratory failure and sepsis, and immediately start general supportive care interventions as indicated (e.g., haemodialysis, vasopressor therapy, fluid resuscitation, ventilation, antimicrobials) as appropriate.[3]

adjunct supportive care

Treatment recommended for SOME patients in selected patient group

» Immediately start supportive care based on the clinical presentation if necessary.

» Oxygen: give supplemental oxygen at a rate of 5 L/minute to patients with severe acute respiratory infection and respiratory distress, hypoxaemia, shock, or SpO₂ <90%. [3] [224] Titrate flow rates to reach a target SpO₂ ≥94% during resuscitation. Use a face mask with a reservoir bag (at 10-15 L/minute) if the patient is in critical condition. Once the patient is stable, the target SpO₂ is >90% in children and non-pregnant adults, and ≥92% to 95% in pregnant women. Nasal prongs or a nasal cannula are preferred in young children.[3] Some guidelines recommend that SpO₂ should be maintained no higher than 96%. [224] Some locations may recommend different targets in order to support prioritisation of oxygen flow for the most severely ill patients in hospital. For example, NHS England recommends a target of 92% to 95% in adults in the first instance (or 90% to 94% if clinically appropriate). [225]

» Intravenous fluids: manage fluids conservatively in adults and children with severe acute respiratory infection when there is no evidence of shock as aggressive fluid resuscitation may worsen oxygenation.[3]

adjunct antipyretic

Treatment recommended for SOME patients in selected patient group

Primary options

» **paracetamol**: children: consult local drug formulary for guidance on dose; adults: 500-1000 mg orally every 4-6 hours when required, maximum 4000 mg/day

OR

Initial

» **ibuprofen**: children: consult local drug formulary for guidance on dose; adults: 300-600 mg orally (immediate-release) every 6-8 hours when required, maximum 2400 mg/day

» Guidelines recommend an antipyretic for the relief of fever.[3] [224] However, current evidence does not support routine antipyretic administration to treat fever in acute respiratory infections.[226] If used, these drugs should only be taken when necessary while symptoms are present.

» Some clinicians have suggested that non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen could worsen COVID-19 or have a negative impact on disease outcome based on anecdotal reports.[227] There is currently no strong evidence to support this. The European Medicines Agency, the Food and Drug Administration, the Commission of Human Medicines, and the WHO do not recommend avoiding NSAIDs in COVID-19 when clinically indicated.[228] [229] [230] [231] However, the National Institute for Health and Care Excellence in the UK recommends paracetamol as the drug of choice until there is more information available.[222] [232]

» Ibuprofen is not recommended in pregnant women (especially in the third trimester) or children <3 months of age (age cut-offs vary by country).

adjunct antitussive

Treatment recommended for SOME patients in selected patient group

Primary options

» **codeine phosphate**: 15-30 mg orally every 4 hours when required initially (up to 4 doses/day), increase to 30-60 mg every 6 hours when required if necessary, maximum 240 mg/day

Secondary options

» **morphine sulfate**: adults: 2.5 to 5 mg orally every 4 hours when required initially, increase to 5-10 mg every 4 hours when required if necessary

» Advise patients to avoid lying on their back as this makes coughing ineffective.

Initial

- » Use simple measures first (e.g., a teaspoon of honey in patients aged 1 year and older).
- » Consider short-term use of an oral opioid in adults if the cough is distressing to the patient. Codeine (linctus or tablet) is the preferred first-line option, with oral morphine solution reserved as a second-line option.[\[222\]](#)

Acute

confirmed COVID-19

- severe illness; mild illness with risk factors

1st hospital admission

- » Promptly admit patients with pneumonia or acute respiratory distress to an appropriate healthcare facility. Patients with impending or established respiratory failure should be admitted to an intensive care unit.[3]
- » Patients with mild illness who have risk factors for poor outcomes (i.e., age >60 years, presence of comorbidities) should also be prioritised for hospital admission when possible.[211]
- » Manage suspected and confirmed cases in pregnant women in a hospital setting with appropriate maternal and fetal monitoring whenever possible. Women with severe illness or complications may require admission to an intensive care unit.[156] [256] [257] Pregnant women should be managed by a multidisciplinary team, including obstetric, perinatal, neonatal, and intensive care specialists, as well as mental health and psychosocial support.[3] [257]

plus infection prevention and control procedures

Treatment recommended for ALL patients in selected patient group

- » Immediately isolate all confirmed cases in an area separate from other patients, and implement appropriate infection prevention and control procedures.
- » [BMJ: covid-19 - PPE guidance]
- » Detailed guidance is available from the WHO and the CDC:
- » [WHO: infection prevention and control during health care when COVID-19 is suspected]
- » [CDC: interim infection prevention and control recommendations for patients with suspected or confirmed coronavirus disease 2019 (COVID-19) in healthcare settings]
- » COVID-19 is a notifiable disease; report all confirmed cases to your local health authorities.
- » The WHO recommends that patients should remain in isolation for 2 weeks after symptoms disappear, and visitors should not be allowed until the end of this period.[220] Guidance

Acute

on when to stop isolation depends on local circumstances and may differ between countries; consult local guidelines.

plus treatment and care planning

Treatment recommended for ALL patients in selected patient group

» Assess all adults for frailty on admission to hospital, irrespective of age and COVID-19 status, using the Clinical Frailty Scale.[223] [Clinical frailty scale]

» Discuss the risks, benefits, and potential outcomes of treatment options with patients and their families, and allow them to express preferences about their management. Take their wishes and expectations into account when considering the ceiling of treatment. Use decision support tools if available. Put treatment escalation plans in place, and discuss any existing advance care plans or advance decisions to refuse treatment with patients who have pre-existing advanced comorbidities.[222]

» Involve critical care teams in discussions about admission to critical care.[223]

plus monitoring

Treatment recommended for ALL patients in selected patient group

» Monitor patients closely for signs of clinical deterioration, such as rapidly progressive respiratory failure and sepsis, and immediately start general supportive care interventions as indicated (e.g., haemodialysis, vasopressor therapy, fluid resuscitation, ventilation, antimicrobials) as appropriate.[3]

adjunct supportive care

Treatment recommended for SOME patients in selected patient group

» Immediately start supportive care, if necessary.

» Oxygen: give supplemental oxygen at a rate of 5 L/minute to patients with severe acute respiratory infection and respiratory distress, hypoxaemia, shock, or SpO₂ <90%. [3] [224] Titrate flow rates to reach a target SpO₂ ≥94% during resuscitation. Use a face mask with a reservoir bag (at 10-15 L/minute) if the patient is in critical condition. Once the patient is stable, the target SpO₂ is >90% in children and non-pregnant adults, and ≥92% to 95% in pregnant women. Nasal prongs or a nasal cannula are preferred in young children.[3] Some guidelines

Acute

recommend that SpO₂ should be maintained no higher than 96%.^[224] Some locations may recommend different targets in order to support prioritisation of oxygen flow for the most severely ill patients in hospital. For example, NHS England recommends a target of 92% to 95% in adults in the first instance (or 90% to 94% if clinically appropriate).^[225]

» Intravenous fluids: manage fluids conservatively in adults and children with severe acute respiratory infection when there is no evidence of shock as aggressive fluid resuscitation may worsen oxygenation.^[3]

» Managing breathlessness: keep the room cool, and encourage relaxation, breathing techniques, and changing body positions. Identify and treat any reversible causes of breathlessness (e.g., pulmonary oedema). Consider a trial of oxygen, if available. Consider an opioid and benzodiazepine combination in patients with moderate to severe breathlessness or patients who are distressed.^[222]

» Managing anxiety, delirium, and agitation: identify and treat any reversible causes (e.g., offer reassurance, treat hypoxia). Consider a benzodiazepine for the management of anxiety or agitation. Consider haloperidol or a phenothiazine for the management of delirium.^[222]

» Implement standard interventions to prevent complications associated with critical illness.^[3]

adjunct empirical antimicrobials

Treatment recommended for SOME patients in selected patient group

» Patients with severe illness may require continued antimicrobial therapy once COVID-19 has been confirmed depending on the clinical circumstances.

adjunct antipyretic

Treatment recommended for SOME patients in selected patient group

Primary options

» **paracetamol**: children: consult local drug formulary for guidance on dose; adults: 500-1000 mg orally every 4-6 hours when required, maximum 4000 mg/day

OR

Acute

» **ibuprofen**: children: consult local drug formulary for guidance on dose; adults: 300-600 mg orally (immediate-release) every 6-8 hours when required, maximum 2400 mg/day

» Guidelines recommend an antipyretic for the relief of fever.[3] [224] However, current evidence does not support routine antipyretic administration to treat fever in acute respiratory infections.[226] If used, these drugs should be taken only when necessary while symptoms are present.

» Some clinicians have suggested that non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen could worsen COVID-19 or have a negative impact on disease outcome based on anecdotal reports.[227] There is currently no strong evidence to support this. The European Medicines Agency, the Food and Drug Administration, the Commission of Human Medicines, and the WHO do not recommend avoiding NSAIDs in COVID-19 when clinically indicated.[228] [229] [230] [231] However, the National Institute for Health and Care Excellence in the UK recommends paracetamol as the drug of choice until there is more information available.[222] [232]

» Ibuprofen is not recommended in pregnant women (especially in the third trimester) or children <3 months of age (age cut-offs vary by country).

adjunct antitussive

Treatment recommended for SOME patients in selected patient group

Primary options

» **codeine phosphate**: 15-30 mg orally every 4 hours when required initially (up to 4 doses/day), increase to 30-60 mg every 6 hours when required if necessary, maximum 240 mg/day

Secondary options

» **morphine sulfate**: adults: 2.5 to 5 mg orally every 4 hours when required initially, increase to 5-10 mg every 4 hours when required if necessary

» Advise patients to avoid lying on their back as this makes coughing ineffective.

Acute

» Use simple measures first (e.g., a teaspoon of honey in patients aged 1 year and older).

» Consider short-term use of an oral opioid in adults if the cough is distressing to the patient. Codeine (linctus or tablet) is the preferred first-line option, with oral morphine solution reserved as a second-line option.[222]

adjunct advanced oxygen/ventilatory support

Treatment recommended for SOME patients in selected patient group

» Provide advanced oxygen/ventilatory support in patients who are deteriorating and failing to respond to standard oxygen therapy.[3] Follow local infection prevention and control procedures to prevent transmission to healthcare workers, especially when performing aerosol-generating procedures. Novel methods to protect clinicians without access to standard personal protective equipment during aerosol-generating procedures have been suggested (e.g., aerosol box, plastic drapes, helmet devices).[233] [234] [235]

» Consider a trial of high-flow nasal oxygen or non-invasive ventilation (e.g., continuous positive airway pressure [CPAP] or bilevel positive airway pressure [BiPAP]) in patients with hypoxaemic respiratory failure.[3] [224] These procedures may avoid the need for intubation and mechanical ventilation; however, they have a higher risk of aerosol generation.[236] There is ongoing debate about the optimal mode of respiratory support before mechanical ventilation, and you should check local guidelines for preferred options.[237] NHS England recommends CPAP as the preferred form of non-invasive ventilation, and doesn't advocate the use of high-flow nasal oxygen based on a lack of efficacy, oxygen use, and infection spread. High-flow oxygen delivery can place a strain on oxygen supplies with the risk of site supply failure. Early CPAP may provide a bridge to invasive mechanical ventilation. Use of BiPAP should be reserved for patients with hypercapnic acute or chronic ventilatory failure.[238] Monitor patients closely for clinical deterioration that could result in the need for urgent intubation.[3] Patients with lower PaO₂/fraction of inspired oxygen (FiO₂) were more likely to experience failure with high-flow nasal oxygen and require ventilation in one study.[239]

» Consider intubation and mechanical ventilation in patients who are acutely deteriorating.[3] Endotracheal intubation should be performed by an experienced provider using airborne

Acute

precautions. Young children, or adults who are obese or pregnant, may desaturate quickly during intubation and therefore require pre-oxygenation with 100% FiO₂ for 5 minutes.[3] Patients who fit standard acute respiratory distress syndrome criteria should receive a lung-protective, low tidal volume/low inspiratory pressure ventilation strategy (lower targets are recommended in children). A higher positive end-expiratory pressure (PEEP) strategy is preferred over a lower PEEP strategy.[3] [224] However, Italian clinicians have warned that protocol-driven ventilator use may be causing lung injury in some patients, and that ventilator settings should be based on physiological findings rather than using standard protocols. They note that many COVID-19 patients have an atypical presentation, showing a dissociation between well-preserved lung mechanics and the severity of hypoxaemia.[241] [242] High PEEP may have a detrimental effect on patients with normal compliance, and a lower PEEP strategy should be considered in these patients. NHS England recommends a low PEEP strategy in patients with normal compliance where recruitment may not be required.[243] You should consult an intensivist with experience in treating COVID-19 patients for more detailed guidance.

» Consider prone ventilation in patients with persistent severe hypoxic failure.[3] [224] [244] Pregnant women may benefit from being placed in the lateral decubitus position.[3] A small cohort study of 12 patients in Wuhan, China, with COVID-19-related acute respiratory distress syndrome suggests that spending periods of time in the prone position may improve lung recruitability.[245]

» A trial of an inhaled pulmonary vasodilator may be considered in adults who have severe acute respiratory distress syndrome and hypoxaemia despite optimising ventilation. Lung recruitment manoeuvres are suggested, but staircase recruitment manoeuvres are not recommended.[224]

» Some patients may require extracorporeal membrane oxygenation (ECMO) according to availability and expertise if the above methods fail.[3] [224] [244] However, ECMO is not suitable for all patients, and only those who meet certain inclusion criteria may be considered for ECMO.[247] Preliminary data on the use of ECMO in patients with COVID-19 is not promising.[248]

Acute

adjunct tailor management to comorbidities

Treatment recommended for SOME patients in selected patient group

» Tailor the management of critical illness to the patient's comorbidities (e.g., decide which chronic therapies should be continued and which therapies should be temporarily stopped, monitor for drug-drug interactions).[3]

» Cardiovascular disease: there is insufficient clinical or scientific evidence to determine how to manage hypertension in patients with COVID-19. There have been advocates for both the use and cessation of ACE inhibitors or angiotensin-II receptor antagonists in patients with hypertension due to theoretical concerns of increased expression of ACE2 in these patients.[262] [263] However, professional societies from all over the world recommend continuing these drugs unless clinically indicated.[264] Individualised treatment decisions should be made according to the haemodynamic status and clinical presentation of each patient.

» [BMJ: drugs and the renin-angiotensin system in covid-19]

» [Centre for Evidence-Based Medicine: angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers in COVID-19]

» Asthma: advise patients to continue taking their regular prescribed medications in line with their asthma action plan to ensure their condition is as stable as possible. Advise patients to follow their asthma action plan in the event of an exacerbation. There is currently no evidence that inhaled/oral corticosteroids or biological agents for asthma increase the risk of getting COVID-19.[266] However, there is some evidence that inhaled corticosteroids may increase the risk of some respiratory infections in patients with asthma, and there is uncertainty over whether higher doses increase the risk of pneumonia.[267]

» Cancer: in patients who require systemic anticancer treatment, take into account the following: the level of immunosuppression associated with cancer types and individual treatments, as well as any other patient-specific factors; resource issues; and balancing the risk of not treating cancer optimally versus the risk of the patient being immunosuppressed and becoming severely ill from COVID-19.[208]

Acute

Radiotherapy should be avoided if the evidence suggests there is little to no benefit or if alternative treatment is available, or should be deferred if clinically appropriate.[268] Clinicians should consider the severity of disease and post-transplant risks of COVID-19 when deciding on treatment plans for haematopoietic stem cell transplantation.[269]

» Chronic kidney disease: the impact of COVID-19 on chronic kidney disease has not been reported as yet; however, there are challenges for patients with suspected or confirmed COVID-19 infection who are on dialysis. Guidelines for patients on dialysis and for dialysis units have been developed.[270] [271] [272] [273] [274]

» Inflammatory bowel disease: there is a lack of data about COVID-19 in patients with inflammatory bowel disease; however, guidelines have been developed. Patients who are already on treatment should continue their current drug regimen if their disease is stable, and contact their healthcare provider to discuss suitable options during disease flares.[275] [276] [277] It has been suggested that patients should be screened for SARS-CoV-2 infection before starting therapy with corticosteroids (for flares) or biologics.[278] [279]

» Guidelines for the management of rheumatological, autoimmune, inflammatory, and metabolic bone disorders are available.[280]

adjunct experimental therapies

Treatment recommended for SOME patients in selected patient group

» Consider using experimental drug therapies. Antivirals and other drugs are being used in patients with COVID-19; however, unlicensed or experimental treatments should only be administered in the context of ethically-approved clinical trials.[3] See the Emerging section for more information about these treatments.

isolation in non-traditional facility or at home

» Patients with mild illness and no risk factors (i.e., age >60 years, presence of comorbidities) can be isolated in non-traditional facilities (e.g., repurposed hotels or stadiums) or at home when management in a healthcare facility is not possible. This will depend on guidance from local health authorities and available

■ **mild illness with no risk factors**

1st

Acute

resources.[211] Forced quarantine orders are being used in some countries.

» Home care can be considered when the patient can be cared for by family members and follow-up with a healthcare provider or public health personnel is possible. The decision requires careful clinical judgement and should be informed by an assessment of the patient's home environment.[211]

» Consider home care in pregnant women with asymptomatic or mild illness, provided the patient has no signs of potentially severe illness (e.g., breathlessness, haemoptysis, new chest pain/pressure, anorexia, dehydration, confusion), no comorbidities, and no obstetric issues; the patient is able to care for herself; and monitoring and follow-up is possible.[156] [256] [257]

» Patients and household members should follow appropriate infection prevention and control measures. Detailed guidance is available from the WHO and the CDC:

» [WHO: home care for patients with COVID-19 presenting with mild symptoms and management of their contacts]

» [CDC: interim guidance for implementing home care of people not requiring hospitalization for coronavirus disease 2019 (COVID-19)]

» Two negative test results (on samples collected at least 24 hours apart) are required before the patient can be released from home isolation. If testing is not possible, the patient should remain in isolation for an additional 2 weeks after symptoms resolve.[211] Guidance on when to stop isolation depends on local circumstances and may differ between countries; consult local guidelines.

plus monitoring

Treatment recommended for ALL patients in selected patient group

» Monitor patients closely and advise them to seek medical care if symptoms worsen as mild illness can rapidly progress to lower respiratory tract disease.

» Ultrasound fetal surveillance is recommended every 2 weeks in pregnant women.[257]

plus supportive care

Treatment recommended for ALL patients in selected patient group

Acute

» Advise patients to keep hydrated but not to take too much fluid as this can worsen oxygenation.[211]

» Advise patients to improve air circulation by opening a window or door (fans can spread infection and should not be used).[222]

adjunct antipyretic

Treatment recommended for SOME patients in selected patient group

Primary options

» **paracetamol**: children: consult local drug formulary for guidance on dose; adults: 500-1000 mg orally every 4-6 hours when required, maximum 4000 mg/day

» **ibuprofen**: children: consult local drug formulary for guidance on dose; adults: 300-600 mg orally (immediate-release) every 6-8 hours when required, maximum 2400 mg/day

» Guidelines recommend an antipyretic for the relief of fever.[3] However, current evidence does not support routine antipyretic administration to treat fever in acute respiratory infections.[226] If used, these drugs should only be taken when necessary while symptoms are present.

» Some clinicians have suggested that non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen could worsen COVID-19 or have a negative impact on disease outcome based on anecdotal reports.[227] There is currently no strong evidence to support this. The European Medicines Agency, the Food and Drug Administration, the Commission of Human Medicines, and the WHO do not recommend avoiding NSAIDs in COVID-19 when clinically indicated.[228] [229] [230] [231] However, the National Institute for Health and Care Excellence in the UK recommends paracetamol as the drug of choice until there is more information available.[222] [232]

» Ibuprofen is not recommended in pregnant women (especially in the third trimester) or children <3 months of age (age cut-offs vary by country).

adjunct antitussive

Treatment recommended for SOME patients in selected patient group

Primary options

Acute

» **codeine phosphate**: 15-30 mg orally every 4 hours when required initially (up to 4 doses/day), increase to 30-60 mg every 6 hours when required if necessary, maximum 240 mg/day

Secondary options

» **morphine sulfate**: adults: 2.5 to 5 mg orally every 4 hours when required initially, increase to 5-10 mg every 4 hours when required if necessary

- » Advise patients to avoid lying on their back as this makes coughing ineffective.
- » Use simple measures first (e.g., a teaspoon of honey in patients aged 1 year and older).
- » Consider short-term use of an oral opioid in adults if the cough is distressing to the patient. Codeine (linctus or tablet) is the preferred first-line option, with oral morphine solution reserved as a second-line option.^[222]

Emerging

Introduction

No treatments have been approved or shown to be safe and effective for the treatment of COVID-19. However, there are several treatments being used off-label (use of a licensed medication for an indication that has not been approved by a national drug regulatory authority), on a compassionate-use basis, or as part of a randomised controlled trial.[281] [282] It is important to note that there may be serious adverse effects associated with these drugs, and that these adverse effects may overlap with the clinical manifestations of COVID-19. These drugs may also increase the risk of death in an older patient or a patient with an underlying health condition. For example, chloroquine/hydroxychloroquine, azithromycin, and lopinavir/ritonavir are all potentially associated with an increased risk of cardiac death.[283] The World Health Organization (WHO) and its partners have launched the Solidarity trial, a large international study to compare different treatments and ensure clear evidence of which treatments are most effective. The study will have five arms: standard of care; remdesivir; lopinavir/ritonavir; lopinavir/ritonavir plus interferon beta; and chloroquine.[284] [WHO: off-label use of medicines for COVID-19]

Chloroquine and hydroxychloroquine

Chloroquine and hydroxychloroquine are oral drugs that have been used for the prophylaxis and treatment of malaria, and the treatment of certain autoimmune conditions such as rheumatoid arthritis and systemic lupus erythematosus. Both drugs have in vitro activity against SARS-CoV-2, with hydroxychloroquine having relatively higher potency.[285] [286] They are being trialled in patients for the treatment of mild to severe COVID-19.[287] [288] [289] They are also being trialled for prevention and post-exposure prophylaxis in the healthcare setting.[290] [291] Initial data is promising, but is currently limited. A small randomised controlled trial found that hydroxychloroquine (with or without azithromycin) was efficient in reducing viral nasopharyngeal carriage of SARS-CoV-2 in 3 to 6 days in most patients.[292] However, this trial has been criticised for its limitations, and results from a similar trial could not replicate these findings.[293] [294] Another randomised trial in 62 patients in China found that hydroxychloroquine may shorten time to clinical recovery (in terms of resolution of fever and cough, and improvement of pneumonia on computed tomographic imaging); however, this study has not been peer reviewed as yet.[295] Early results from the largest randomised controlled trial completed so far of 150 people in China found that the overall 28-day negative conversion rate was not significantly different between patients who received hydroxychloroquine and those who received standard of care. However, addition of hydroxychloroquine led to more rapid normalisation of C-reactive protein levels and recovery of baseline lymphopenia, which may be important. The time to alleviation of symptoms was shorter compared with standard of care in the subgroup of patients who did not receive antiviral treatment in the post-hoc analysis. The rate of adverse effects was higher in the hydroxychloroquine group (diarrhoea being the most common adverse effect). This study has not been peer reviewed yet and has several limitations (e.g., delay between symptom onset and starting treatment, inclusion of other antiviral therapies in the standard of care group).[296] Caution is recommended with the dosing regimen used for chloroquine due to the risk of chloroquine poisoning.[297] Hydroxychloroquine has similar therapeutic effects to chloroquine, but fewer adverse effects, is considered safe in pregnancy, and is more readily available in some countries.[298] Both drugs must be used with caution in patients with pre-existing cardiovascular disease due to the risk of arrhythmias.[299] Guidelines in China and Italy recommend these drugs for the treatment of COVID-19; however, this is based on weak evidence.[300] Surviving Sepsis Campaign guidelines concluded that there is insufficient evidence to offer any recommendation on use of these drugs in the intensive care unit.[224] The American Thoracic Society recommends that either drug may be used on a case-by-case basis provided the patient's condition is severe enough to warrant investigational therapy, the benefits and risks of treatment are discussed with the patient, data is collected on outcomes, and the drug is not in short supply.[244] The European Medicines Agency (EMA) has stressed that these drugs have not been shown to be effective in treating COVID-19 as yet, and should only be used in the context of clinical trials or emergency-use programmes.[301] In the US, the Food and Drug Administration (FDA) has granted an emergency-use authorisation for chloroquine and hydroxychloroquine to treat patients when a clinical trial is not available or participation is not feasible.[302] There is currently no strong evidence of efficacy of hydroxychloroquine or chloroquine in the treatment or prevention of COVID-19. [Centre for Evidence-Based Medicine: hydroxychloroquine for COVID-19 - what do the clinical trials tell us?]

Remdesivir (GS-5734®)

A novel, investigational, intravenous nucleoside analogue with broad antiviral activity that shows in vitro activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clinical trials with remdesivir have started in patients with mild to severe COVID-19.[285] [303] [304] [305] [306] [307] [308] It has been used on a compassionate-use basis in areas where clinical trials are not available; however, the manufacturer has paused access to the drug via this route due to overwhelming demand while they transition to an expanded access programme. Exceptions will be made for patients with severe illness, and pregnant women and children with confirmed infection.[309] It appears to be safe to use in pregnancy.[254] The EMA has published recommendations on compassionate use of remdesivir for COVID-19.[310] Early results from one trial of patients treated with remdesivir on a compassionate-use basis indicated that approximately two-thirds of patients showed signs of clinical improvement (68% of patients had an improvement in oxygen support requirements); however, the study had no control arm and the majority of patients reported adverse effects.[311]

Lopinavir/ritonavir

An oral antiretroviral protease inhibitor currently approved for the treatment of HIV infection. Lopinavir/ritonavir has been used in clinical trials for the treatment of COVID-19. Results from one small case series found that evidence of clinical benefit with lopinavir/ritonavir was equivocal.[312] A randomised controlled trial of approximately 200 patients in China found that treatment with lopinavir/ritonavir was not beneficial compared with standard care alone (primary outcome was time to improvement) in hospitalised patients with severe COVID-19.[313] It is considered safe in pregnancy.[254] There is currently no strong evidence of efficacy of lopinavir/ritonavir in the treatment of COVID-19. [Centre for Evidence-Based Medicine: lopinavir/ritonavir - a rapid review of effectiveness in COVID-19]

Convalescent plasma

Convalescent plasma from patients who have recovered from viral infections has been used as a treatment in previous virus outbreaks including SARS, avian influenza, and Ebola virus infection.[314] Clinical trials to determine the safety and efficacy of convalescent plasma that contains antibodies to SARS-CoV-2 in patients with COVID-19 have started.[315] A small preliminary case series of five critically ill patients reported clinical improvement after treatment with convalescent plasma; however, this study had many limitations.[316] Another study of 10 patients with severe illness in China noted symptomatic improvement within 3 days. Viral load was undetectable within 7 days in 70% of patients. No serious adverse reactions were noted.[317] In the US, the FDA is facilitating access to COVID-19 convalescent plasma for use in patients with serious or immediately life-threatening COVID-19 infections through the process of single patient emergency investigational new drug applications, and has issued guidance for its use. The FDA is encouraging patients who have recovered (for at least 2 weeks) to donate their plasma.[318] [319] [320]

Stem cell therapy

Stem cell therapy is being investigated to treat patients with COVID-19 in clinical trials. It is thought that mesenchymal stem cells can reduce the pathological changes that occur in the lungs, and inhibit the cell-mediated immune inflammatory response.[321]

Intravenous immunoglobulin

Intravenous immunoglobulin (IVIG) is being trialled in some patients with COVID-19; however, there are no data to support this.[20] [322] Novel multi-antibody cocktail therapies are also in development for prophylaxis or treatment.[323] A retrospective study of 58 patients with severe COVID-19 found that IVIG, when used as an adjuvant treatment within 48 hours of admission, may reduce the use of mechanical ventilation, reduce hospital/intensive care unit stay, and reduce 28-day mortality; however, this study had several limitations.[324]

Treatments for cytokine release syndrome

Interleukin-6 receptor antagonist monoclonal antibodies (e.g., tocilizumab, sarilumab, siltuximab) are being trialled in COVID-19 patients for the treatment of virus-induced cytokine release syndrome.[\[325\]](#) [\[326\]](#) [\[327\]](#) [\[328\]](#) [\[329\]](#) [\[330\]](#) [\[331\]](#) [\[332\]](#) Tocilizumab and sarilumab are already approved in some countries for the treatment of rheumatological conditions, siltuximab is approved in some countries for Castleman's disease, and tocilizumab is approved in some countries for the treatment of chimeric antigen receptor (CAR) T-cell-induced severe or life-threatening cytokine release syndrome. However, the decision to suppress the immune system of a critically unwell patient with COVID-19 is a difficult one; the beneficial anti-inflammatory effects of anti-inflammatory drugs must be weighed against the possibly detrimental effects of impairment of immunity.[\[333\]](#) Other drugs currently in clinical trials for the treatment of COVID-19-associated cytokine release syndrome include anakinra, the Janus kinase inhibitor fedratinib, and the C-C chemokine receptor type 5 (CCR5) antagonist leronlimab.[\[334\]](#) [\[335\]](#) [\[336\]](#)

Bacille Calmette-Guerin (BCG) vaccine

The BCG vaccine is being trialled in some countries for the prevention of COVID-19, including in healthcare workers. However, there is no evidence to support its use, and the WHO does not recommend it for the prevention of COVID-19.[\[337\]](#)

Angiotensin-II receptor antagonists

Angiotensin-II receptor antagonists such as losartan are being investigated as a potential treatment because it is thought that the angiotensin-converting enzyme-2 (ACE2) receptor is the main binding site for the virus.[\[338\]](#) [\[339\]](#) [\[340\]](#) However, some experts believe that these drugs may worsen COVID-19 due to overexpression of ACE2 in people taking these drugs. See Management Approach for a discussion of the controversy.

Other antivirals

Various other antiviral drugs (monotherapy and combination therapy) are being trialled in patients with COVID-19 (e.g., oseltamivir, darunavir, ganciclovir, favipiravir, baloxavir marboxil, umifenovir, ribavirin, interferon alfa, nebulised interferon beta).[\[341\]](#) [\[342\]](#) [\[343\]](#) [\[344\]](#) [\[345\]](#) [\[346\]](#) [\[347\]](#) [\[348\]](#) [\[349\]](#) Umifenovir monotherapy may be superior to lopinavir/ritonavir in treating COVID-19 in terms of reduced viral load and shorter duration of positive molecular tests.[\[350\]](#)

Intravenous vitamin C

High-dose intravenous vitamin C is being trialled in China for the treatment of severe COVID-19.[\[351\]](#)

Traditional Chinese medicine

Traditional Chinese medicine is being used in patients with COVID-19 in China according to local guidelines and as part of clinical trials.[\[352\]](#)

Recommendations

Monitoring

Monitor vital signs (i.e., temperature, respiratory rate, heart rate, blood pressure, oxygen saturation) and perform haematology and biochemistry laboratory testing and ECG as clinically indicated during admission. Utilise medical early warning scores that facilitate early recognition and escalation of treatment of deteriorating patients (e.g., National Early Warning Score 2 [NEWS2]) where possible.[3] However, there are no data on the value of using these scores in patients with COVID-19 in the primary care setting.[419] A new prediction score for COVID-19 progression risk has been proposed (the CALL score), but it has not been validated as yet.[420]

Monitor vital signs three to four times daily and fetal heart rate in pregnant women with confirmed infection who are symptomatic and admitted to hospital. Perform fetal growth ultrasounds and Doppler assessments to monitor for potential intrauterine growth restriction in pregnant women with confirmed infection who are asymptomatic.[257]

Perform molecular testing regularly during admission. Two consecutive negative tests (at least 24 hours apart) are required in a clinically recovered patient before discharge.[3] However, it is important to note that the rate of false-negative tests appears to be high, and patients are retesting positive after discharge; therefore, these measures may not be stringent enough to ensure patients are no longer contagious.[421]

Patient instructions

General prevention measures

- Wash hands often with soap and water for at least 20 seconds or an alcohol-based hand sanitiser (that contains at least 60% alcohol), especially after being in a public place, blowing your nose, or coughing/sneezing. Avoid touching the eyes, nose, and mouth with unwashed hands.
- Avoid close contact with people (i.e., maintain a distance of at least 1 metre [3 feet]) including shaking hands, particularly those who are sick, have a fever, or are coughing or sneezing. It is important to note that recommended distances differ between countries (for example, 2 metres [6 feet] is recommended in the US and UK) and you should consult local guidance.
- Practice respiratory hygiene (i.e., cover mouth and nose when coughing or sneezing, discard tissue immediately in a closed bin, and wash hands).
- Stay at home if you are sick, even with mild symptoms, until you recover (except to get medical care)
- Clean and disinfect frequently touched surfaces daily (e.g., light switches, door knobs, countertops, handles, phones).[105] [106]
- [\[BMJ Learning: Covid-19 - handwashing technique and PPE videos\]](#)
- [\[WHO: coronavirus disease \(COVID-19\) advice for the public\]](#)

Face masks

- The World Health Organization recommends that people with symptoms should wear a medical mask, self-isolate, and seek medical advice as soon as possible. Masks are also recommended for those caring for a sick person at home when in the same room. Use of a mask alone is insufficient to provide adequate protection, and they should be used in conjunction with other infection prevention and control measures such as frequent hand hygiene and social distancing. It is important to wash your hands with soap and water (or an alcohol-based sanitiser) prior to putting on a face mask, and to remove it correctly. Used masks should be disposed of properly.[108] [112]
- The Centers for Disease Control and Prevention recommends that homemade cloth face coverings can be worn in public settings where social distancing measures are difficult to maintain

(e.g., pharmacies, supermarkets), especially in areas where there is significant community transmission.[109]

- [CDC: use of cloth face coverings to help slow the spread of COVID-19 (includes instructions on how to make masks)]

Travel advice

- Many countries have implemented international travel bans/closed their borders, have issued advice for domestic travel, and are requesting that citizens travelling abroad should come home immediately if they are able to. Some countries are restricting entry to foreign nationals who have been to affected areas in the preceding 14 days, or are enforcing 14-day quarantine periods where the person's health should be closely monitored (e.g., twice-daily temperature readings).
- Consult local guidance for specific travel restriction recommendations in your country:
 - [WHO: coronavirus disease (COVID-19) travel advice]
 - [CDC: coronavirus disease 2019 (COVID-19) – travel]
 - [NaTHNaC: travel health pro]
 - [Public Health England: travel advice - coronavirus (COVID-19)]
 - [Smartraveller Australia: coronavirus (COVID-19)]
 - [Government of Canada: coronavirus disease (COVID-19) - travel restrictions and exemptions]
 - [Ministry of Manpower Singapore: advisories on COVID-19]

Pets

- At this time, there is no evidence that companion animals (including pets and other animals) can spread COVID-19 or that they might be a source of infection, but caution is advised until more information is available.[422]
- A very small number of pets have been reported to be infected with the virus after close contact with people with confirmed COVID-19; however, thousands of pets have been tested in the US with none testing positive. A tiger tested positive in a zoo in New York.[422] [423] There is emerging evidence that cats and ferrets are highly susceptible to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, while dogs and other livestock have no or low susceptibility.[424]
- Advise patients to limit their contact with their pets and other animals, especially while they are symptomatic. Advise people to not let pets interact with people or animals outside the household, and if a member of the household becomes unwell to isolate them from everyone else, including pets.[422]
- [CDC: coronavirus disease 2019 (COVID-19) - if you have animals]

Resources

- [WHO: coronavirus disease (COVID-19) pandemic]
- [WHO: stay physically active during self-quarantine]
- [CDC: coronavirus (COVID-19)]
- [NHS UK: advice for everyone - coronavirus (COVID-19)]

Complications

Complications	Timeframe	Likelihood
acute respiratory distress syndrome (ARDS)	short term	medium
<p>Reported in 15% to 33% of patients in case series.[19] [20] [38] [133] [174]</p> <p>Children can quickly progress to ARDS.[14]</p> <p>Factors that increase the risk of developing ARDS and death include older age, neutrophilia, elevated lactate dehydrogenase level, and elevated D-dimer levels.[379]</p> <p>Lung transplant has been reported in a small number of cases in China as the sole therapy for end-stage pulmonary fibrosis related to ARDS in COVID-19 patients.[380]</p>		
acute respiratory failure	short term	medium
<p>Reported in 8% of patients in case series.[20]</p> <p>Leading cause of mortality in patients with COVID-19.[365]</p> <p>Children can quickly progress to respiratory failure.[14]</p>		
cardiovascular complications	short term	medium
<p>COVID-19 is associated with a high inflammatory burden that can cause vascular inflammation, cardiac arrhythmias, and myocarditis.[381] [382] Inflammation in the vascular system can result in diffuse microangiopathy with thrombosis. Inflammation in the myocardium can result in myocarditis, heart failure, arrhythmias, acute coronary syndrome, rapid deterioration, and sudden death.[383]</p> <p>Acute cardiac injury has been reported in 7% to 20% of patients in case series, and is indicated by elevated cardiac biomarkers.[19] [38] [174] [384] Prevalence is high among patients who are severely or critically ill, and these patients have a higher rate of in-hospital mortality. Patients with cardiac injury were more likely to require non-invasive or invasive ventilation compared with patients without cardiac injury.[384] [385] [386] Patients with underlying cardiovascular disease but without myocardial injury have a relatively favourable prognosis.[387]</p> <p>Generally presents in two ways: acute myocardial injury and dysfunction on presentation; and myocardial injury that develops as the severity of illness worsens.[386]</p> <p>Fulminant myocarditis has been reported.[365] [388] Early corticosteroid therapy and immunoglobulin may be beneficial in these patients.[389]</p> <p>Cardiomyopathy has been reported in 33% of critically ill patients. It is unknown whether it is a direct cardiac complication of COVID-19 or due to overwhelming clinical illness.[363]</p> <p>Myopericarditis with systolic dysfunction has been reported in a patient without signs/symptoms of pneumonia 1 week after the resolution of upper respiratory tract symptoms, highlighting the need for strict monitoring of patients with a history of cardiovascular disease.[390]</p> <p>A case of cardiac tamponade has been reported in a patient with a previous history of myopericarditis.[391]</p> <p>A case of takotsubo syndrome triggered by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been reported in a patient with a history of chronic hypertension.[392]</p>		

Complications	Timeframe	Likelihood
Infection may have longer-term implications for overall cardiovascular health; however, further research is required.[393]		
acute liver injury	short term	medium
Reported in 14% to 53% of patients in case series. Occurs more commonly in patients with severe disease.[394] Although data support a higher prevalence of abnormal aminotransferase levels in patients with severe illness, evidence suggests that clinically significant liver injury is uncommon.[395]		
cytokine release syndrome	short term	low
<p>Cytokine release syndrome may cause ARDS or multiple-organ dysfunction, which may lead to death.[396] Elevated serum proinflammatory cytokines (e.g., tumour necrosis factor alpha, interleukin-2, interleukin-6, interleukin-8, interleukin-10, granulocyte-colony stimulating factor, monocyte chemoattractant protein 1) and inflammatory markers (e.g., C-reactive protein, serum ferritin) have been commonly reported in patients with severe COVID-19. This likely represents a type of virus-induced secondary haemophagocytic lymphohistiocytosis, which may be fatal.[19] [367] [397] [199]</p> <p>One study found that patients who require admission to the intensive care unit have significantly higher levels of interleukin-6, interleukin-10, and tumour necrosis factor alpha, and fewer CD4+ and CD8+ T cells.[398]</p> <p>Anti-inflammatory/immunosuppressive treatments (e.g., tocilizumab, hydroxychloroquine/chloroquine, Janus kinase inhibitors) are being trialled in COVID-19 patients.[399] See our Emerging section for more information.</p>		
septic shock	short term	low
<p>Reported in 4% to 8% of patients in case series.[19] [20] [38] [174]</p> <p>Guidelines for the management of shock in critically ill patients with COVID-19 recommend a conservative fluid strategy (crystalloids preferred over colloids) and a vasoactive agent. Noradrenaline (norepinephrine) is the preferred first-line agent, with vasopressin or adrenaline (epinephrine) considered suitable alternatives. Vasopressin can be added to noradrenaline if target mean arterial pressure cannot be achieved with noradrenaline alone.[224]</p>		
disseminated intravascular coagulation	short term	low
<p>Reported in 71% of non-survivors.[197]</p> <p>Anticoagulant therapy with a low molecular weight heparin or unfractionated heparin has been associated with a better prognosis in patients with severe COVID-19 who have a sepsis-induced coagulopathy (SIC) score of ≥ 4 or a markedly elevated D-dimer level.[400]</p>		
secondary infection	short term	low
Reported in 6% to 10% of patients in case series.[19] [174]		
acute kidney injury	short term	low
<p>Reported in 3% to 8% of patients in case series.[19] [20] [174] A large prospective cohort study of over 700 patients in China found that over 40% of patients with COVID-19 had proteinuria on admission, and 26% had haematuria. Approximately 13% to 14% of patients had elevated creatinine, elevated urea, and an estimated glomerular filtration rate < 60 mL/minute/1.73 m². During the study, acute kidney injury developed in 5% of patients, and these patients had an increased risk of in-hospital mortality.[401] However, a retrospective study of 116 hospitalised patients in Wuhan found that the few patients who</p>		

Complications	Timeframe	Likelihood
had elevated urea, serum creatinine, or albuminuria did not meet the diagnostic criteria for acute kidney injury.[402]		
pancreatic injury	short term	low
Mild pancreatic injury (defined as elevated serum amylase or lipase levels) has been reported in 17% of patients in one case series. It is unknown whether this is a direct viral effect or due to the harmful immune response that occurs in some patients. Further research is required.[403]		
neurological complications	short term	low
<p>Patients with severe illness commonly have neurological complications, likely due to viral invasion of the central nervous system (SARS-CoV-2 has been detected in the brain and cerebrospinal fluid). In a case series of 214 patients, neurological symptoms were seen in 36% of patients, and were more common in patients with severe illness.[404]</p> <p>Complications include acute cerebrovascular disease, impairment of consciousness, ataxia, seizures, neuralgia, skeletal muscle injury, meningitis, encephalitis, and encephalopathy. Patients may present with these signs/symptoms, or they may develop them during the course of the disease. These patients have a poor prognosis.[404] [405] [406] [407] [408] [409] [410]</p> <p>A case of COVID-19 initially presenting with acute Guillain-Barre syndrome has been reported.[411]</p>		
venous thromboembolism	short term	low
Reported in 25% to 31% of patients with severe COVID-19 in the intensive care unit, and may be associated with poor prognosis.[412] [413] Identifying patients with COVID-19 who are at high risk is important so that venous thromboembolism prophylaxis measures (pharmacological or mechanical thromboprophylaxis) can be instituted.[414] Low molecular weight heparin is preferred over unfractionated heparin in order to reduce patient contact (depending on the patient's bleeding risk and creatinine clearance). Fondaparinux is recommended in patients with a history of heparin-induced thrombocytopenia.[415]		
rhabdomyolysis	short term	low
Reported as a late complication in one case report.[416]		
pregnancy-related complications	short term	low
Retrospective reviews of pregnant women with COVID-19 found that women appeared to have fewer adverse maternal and neonatal complications and outcomes than would be expected for those with severe acute respiratory syndrome (SARS) or Middle East respiratory syndrome (MERS). Adverse effects on the newborn including fetal distress, premature labour, respiratory distress, thrombocytopenia, and abnormal liver function have been reported; however, it is unclear whether these effects are related to maternal SARS-CoV-2 infection. No maternal deaths have been reported so far, but miscarriage, intrauterine growth restriction, perinatal death, and preterm birth have been reported. It is unclear whether this is related to COVID-19.[68] [69] [72] [254] [417] [418]		

Prognosis

Case fatality rate

The overall global case fatality rate is currently approximately 6.5% based on World Health Organization data as of 16 April 2020. The case fatality rate varies between countries; for example, it is currently higher in countries such as France, Italy, and Spain, and lower in countries such as the US, Germany, and Australia.[353] It is important to note that daily death counts need to be interpreted with caution. The number of deaths reported on a particular day may not accurately reflect the number of deaths from the previous day due to delays associated with reporting deaths. This makes it difficult to know whether deaths are falling over time in the short term.[354]

The overall case fatality rate in China has been estimated to be 2.3% (0.9% in patients without comorbidities) based on a large case series of 72,314 reported cases from 31 December 2019 to 11 February 2020 (mainly among hospitalised patients).[6] However, another study estimates the case fatality rate in China to be lower at 1.38% (after adjusting the crude estimate for censoring, demography, and under-ascertainment).[355]

Estimated case fatality rates should be treated with extreme caution as the situation is evolving rapidly, and case fatality rates are often overestimated at the onset of outbreaks owing to increased case detection of patients with severe disease.[356] For example, at the start of the 2009 H1N1 influenza pandemic the case fatality rate varied from 0.1% to 5.1% depending on the country, but ended up being around 0.02%. Other factors that can affect case fatality rates include testing rates in each country, delays between symptom onset and death, and local factors (e.g., patient demographics, availability and quality of health care, other endemic diseases). For example, the case fatality rate in Italy may be higher than in other countries because Italy has the second oldest population in the world, the highest rates of antibiotic resistance deaths in Europe, and a higher incidence of smoking. The way COVID-19 related deaths are identified and reported in Italy may have also resulted in an overestimation of cases. Patients who die 'with' COVID-19 and patients who die 'from' COVID-19 are both counted towards the death toll[357] [358]

Estimates that take into account asymptomatic patients and mild cases who have not been tested put the case fatality rate in the total population at around 0.125%; however, this estimate does not take into account exceptional cases (e.g., the current situation in Italy).[357] The case fatality rate among people on board the Diamond Princess cruise ship, a unique situation where a more accurate assessment of the case fatality rate in a quarantined population can be made, was 0.99%. However, it should be noted that the rate in a younger, healthier population could be lower.[359]

The overall case fatality rate appears to be less than that reported for severe acute respiratory syndrome coronavirus (SARS) (10%) and Middle East respiratory syndrome (MERS) (37%).[19] Despite the lower case fatality rate, COVID-19 has so far resulted in more deaths than both SARS and MERS combined.[360]

Case fatality rate according to age and presence of comorbidities

The case fatality rate increases with age.[355] The presence of comorbidities is associated with greater disease severity and poor clinical outcomes, and the risk increases with the number of comorbidities a patient has.[361]

The majority of deaths in China have been in patients aged 60 years and older and/or those who have pre-existing underlying health conditions (e.g., hypertension, diabetes, cardiovascular disease). The case fatality rate was highest among critical cases (49%). It was also higher in patients aged 80 years and older (15%), males (2.8% versus 1.7% for females), and patients with comorbidities (10.5% for cardiovascular disease, 7.3% for diabetes, 6.3% for chronic respiratory disease, 6% for hypertension, and 5.6% for cancer).[6] Another study found the case fatality rate in China to be 6.4% in patients aged ≥ 60 years versus 0.32% in patients aged < 60 years, and 13.4% in patients aged ≥ 80 years.[355]

In Italy, the case fatality rate was 8.5% in patients aged 60 to 69 years, 35.5% in patients aged 70 to 79 years, and 52.5% in patients aged ≥ 80 years.[94] In a case series of 1591 critically ill patients in Lombardy, the majority of patients were older men, a large proportion required mechanical ventilation and high levels of positive end-expiratory pressure, and the mortality rate in the intensive care unit was 26%.[362]

In the US, the case fatality rate was highest among patients aged ≥ 85 years (10% to 27%), followed by those aged 65 to 84 years (3% to 11%), 55 to 64 years (1% to 3%), 20 to 54 years ($< 1\%$), and ≤ 19 years (no deaths). Patients aged ≥ 65 years accounted for 80% of deaths.[8] The case fatality rate among critically ill patients admitted to the intensive care unit reached 67% in one hospital in Washington state. Most of these patients had underlying health conditions, with congestive heart failure and chronic kidney disease being the most common.[363] The case fatality rate in residents in a long-term care facility in Washington was reported to be 34%.[364]

Children have a better prognosis than adults, and deaths have been extremely rare.[9] Three deaths have been reported in children in the US.[10]

Mortality

The leading cause of death in patients with COVID-19 is respiratory failure from acute respiratory distress syndrome.[365] The other most common complications in deceased patients are myocardial injury, liver or kidney injury, and multi-organ dysfunction.[366]

Factors that have been found more commonly in non-survivors compared with survivors include:[195] [196] [367] [368] [369] [370] [371] [372]

- Older age ≥ 65 years
- Male sex
- Dyspnoea and higher respiratory rate
- Hypertension
- Cardiovascular or cerebrovascular disease
- Elevated cardiac biomarkers (e.g., cardiac troponin I)
- Lymphopenia and leukocytosis
- High neutrophil-to-lymphocyte ratio
- Elevated lactate dehydrogenase
- Elevated inflammatory markers
- Decreased CD3+CD8+ T cells
- Acute respiratory distress syndrome
- Use of mechanical ventilation
- Use of high-dose corticosteroids
- Multi-organ dysfunction.

In one retrospective study of 52 critically ill patients in Wuhan City, 61.5% of patients died by 28 days, and the median time from admission to the intensive care unit to death was 7 days for patients who didn't survive.[369]

Prognostic factors

Factors associated with disease progression and a poorer prognosis in one retrospective analysis of 78 patients in Wuhan City include older age, history of smoking, maximum body temperature on admission, respiratory failure, significantly decreased serum albumin level, and significantly elevated C-reactive protein.[99]

Thrombocytopenia has been associated with increased risk of severe disease and mortality and may be useful as a clinical indicator for monitoring disease progression.[193]

Other factors associated with a poor prognosis include higher Sequential Organ Failure Assessment (SOFA) score and a D-dimer level > 1 microgram/L. Viral shedding continued until death in non-survivors.[85]

Refractory disease

Refractory disease (patients who do not reach obvious clinical and radiological remission within 10 days after hospitalisation) has been reported in nearly 50% of hospitalised patients in one retrospective single-

centre study of 155 patients in China. Risk factors for refractory disease include older age, male sex, and the presence of comorbidities. These patients generally require longer hospital stays as their recovery is slower.[373]

Infectivity of recovered cases

Potential infectivity of recovered cases is still unclear. There have been case reports of patients testing positive again after being discharged (i.e., after symptom resolution and two consecutive negative test results two days apart). This suggests that some patients in convalescence may still be contagious, although this is yet to be confirmed.[374] [375]

Reinfection/relapse/reactivation

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reactivation has been reported in patients after hospital discharge. In a retrospective review of 55 patients in China, 9% of patients presented with SARS-CoV-2 reactivation. The clinical characteristics were similar to those of non-reactivated patients.[376] Other studies have shown that 14% to 21% of patients return a positive reverse-transcription polymerase chain reaction (RT-PCR) test again after two negative RT-PCR tests and after hospital discharge.[377] [378] It is unclear whether these cases are reinfections/relapses/reactivations, or whether the test result was a false-negative at the time of discharge. Further research is required.

Diagnostic guidelines

Europe

COVID-19: guidance for health professionals

Published by: Public Health England

Last published: 2020

COVID-19

Published by: European Centre for Disease Prevention and Control

Last published: 2020

International

Country & technical guidance - coronavirus disease (COVID-19)

Published by: World Health Organization

Last published: 2020

Laboratory testing strategy recommendations for COVID-19

Published by: World Health Organization

Last published: 2020

Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases

Published by: World Health Organization

Last published: 2020

Global surveillance for COVID-19 caused by human infection with COVID-19 virus

Published by: World Health Organization

Last published: 2020

Infection prevention and control during health care when COVID-19 is suspected

Published by: World Health Organization

Last published: 2020

North America

Information for laboratories

Published by: Centers for Disease Control and Prevention

Last published: 2020

Interim infection prevention and control recommendations for patients with suspected or confirmed coronavirus disease 2019 (COVID-19) in healthcare settings

Published by: Centers for Disease Control and Prevention

Last published: 2020

COVID-19: resource center

Published by: Infectious Diseases Society of America

Last published: 2020

Asia

A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia

Published by: Zhongnan Hospital of Wuhan University Novel Coronavirus Management and Research Team; Evidence-Based Medicine Chapter of China International Exchange and Promotive Association for Medical and Health Care

Last published: 2020

Diagnosis and clinical management of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection

Published by: Peking Union Medical College Hospital

Last published: 2020

Treatment guidelines

Europe

Coronavirus specialty guides

Published by: NHS England

Last published: 2020

COVID-19 rapid guideline: critical care in adults

Published by: National Institute for Health and Care Excellence

Last published: 2020

Coronavirus (COVID-19): rapid guidelines and evidence reviews

Published by: National Institute for Health and Care Excellence

Last published: 2020

COVID-19: guidance for health professionals

Published by: Public Health England

Last published: 2020

BMJ's coronavirus (covid-19) hub

Published by: BMJ

Last published: 2020

COVID-19

Published by: European Centre for Disease Prevention and Control

Last published: 2020

Coronavirus (COVID-19) infection in pregnancy

Published by: Royal College of Obstetricians and Gynaecologists

Last published: 2020

Guideline for the treatment of people with COVID-19 disease

Published by: Italian Society of Infectious and Tropical Diseases

Last published: 2020

Recommendations for COVID-19 clinical management

Published by: National Institute for the Infectious Diseases (Italy)

Last published: 2020

Recommendations on the clinical management of the COVID-19 infection by the new coronavirus SARS-CoV2

Published by: Spanish Paediatric Association

Last published: 2020

International

Country & technical guidance - coronavirus disease (COVID-19)

Published by: World Health Organization

Last published: 2020

Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected

Published by: World Health Organization

Last published: 2020

Home care for patients with COVID-19 presenting with mild symptoms and management of their contacts

Published by: World Health Organization

Last published: 2020

Advice on the use of masks in the context of COVID-19

Published by: World Health Organization

Last published: 2020

COVID-19 guidance and the latest research in the Americas

Published by: Pan American Health Organization

Last published: 2020

Surviving Sepsis Campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19)

Published by: Surviving Sepsis Campaign

Last published: 2020

Global interim guidance on coronavirus disease 2019 (COVID-19) during pregnancy and puerperium from FIGO and allied partners: information for healthcare professionals

Published by: International Federation of Gynecology and Obstetrics

Last published: 2020

ISUOG interim guidance on 2019 novel coronavirus infection during pregnancy and puerperium: information for healthcare professionals

Published by: International Society of Ultrasound in Obstetrics and Gynecology

Last published: 2020

North America

Coronavirus disease 2019 (COVID-19): for healthcare professionals

Published by: Centers for Disease Control and Prevention

Last published: 2020

Interim clinical guidance for management of patients with confirmed coronavirus disease (COVID-19)

Published by: Centers for Disease Control and Prevention

Last published: 2020

Information for clinicians on investigational therapeutics for COVID-19 patients

Published by: Centers for Disease Control and Prevention

Last published: 2020

Interim guidance for implementing home care of people not requiring hospitalization for coronavirus disease 2019 (COVID-19)

Published by: Centers for Disease Control and Prevention

Last published: 2020

Discontinuation of in-home isolation for immunocompromised persons with COVID-19 (interim guidance)

Published by: Centers for Disease Control and Prevention

Last published: 2020

Discontinuation of isolation for persons with COVID-19 not in healthcare settings (interim guidance)

Published by: Centers for Disease Control and Prevention

Last published: 2020

Interim U.S. guidance for risk assessment and public health management of healthcare personnel with potential exposure in a healthcare setting to patients with coronavirus disease (COVID-19)

Published by: Centers for Disease Control and Prevention

Last published: 2020

Coronavirus disease 2019 (COVID-19): considerations for inpatient obstetric healthcare settings

Published by: Centers for Disease Control and Prevention

Last published: 2020

Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19 infection

Published by: Infectious Diseases Society of America

Last published: 2020

COVID#19: interim guidance on management pending empirical evidence

Published by: American Thoracic Society

Last published: 2020

COVID-19 resource center

Published by: Infectious Diseases Society of America

Last published: 2020

Management of infants born to mothers with COVID-19

Published by: American Academy of Pediatrics

Last published: 2020

North America

Novel coronavirus 2019 (COVID-19)

Published by: American College of Obstetricians and Gynecologists

Last published: 2020

Coronavirus disease (COVID-19): outbreak update

Published by: Government of Canada

Last published: 2020

Asia

Coronavirus disease

Published by: Chinese Center for Disease Control and Prevention

Last published: 2020

Handbook of COVID-19 prevention and treatment

Published by: First Affiliated Hospital, Zhejiang University School of Medicine

Last published: 2020

A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia

Published by: Zhongnan Hospital of Wuhan University Novel Coronavirus Management and Research Team; Evidence-Based Medicine Chapter of China International Exchange and Promotive Association for Medical and Health Care

Last published: 2020

Diagnosis and treatment protocol for novel coronavirus pneumonia (trial version 7)

Published by: National Health Commission of the People's Republic of China; National Administration of Traditional Chinese Medicine of the People's Republic of China

Last published: 2020

Diagnosis and clinical management of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection

Published by: Peking Union Medical College Hospital

Last published: 2020

Updates on COVID-19 (coronavirus disease 2019) local situation

Published by: Ministry of Health Singapore

Last published: 2020

New coronavirus (COVID-19)#

Published by: National Institute of Infectious Diseases Japan

Last published: 2020

New coronavirus infection

Published by: Japanese Association for Infectious Diseases

Last published: 2020

Perinatal and neonatal management plan for prevention and control of SARS-CoV-2 infection (2nd edition)

Published by: Working Group for the Prevention and Control of Neonatal SARS-CoV-2 Infection in the Perinatal Period of the Editorial Committee of Chinese Journal of Contemporary Pediatrics

Last published: 2020

Oceania

Coronavirus disease 2019 (COVID-19)

Published by: Department of Health Australia

Last published: 2020

Online resources

1. [Johns Hopkins University: coronavirus COVID-19 global cases \(external link\)](#)
2. [BMJ talk medicine podcast: Covid-19 update \(external link\)](#)
3. [WHO: coronavirus disease \(COVID-19\) emergency dashboard \(external link\)](#)
4. [WHO: coronavirus disease \(COVID-2019\) situation reports \(external link\)](#)
5. [CDC: coronavirus disease 2019 \(COVID-19\) – cases in US \(external link\)](#)
6. [CDC: COVIDView \(external link\)](#)
7. [GenBank \(external link\)](#)
8. [BMJ Learning: Covid-19 - handwashing technique and PPE videos \(external link\)](#)
9. [WHO: coronavirus disease \(COVID-19\) advice for the public \(external link\)](#)
10. [BMJ: facemasks for the prevention of infection in healthcare and community settings \(external link\)](#)
11. [BMJ: analysis - face masks for the public during the covid-19 crisis \(external link\)](#)
12. [WHO: coronavirus disease \(COVID-19\) advice for the public - when and how to use masks \(external link\)](#)
13. [Public Health England: guidance on social distancing for everyone in the UK \(external link\)](#)
14. [Public Health England: guidance on shielding and protecting people defined on medical grounds as extremely vulnerable from COVID-19 \(external link\)](#)
15. [BMJ: covid-19 in primary care \(UK\) \(external link\)](#)
16. [BMJ: covid-19 - a remote assessment in primary care \(external link\)](#)
17. [BMJ: covid-19 - PPE guidance \(external link\)](#)
18. [WHO: infection prevention and control during health care when COVID-19 is suspected \(external link\)](#)
19. [CDC: interim infection prevention and control recommendations for patients with suspected or confirmed coronavirus disease 2019 \(COVID-19\) in healthcare settings \(external link\)](#)
20. [CDC: strategies to optimize the supply of PPE and equipment \(external link\)](#)
21. [BSTI: radiology decision support tool for suspected COVID-19 \(external link\)](#)
22. [WHO: global surveillance for COVID-19 caused by human infection with COVID-19 virus \(external link\)](#)

23. [CDC: evaluating and testing persons for coronavirus disease 2019 \(COVID-19\) \(external link\)](#)
24. [CDC: priorities for testing patients with suspected COVID-19 infection \(external link\)](#)
25. [IDSA: COVID-19 prioritization of diagnostic testing \(external link\)](#)
26. [BMJ talk medicine podcast: coping with Covid-19 - advice from a New York City intensivist \(external link\)](#)
27. [Clinical frailty scale \(external link\)](#)
28. [WHO: home care for patients with COVID-19 presenting with mild symptoms and management of their contacts \(external link\)](#)
29. [CDC: interim guidance for implementing home care of people not requiring hospitalization for coronavirus disease 2019 \(COVID-19\) \(external link\)](#)
30. [ACOG: outpatient assessment and management for pregnant women with suspected or confirmed novel coronavirus \(COVID-19\) \(external link\)](#)
31. [BMJ: drugs and the renin-angiotensin system in covid-19 \(external link\)](#)
32. [Centre for Evidence-Based Medicine: angiotensin converting enzyme \(ACE\) inhibitors and angiotensin receptor blockers in COVID-19 \(external link\)](#)
33. [WHO: off-label use of medicines for COVID-19 \(external link\)](#)
34. [Centre for Evidence-Based Medicine: hydroxychloroquine for COVID-19 - what do the clinical trials tell us? \(external link\)](#)
35. [Centre for Evidence-Based Medicine: lopinavir/ritonavir - a rapid review of effectiveness in COVID-19 \(external link\)](#)
36. [CDC: use of cloth face coverings to help slow the spread of COVID-19 \(includes instructions on how to make masks\) \(external link\)](#)
37. [WHO: coronavirus disease \(COVID-19\) travel advice \(external link\)](#)
38. [CDC: coronavirus disease 2019 \(COVID-19\) – travel \(external link\)](#)
39. [NaTHNac: travel health pro \(external link\)](#)
40. [Public Health England: travel advice - coronavirus \(COVID-19\) \(external link\)](#)
41. [Smartraveller Australia: coronavirus \(COVID-19\) \(external link\)](#)
42. [Government of Canada: coronavirus disease \(COVID-19\) - travel restrictions and exemptions \(external link\)](#)

43. [Ministry of Manpower Singapore: advisories on COVID-19](#) (*external link*)
44. [CDC: coronavirus disease 2019 \(COVID-19\) - if you have animals](#) (*external link*)
45. [WHO: coronavirus disease \(COVID-19\) pandemic](#) (*external link*)
46. [WHO: stay physically active during self-quarantine](#) (*external link*)
47. [CDC: coronavirus \(COVID-19\)](#) (*external link*)
48. [NHS UK: advice for everyone - coronavirus \(COVID-19\)](#) (*external link*)

Key articles

References

1. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. *Nat Microbiol.* 2020 Apr;5(4):536-44. [Full text](#) [Abstract](#)
2. Ren LL, Wang YM, Wu ZQ, et al. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. *Chin Med J (Engl).* 2020 Jan 30 [Epub ahead of print]. [Abstract](#)
3. World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. 2020 [internet publication]. [Full text](#)
4. World Health Organization. Pneumonia of unknown cause – China. 2020 [internet publication]. [Full text](#)
5. World Health Organization. Novel coronavirus – China. 2020 [internet publication]. [Full text](#)
6. Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China [in Chinese]. *Zhonghua Liu Xing Bing Xue Za Zhi.* 2020 Feb 17;41(2):145-51. [Full text](#) [Abstract](#)
7. Zhan M, Qin Y, Xue X, et al. Death from Covid-19 of 23 health care workers in China. *N Engl J Med.* 2020 Apr 15 [Epub ahead of print]. [Full text](#)
8. CDC COVID-19 Response Team. Severe outcomes among patients with coronavirus disease 2019 (COVID-19): United States, February 12 - March 16, 2020. *MMWR Morb Mortal Wkly Rep.* 2020 Mar 27;69(12):343-6. [Full text](#) [Abstract](#)
9. Ludvigsson JF. Systematic review of COVID-19 in children show milder cases and a better prognosis than adults. *Acta Paediatr.* 2020 Mar 23 [Epub ahead of print]. [Full text](#) [Abstract](#)
10. CDC COVID-19 Response Team. Coronavirus disease 2019 in children: United States, February 12 - April 2, 2020. *MMWR Morb Mortal Wkly Rep.* 2020 Apr 10;69(14):422-6. [Full text](#) [Abstract](#)
11. Chen ZM, Fu JF, Shu Q, et al. Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus. *World J Pediatr.* 2020 Feb 5 [Epub ahead of print]. [Full text](#) [Abstract](#)
12. Shen KL, Yang YH. Diagnosis and treatment of 2019 novel coronavirus infection in children: a pressing issue. *World J Pediatr.* 2020 Feb 5 [Epub ahead of print]. [Full text](#) [Abstract](#)
13. Hong H, Wang Y, Chung HT, et al. Clinical characteristics of novel coronavirus disease 2019 (COVID-19) in newborns, infants and children. *Pediatr Neonatol.* 2020 Apr;61(2):131-2. [Full text](#) [Abstract](#)

14. Dong Y, Mo X, Hu Y, et al. Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in China. *Pediatrics*. 2020 Mar 16 [Epub ahead of print]. [Full text](#) [Abstract](#)
15. Yao Y, Pan J, Liu Z, et al. No association of COVID-19 transmission with temperature or UV radiation in Chinese cities. *Eur Respir J*. 2020 Apr 8 [Epub ahead of print]. [Full text](#) [Abstract](#)
16. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. *N Engl J Med*. 2020 Feb 20;382(8):727-33. [Full text](#) [Abstract](#)
17. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. *Lancet*. 2020 Feb 22;395(10224):565-74. [Full text](#) [Abstract](#)
18. Tang X, Wu C, Li X, et al. On the origin and continuing evolution of SARS-CoV-2. *Nat Sci Review*. 2020 Mar 3 [Epub ahead of print]. [Full text](#)
19. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020 Feb 15;395(10223):497-506. [Full text](#) [Abstract](#)
20. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet*. 2020 Feb 15;395(10223):507-13. [Full text](#) [Abstract](#)
21. Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. *N Engl J Med*. 2020 Mar 26;382(13):1199-207. [Full text](#) [Abstract](#)
22. Paraskevis D, Kostaki EG, Magiorkinis G, et al. Full-genome evolutionary analysis of the novel coronavirus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event. *Infect Genet Evol*. 2020 Jan 29;79:104212. [Abstract](#)
23. Ji W, Wang W, Zhao X, et al. Cross-species transmission of the newly identified coronavirus 2019-nCoV. *J Med Virol*. 2020 Apr;92(4):433-40. [Full text](#) [Abstract](#)
24. Zhang T, Wu Q, Zhang Z. Probable pangolin origin of SARS-CoV-2 associated with the COVID-19 outbreak. *Curr Biol*. 2020 Apr 6;30(7):1346-51. [Full text](#) [Abstract](#)
25. Lam TT, Shum MH, Zhu HC, et al. Identifying SARS-CoV-2 related coronaviruses in Malayan pangolins. *Nature*. 2020 Mar 26 [Epub ahead of print]. [Full text](#) [Abstract](#)
26. Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. *Lancet*. 2020 Feb 15;395(10223):514-23. [Full text](#) [Abstract](#)
27. Burke RM, Midgley CM, Dratch A, et al. Active monitoring of persons exposed to patients with confirmed COVID-19 - United States, January-February 2020. *MMWR Morb Mortal Wkly Rep*. 2020 Mar 6;69(9):245-6. [Full text](#) [Abstract](#)
28. van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. *N Engl J Med*. 2020 Mar 17 [Epub ahead of print]. [Full text](#) [Abstract](#)

29. World Health Organization. Modes of transmission of virus causing COVID-19: implications for IPC precaution recommendations. 2020 [internet publication]. [Full text](#)
30. Guo ZD, Wang ZY, Zhang SF, et al. Aerosol and surface distribution of severe acute respiratory syndrome coronavirus 2 in hospital wards, Wuhan, China, 2020. *Emerg Infect Dis*. 2020 Apr 10;26(7). [Full text](#) [Abstract](#)
31. Zhang H, Kang Z, Gong H, et al. The digestive system is a potential route of 2019-nCov infection: a bioinformatics analysis based on single-cell transcriptomes. 2020 [internet publication]. [Full text](#)
32. Zhang W, Du RH, Li B, et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. *Emerg Microbes Infect*. 2020 Dec;9(1):386-9. [Full text](#) [Abstract](#)
33. To KK, Tsang OT, Chik-Yan Yip C, et al. Consistent detection of 2019 novel coronavirus in saliva. *Clin Infect Dis*. 2020 Feb 12 [Epub ahead of print]. [Abstract](#)
34. Centre for Evidence-Based Medicine; Ferner RE, Murray PI, Aronson JK. Spreading SARS-CoV-2 through ocular fluids. 2020 [internet publication]. [Full text](#)
35. Sun T, Guan J. Novel coronavirus and central nervous system. *Eur J Neurol*. 2020 Mar 26 [Epub ahead of print]. [Full text](#) [Abstract](#)
36. Cheung KS, Hung IF, Chan PP, et al. Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from the Hong Kong cohort and systematic review and meta-analysis. *Gastroenterology*. 2020 Apr 3 [Epub ahead of print]. [Full text](#) [Abstract](#)
37. Seah IYJ, Anderson DE, Kang AEZ, et al. Assessing viral shedding and infectivity of tears in coronavirus disease 2019 (COVID-19) patients. *Ophthalmology*. 2020 Mar 24 [Epub ahead of print]. [Full text](#) [Abstract](#)
38. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA*. 2020 Feb 7 [Epub ahead of print]. [Full text](#) [Abstract](#)
39. CDC COVID-19 Response Team. Characteristics of health care personnel with COVID-19: United States, February 12 – April 9, 2020. *MMWR Morb Mortal Wkly Rep*. 2020 Apr 14 [Epub ahead of print]. [Full text](#)
40. McMichael TM, Clark S, Pogojans S, et al. COVID-19 in a long-term care facility: King County, Washington, February 27 – March 9, 2020. *MMWR Morb Mortal Wkly Rep*. 2020 Mar 27;69(12):339-42. [Full text](#) [Abstract](#)
41. Moriarty LF, Plucinski MM, Marston BJ, et al. Public health responses to COVID-19 outbreaks on cruise ships: worldwide, February-March 2020. *MMWR Morb Mortal Wkly Rep*. 2020 Mar 27;69(12):347-52. [Full text](#) [Abstract](#)

42. Ghinai I, Woods S, Ritger KA, et al. Community transmission of SARS-CoV-2 at two family gatherings: Chicago, Illinois, February – March 2020. *MMWR Morb Mortal Wkly Rep*. 2020 Apr 8 [Epub ahead of print]. [Full text](#)
43. Wang Z, Ma W, Zheng X, et al. Household transmission of SARS-CoV-2. *J Infect*. 2020 Apr 10 [Epub ahead of print]. [Full text](#) [Abstract](#)
44. World Health Organization. Novel coronavirus (2019-nCoV) situation report - 6. 2020 [internet publication]. [Full text](#)
45. Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19): symptoms of coronavirus. 2020 [internet publication]. [Full text](#)
46. Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. *Ann Intern Med*. 2020 Mar 10 [Epub ahead of print]. [Full text](#) [Abstract](#)
47. Jiang X, Niu Y, Li X, et al. Is a 14-day quarantine period optimal for effectively controlling coronavirus disease 2019 (COVID-19)? 2020 [internet publication]. [Full text](#)
48. Yu P, Zhu J, Zhang Z, et al. A familial cluster of infection associated with the 2019 novel coronavirus indicating potential person-to-person transmission during the incubation period. *J Infect Dis*. 2020 Feb 18 [Epub ahead of print]. [Full text](#) [Abstract](#)
49. Du Z, Xu X, Wu Y, et al. Serial interval of COVID-19 among publicly reported confirmed cases. *Emerg Infect Dis*. 2020 Mar 19;26(6). [Full text](#) [Abstract](#)
50. Wei WE, Li Z, Chiew CJ, et al. Presymptomatic transmission of SARS-CoV-2: Singapore, January 23 - March 16, 2020. *MMWR Morb Mortal Wkly Rep*. 2020 Apr 10;69(14):411-5. [Full text](#) [Abstract](#)
51. Rothe C, Schunk M, Sothmann P, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. *N Engl J Med*. 2020 Mar 5;382(10):970-71. [Full text](#) [Abstract](#)
52. Kupferschmidt K. Study claiming new coronavirus can be transmitted by people without symptoms was flawed. 2020 [internet publication]. [Full text](#)
53. Tong ZD, Tang A, Li KF, et al. Potential presymptomatic transmission of SARS-CoV-2, Zhejiang province, China, 2020. *Emerg Infect Dis*. 2020 May 17;26(5). [Full text](#) [Abstract](#)
54. Hu Z, Song C, Xu C, et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. *Sci China Life Sci*. 2020 Mar 4 [Epub ahead of print]. [Full text](#) [Abstract](#)
55. Luo SH, Liu W, Liu ZJ, et al. A confirmed asymptomatic carrier of 2019 novel coronavirus (SARS-CoV-2). *Chin Med J (Engl)*. 2020 Mar 6 [Epub ahead of print]. [Full text](#) [Abstract](#)
56. Lu S, Lin J, Zhang Z, et al. Alert for non-respiratory symptoms of Coronavirus Disease 2019 (COVID-19) patients in epidemic period: a case report of familial cluster with three asymptomatic COVID-19 patients. *J Med Virol*. 2020 Mar 19 [Epub ahead of print]. [Full text](#) [Abstract](#)

57. Li C, Ji F, Wang L, et al. Asymptomatic and human-to-human transmission of SARS-CoV-2 in a 2-family cluster, Xuzhou, China. *Emerg Infect Dis*. 2020 Mar 31;26(7). [Full text](#) [Abstract](#)
58. Mizumoto K, Kagaya K, Zarebski A, et al. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. *Euro Surveill*. 2020 Mar;25(10). [Full text](#) [Abstract](#)
59. Nishiura H, Kobayashi T, Suzuki A, et al. Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). *Int J Infect Dis*. 2020 Mar 13 [Epub ahead of print]. [Full text](#) [Abstract](#)
60. Kimball A, Hatfield KM, Arons M, et al. Asymptomatic and presymptomatic SARS-CoV-2 infections in residents of a long-term care skilled nursing facility: King County, Washington, March 2020. *MMWR Morb Mortal Wkly Rep*. 2020 Apr 3;69(13):377-81. [Full text](#) [Abstract](#)
61. Day M. Covid-19: identifying and isolating asymptomatic people helped eliminate virus in Italian village. *BMJ*. 2020 Mar 23;368:m1165. [Full text](#) [Abstract](#)
62. Centre for Evidence-Based Medicine; Heneghan C, Brassey J, Jefferson T. COVID-19: What proportion are asymptomatic? 2020 [internet publication]. [Full text](#)
63. Sutton D, Fuchs K, D'Alton M, et al. Universal screening for SARS-CoV-2 in women admitted for delivery. *N Engl J Med*. 2020 Apr 13 [Epub ahead of print]. [Full text](#) [Abstract](#)
64. Qiu H, Wu J, Hong L, et al. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. *Lancet Infect Dis*. 2020 Mar 25 [Epub ahead of print]. [Full text](#) [Abstract](#)
65. Frieden TR, Lee CT. Identifying and interrupting superspreading events-implications for control of severe acute respiratory syndrome coronavirus 2. *Emerg Infect Dis*. 2020 Mar 18;26(6). [Full text](#) [Abstract](#)
66. Stein RA. Super-spreaders in infectious diseases. *Int J Infect Dis*. 2011 Aug;15(8):e510-3. [Full text](#) [Abstract](#)
67. Hui DS. Super-spreading events of MERS-CoV infection. *Lancet*. 2016 Sep 3;388(10048):942-3. [Full text](#) [Abstract](#)
68. Chen H, Guo J, Wang C, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. *Lancet*. 2020 Mar 7;395(10226):809-15. [Full text](#) [Abstract](#)
69. Schwartz DA. An analysis of 38 pregnant women with COVID-19, their newborn infants, and maternal-fetal transmission of SARS-CoV-2: maternal coronavirus infections and pregnancy outcomes. *Arch Pathol Lab Med*. 2020 Mar 17 [Epub ahead of print]. [Full text](#) [Abstract](#)
70. Karimi-Zarchi M, Neamatzadeh H, Dastgheib SA, et al. Vertical transmission of coronavirus disease 19 (COVID-19) from infected pregnant mothers to neonates: a review. *Fetal Pediatr Pathol*. 2020 Apr 2;:1-5. [Full text](#) [Abstract](#)

71. Wang S, Guo L, Chen L, et al. A case report of neonatal COVID-19 infection in China. *Clin Infect Dis*. 2020 Mar 12 [Epub ahead of print]. [Full text](#) [Abstract](#)
72. Zhu H, Wang L, Fang C, et al. Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia. *Transl Pediatr*. 2020 Feb;9(1):51-60. [Full text](#) [Abstract](#)
73. Zeng H, Xu C, Fan J, et al. Antibodies in infants born to mothers with COVID-19 pneumonia. *JAMA*. 2020 Mar 26 [Epub ahead of print]. [Full text](#) [Abstract](#)
74. Dong L, Tian J, He S, et al. Possible vertical transmission of SARS-CoV-2 from an infected mother to her newborn. *JAMA*. 2020 Mar 26 [Epub ahead of print]. [Full text](#) [Abstract](#)
75. Zeng L, Xia S, Yuan W, et al. Neonatal early-onset infection with SARS-CoV-2 in 33 neonates born to mothers with COVID-19 in Wuhan, China. *JAMA Pediatr*. 2020 Mar 26 [Epub ahead of print]. [Full text](#) [Abstract](#)
76. Liu Y, Gayle AA, Wilder-Smith A, et al. The reproductive number of COVID-19 is higher compared to SARS coronavirus. *J Travel Med*. 2020 Mar 13;27(2). [Full text](#) [Abstract](#)
77. Yan R, Zhang Y, Li Y, et al. Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2. *Science*. 2020 Mar 27;367(6485):1444-8. [Full text](#) [Abstract](#)
78. Chen Y, Guo Y, Pan Y, et al. Structure analysis of the receptor binding of 2019-nCoV. *Biochem Biophys Res Commun*. 2020 Feb 17 [Epub ahead of print]. [Full text](#) [Abstract](#)
79. Coutard B, Valle C, de Lamballerie X, et al. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. *Antiviral Res*. 2020 Feb 10;176:104742. [Abstract](#)
80. Zou X, Chen K, Zou J, et al. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. *Front Med*. 2020 Mar 12 [Epub ahead of print]. [Full text](#) [Abstract](#)
81. Hanff TC, Harhay MO, Brown TS, et al. Is there an association between COVID-19 mortality and the renin-angiotensin system: a call for epidemiologic investigations. *Clin Infect Dis*. 2020 Mar 26 [Epub ahead of print]. [Full text](#) [Abstract](#)
82. Zou L, Ruan F, Huang M, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. *N Engl J Med*. 2020 Mar 19;382(12):1177-9. [Full text](#) [Abstract](#)
83. To KK, Tsang OT, Leung WS, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. *Lancet Infect Dis*. 2020 Mar 23 [Epub ahead of print]. [Full text](#) [Abstract](#)
84. Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. *Nature*. 2020 Apr 1 [Epub ahead of print]. [Full text](#) [Abstract](#)

85. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*. 2020 Mar 28;395(10229):1054-62. [Full text](#) [Abstract](#)

86. Chang, Mo G, Yuan X, et al. Time kinetics of viral clearance and resolution of symptoms in novel coronavirus infection. *Am J Respir Crit Care Med*. 2020 Mar 23 [Epub ahead of print]. [Full text](#) [Abstract](#)

87. Chen C, Gao G, Xu Y, et al. SARS-CoV-2-positive sputum and feces after conversion of pharyngeal samples in patients with COVID-19. *Ann Intern Med*. 2020 Mar 30 [Epub ahead of print]. [Full text](#) [Abstract](#)

88. Zhang T, Cui X, Zhao X, et al. Detectable SARS-CoV-2 viral RNA in feces of three children during recovery period of COVID-19 pneumonia. *J Med Virol*. 2020 Mar 29 [Epub ahead of print]. [Full text](#) [Abstract](#)

89. Xu K, Chen Y, Yuan J, et al. Factors associated with prolonged viral RNA shedding in patients with COVID-19. *Clin Infect Dis*. 2020 Apr 9 [Epub ahead of print]. [Full text](#) [Abstract](#)

90. World Health Organization. Global surveillance for COVID-19 caused by human infection with COVID-19 virus. 2020 [internet publication]. [Full text](#)

91. Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19): people who are at higher risk for severe illness. 2020 [internet publication]. [Full text](#)

92. CDC COVID-19 Response Team. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 - United States, February 12-March 28, 2020. *MMWR Morb Mortal Wkly Rep*. 2020 Apr 3;69(13):382-6. [Full text](#) [Abstract](#)

93. Emami A, Javanmardi F, Pirbonyeh N, et al. Prevalence of underlying diseases in hospitalized patients with COVID-19: a systematic review and meta-analysis. *Arch Acad Emerg Med*. 2020 Mar 24;8(1):e35. [Full text](#) [Abstract](#)

94. Sorbello M, El-Boghdadly K, Di Giacinto I, et al. The Italian COVID-19 outbreak: experiences and recommendations from clinical practice. *Anaesthesia*. 2020 Mar 27 [Epub ahead of print]. [Full text](#) [Abstract](#)

95. Simonnet A, Chetboun M, Poissy J, et al. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. *Obesity (Silver Spring)*. 2020 Apr 9 [Epub ahead of print]. [Full text](#) [Abstract](#)

96. Lighter J, Phillips M, Hochman S, et al. Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission. *Clin Infect Dis*. 2020 Apr 9 [Epub ahead of print]. [Full text](#) [Abstract](#)

97. D'Antiga L. Coronaviruses and immunosuppressed patients: the facts during the third epidemic. *Liver Transpl*. 2020 Mar 20 [Epub ahead of print]. [Full text](#) [Abstract](#)

98. Yu J Ouyang W, Chua ML, et al. SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China. *JAMA Oncol*. 2020 Mar 25 [Epub ahead of print]. [Full text](#) [Abstract](#)

99. Liu W, Tao ZW, Lei W, et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. *Chin Med J (Engl)*. 2020 Feb 28 [Epub ahead of print]. [Full text](#) [Abstract](#)
100. Vardavas CI, Nikitara K. COVID-19 and smoking: a systematic review of the evidence. *Tob Induc Dis*. 2020 Mar 20;18:20. [Full text](#) [Abstract](#)
101. Zhao Q, Meng M, Kumar R, et al. The impact of COPD and smoking history on the severity of Covid-19: a systemic review and meta-analysis. *J Med Virol*. 2020 Apr 15 [Epub ahead of print]. [Full text](#) [Abstract](#)
102. Patanavanich R, Glantz SA; medRxiv. Smoking is associated with COVID-19 progression: a meta-analysis. 2020 [internet publication]. [Full text](#)
103. Leung JM, Yang CX, Tam A, et al. ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19. *Eur Respir J*. 2020 Apr 8 [Epub ahead of print]. [Full text](#) [Abstract](#)
104. Lei S, Jiang F, Su W, et al. Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection. *Lancet*. 2020 Apr 4 [Epub ahead of print]. [Full text](#)
105. World Health Organization. Coronavirus disease (COVID-19) advice for the public. 2020 [internet publication]. [Full text](#)
106. Centers for Disease Control and Prevention. How to protect yourself and others. 2020 [internet publication]. [Full text](#)
107. Feng S, Shen C, Xia N, et al. Rational use of face masks in the COVID-19 pandemic. *Lancet Respir Med*. 2020 Mar 20 [Epub ahead of print]. [Full text](#) [Abstract](#)
108. World Health Organization. Advice on the use of masks in the context of COVID-19. 2020 [internet publication]. [Full text](#)
109. Centers for Disease Control and Prevention. Recommendation regarding the use of cloth face coverings, especially in areas of significant community-based transmission. 2020 [internet publication]. [Full text](#)
110. Mahase E. Covid-19: What is the evidence for cloth masks? *BMJ*. 2020 Apr 7;369:m1422. [Full text](#) [Abstract](#)
111. Desai AN, Mehrotra P. Medical masks. *JAMA*. 2020 Mar 4 [Epub ahead of print]. [Full text](#) [Abstract](#)
112. Centre for Evidence-Based Medicine; Greenhalgh T, Chan XH, Khunti K, et al. What is the efficacy of standard face masks compared to respirator masks in preventing COVID-type respiratory illnesses in primary care staff? 2020 [internet publication]. [Full text](#)
113. Bae S, Kim MC, Kim JY, et al. Effectiveness of surgical and cotton masks in blocking SARS-CoV-2: a controlled comparison in 4 patients. *Ann Intern Med*. 2020 Apr 6 [Epub ahead of print]. [Full text](#) [Abstract](#)

114. Quilty BJ, Clifford S, CMMID nCoV working group², et al. Effectiveness of airport screening at detecting travellers infected with novel coronavirus (2019-nCoV). *Eurosurveillance*. 2020 Feb;25(5). [Full text](#)
115. Hoehl S, Berger A, Kortzenbusch M, et al. Evidence of SARS-CoV-2 infection in returning travelers from Wuhan, China. *N Engl J Med*. 2020 Mar 26;382(13):1278-80. [Full text](#) [Abstract](#)
116. Kakimoto K, Kamiya H, Yamagishi T, et al. Initial investigation of transmission of COVID-19 among crew members during quarantine of a cruise ship: Yokohama, Japan, February 2020. *MMWR Morb Mortal Wkly Rep*. 2020 Mar 20;69(11):312-3. [Full text](#) [Abstract](#)
117. Mahase E. China coronavirus: what do we know so far? *BMJ*. 2020 Jan 24;368:m308. [Full text](#) [Abstract](#)
118. Brooks SK, Webster RK, Smith LE, et al. The psychological impact of quarantine and how to reduce it: rapid review of the evidence. *Lancet*. 2020 Mar 14;395(10227):912-20. [Full text](#) [Abstract](#)
119. Nussbaumer-Streit B, Mayr V, Dobrescu AI, et al. Quarantine alone or in combination with other public health measures to control COVID-19: a rapid review. *Cochrane Database Syst Rev*. 2020 Apr 8; (4):CD013574. [Full text](#) [Abstract](#)
120. Centre for Evidence-Based Medicine; Mahtani KR, Heneghan C, Aronson JK. What is the evidence for social distancing during global pandemics? 2020 [internet publication]. [Full text](#)
121. Lewnard JA, Lo NC. Scientific and ethical basis for social-distancing interventions against COVID-19. *Lancet Infect Dis*. 2020 Mar 23 [Epub ahead of print]. [Full text](#) [Abstract](#)
122. Koo JR, Cook AR, Park M, et al. Interventions to mitigate early spread of SARS-CoV-2 in Singapore: a modelling study. *Lancet Infect Dis*. 2020 Mar 23 [Epub ahead of print]. [Full text](#) [Abstract](#)
123. Public Health England. Guidance on shielding and protecting people defined on medical grounds as extremely vulnerable from COVID-19. 2020 [internet publication]. [Full text](#)
124. ClinicalTrials.gov. Safety and immunogenicity study of 2019-nCov vaccine (mRNA-1273) to treat novel coronavirus. 2020 [internet publication]. [Full text](#)
125. Chinese Clinical Trial Registry. A phase I clinical trial for recombinant novel coronavirus (2019-COV) vaccine (adenoviral vector). 2020 [internet publication]. [Full text](#)
126. Thanh Le T, Andreadakis Z, Kumar A, et al. The COVID-19 vaccine development landscape. *Nat Rev Drug Discov*. 2020 Apr 9 [Epub ahead of print]. [Full text](#) [Abstract](#)
127. Razai MS, Doerholt K, Ladhani S, et al. Coronavirus disease 2019 (covid-19): a guide for UK GPs. *BMJ*. 2020 Mar 5;368:m800. [Full text](#) [Abstract](#)
128. Greenhalgh T, Koh GCH, Car J. Covid-19: a remote assessment in primary care. *BMJ*. 2020 Mar 25;368:m1182. [Full text](#) [Abstract](#)

129. World Health Organization. Infection prevention and control during health care when COVID-19 is suspected. 2020 [internet publication]. [Full text](#)
130. Kampf G, Todt D, Pfaender S, et al. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. *J Hosp Infect*. 2020 Mar;104(3):246-51. [Full text](#) [Abstract](#)
131. Spellberg B, Haddix M, Lee R, et al. Community prevalence of SARS-CoV-2 among patients with influenzalike illnesses presenting to a Los Angeles medical center in March 2020. *JAMA*. 2020 Mar 31 [Epub ahead of print]. [Full text](#) [Abstract](#)
132. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med*. 2020 Feb 28 [Epub ahead of print]. [Full text](#) [Abstract](#)
133. Sun P, Qie S, Liu Z, et al. Clinical characteristics of 50466 hospitalized patients with 2019-nCoV infection. *J Med Virol*. 2020 Feb 28 [Epub ahead of print]. [Full text](#) [Abstract](#)
134. Li LQ, Huang T, Wang YQ, et al. 2019 novel coronavirus patients' clinical characteristics, discharge rate and fatality rate of meta-analysis. *J Med Virol*. 2020 Mar 12 [Epub ahead of print]. [Full text](#) [Abstract](#)
135. Sommer P, Lukovic E, Fagley E, et al. Initial clinical impressions of the critical care of COVID-19 patients in Seattle, New York City, and Chicago. *Anesth Analg*. 2020 Mar 25 [Epub ahead of print]. [Full text](#) [Abstract](#)
136. Xu XW, Wu XX, Jiang XG, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. *BMJ*. 2020 Feb 19;368:m606. [Full text](#) [Abstract](#)
137. Kim D, Quinn J, Pinsky B, et al. Rates of co-infection between SARS-CoV-2 and other respiratory pathogens. *JAMA*. 2020 Apr 15 [Epub ahead of print]. [Full text](#)
138. Ding Q, Lu P, Fan Y, et al. The clinical characteristics of pneumonia patients co-infected with 2019 novel coronavirus and influenza virus in Wuhan, China. *J Med Virol*. 2020 Mar 20 [Epub ahead of print]. [Full text](#) [Abstract](#)
139. Touzard-Romo F, Tapé C, Lonks JR. Co-infection with SARS-CoV-2 and human metapneumovirus. *R I Med J* (2013). 2020 Mar 19;103(2):75-6. [Abstract](#)
140. Wang XF, Yuan J, Zheng YJ, et al. Clinical and epidemiological characteristics of 34 children with 2019 novel coronavirus infection in Shenzhen [in Chinese]. *Zhonghua Er Ke Za Zhi*. 2020 Feb 17;58(0):E008. [Abstract](#)
141. Lu X, Zhang L, Du H, et al. SARS-CoV-2 infection in children. *N Engl J Med*. 2020 Mar 18 [Epub ahead of print]. [Full text](#) [Abstract](#)
142. Cai J, Xu J, Lin D, et al. A case series of children with 2019 novel coronavirus infection: clinical and epidemiological features. *Clin Infect Dis*. 2020 Feb 28 [Epub ahead of print]. [Full text](#) [Abstract](#)

143. Liu W, Zhang Q, Chen J, et al. Detection of COVID-19 in children in early January 2020 in Wuhan, China. *N Engl J Med*. 2020 Apr 2;382(14):1370-1. [Full text](#) [Abstract](#)
144. Sun D, Li H, Lu XX, et al. Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center's observational study. *World J Pediatr*. 2020 Mar 19 [Epub ahead of print]. [Full text](#) [Abstract](#)
145. Chen F, Liu ZS, Zhang FR, et al. First case of severe childhood novel coronavirus pneumonia in China [in Chinese]. *Zhonghua Er Ke Za Zhi*. 2020 Feb 11;58(0):E005. [Abstract](#)
146. Wang J, Wang D, Chen GC, et al. SARS-CoV-2 infection with gastrointestinal symptoms as the first manifestation in a neonate [in Chinese]. *Zhongguo Dang Dai Er Ke Za Zhi*. 2020 Mar;22(3):211-4. [Abstract](#)
147. Xia W, Shao J, Guo Y, et al. Clinical and CT features in pediatric patients with COVID-19 infection: different points from adults. *Pediatr Pulmonol*. 2020 May;55(5):1169-74. [Full text](#) [Abstract](#)
148. Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. *Clin Infect Dis*. 2020 Mar 12 [Epub ahead of print]. [Full text](#) [Abstract](#)
149. Xie J, Tong Z, Guan X, et al. Critical care crisis and some recommendations during the COVID-19 epidemic in China. *Intensive Care Med*. 2020 Mar 2 [Epub ahead of print]. [Full text](#) [Abstract](#)
150. Royal College of Physicians. NEWS2 and deterioration in COVID-19. 2020 [internet publication]. [Full text](#)
151. World Health Organization. Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases. 2020 [internet publication]. [Full text](#)
152. Ruan ZR, Gong P, Han W, et al. A case of 2019 novel coronavirus infected pneumonia with twice negative 2019-nCoV nucleic acid testing within 8 days. *Chin Med J (Engl)*. 2020 Mar 5 [Epub ahead of print]. [Abstract](#)
153. Wu X, Cai Y, Huang X, et al. Co-infection with SARS-CoV-2 and influenza A virus in patient with pneumonia, China. *Emerg Infect Dis*. 2020 Mar 11;26(6). [Full text](#) [Abstract](#)
154. Li Z, Yi Y, Luo X, et al. Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. *J Med Virol*. 2020 Feb 27 [Epub ahead of print]. [Abstract](#)
155. Xiao DAT, Gao DC, Zhang DS. Profile of specific antibodies to SARS-CoV-2: the first report. *J Infect*. 2020 Mar 21 [Epub ahead of print]. [Full text](#) [Abstract](#)
156. Poon LC, Yang H, Kapur A, et al. Global interim guidance on coronavirus disease 2019 (COVID-19) during pregnancy and puerperium from FIGO and allied partners: information for healthcare professionals. 2020 [internet publication]. [Full text](#)
157. Song F, Shi N, Shan F, et al. Emerging coronavirus 2019-nCoV pneumonia. *Radiology*. 2020 Feb 6;200274. [Full text](#) [Abstract](#)

158. British Society of Thoracic Imaging. Thoracic imaging in COVID-19 infection: guidance for the reporting radiologist - version 2. 2020 [internet publication]. [Full text](#)
159. American College of Radiology. ACR recommendations for the use of chest radiography and computed tomography (CT) for suspected COVID-19 infection. 2020 [internet publication]. [Full text](#)
160. Shi H, Han X, Jiang N, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. *Lancet Infect Dis*. 2020 Apr;20(4):425-34. [Full text](#) [Abstract](#)
161. Yang W, Cao Q, Qin L, et al. Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): a multi-center study in Wenzhou city, Zhejiang, China. *J Infect*. 2020 Apr;80(4):388-93. [Full text](#) [Abstract](#)
162. Long C, Xu H, Shen Q, et al. Diagnosis of the coronavirus disease (COVID-19): rRT-PCR or CT? *Eur J Radiol*. 2020 Mar 25;126:108961. [Full text](#) [Abstract](#)
163. Salehi S, Abedi A, Balakrishnan S, et al. Coronavirus disease 2019 (COVID-19): a systematic review of imaging findings in 919 patients. *AJR Am J Roentgenol*. 2020 Mar 14;:1-7. [Full text](#) [Abstract](#)
164. Zhao D, Yao F, Wang L, et al. A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias. *Clin Infect Dis*. 2020 Mar 12 [Epub ahead of print]. [Full text](#) [Abstract](#)
165. Zhu T, Wang Y, Zhou S, et al. A comparative study of chest computed tomography features in young and older adults with corona virus disease (COVID-19). *J Thorac Imaging*. 2020 Mar 31 [Epub ahead of print]. [Full text](#) [Abstract](#)
166. Feng K, Yun YX, Wang XF, et al. Analysis of CT features of 15 children with 2019 novel coronavirus infection [in Chinese]. *Zhonghua Er Ke Za Zhi*. 2020 Feb 16;58(0):E007. [Full text](#) [Abstract](#)
167. Ai T, Yang Z, Hou H, et al. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases. *Radiology*. 2020 Feb 26:200642. [Full text](#) [Abstract](#)
168. Buonsenso D, Piano A, Raffaelli F, et al. Point-of-care lung ultrasound findings in novel coronavirus disease-19 pneumoniae: a case report and potential applications during COVID-19 outbreak. *Eur Rev Med Pharmacol Sci*. 2020 Mar;24(5):2776-80. [Full text](#) [Abstract](#)
169. Soldati G, Smargiassi A, Inchingolo R, et al. Is there a role for lung ultrasound during the COVID-19 pandemic? *J Ultrasound Med*. 2020 Mar 20 [Epub ahead of print]. [Full text](#) [Abstract](#)
170. Soldati G, Smargiassi A, Inchingolo R, et al. Proposal for international standardization of the use of lung ultrasound for COVID-19 patients; a simple, quantitative, reproducible method. *J Ultrasound Med*. 2020 Mar 30 [Epub ahead of print]. [Full text](#) [Abstract](#)
171. Moro F, Buonsenso D, Moruzzi MC, et al. How to perform lung ultrasound in pregnant women with suspected COVID-19 infection. *Ultrasound Obstet Gynecol*. 2020 Mar 24 [Epub ahead of print]. [Full text](#) [Abstract](#)
172. Cheung JC, Lam KN. POCUS in COVID-19: pearls and pitfalls. *Lancet Respir Med*. 2020 Apr 7 [Epub ahead of print]. [Full text](#) [Abstract](#)

173. Smith MJ, Hayward SA, Innes SM, et al. Point-of-care lung ultrasound in patients with COVID-19: a narrative review. *Anaesthesia*. 2020 Apr 10 [Epub ahead of print]. [Full text](#) [Abstract](#)
174. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, et al. Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis. *Travel Med Infect Dis*. 2020 Mar 13:101623. [Full text](#) [Abstract](#)
175. Eliezer M, Hautefort C, Hamel AL, et al. Sudden and complete olfactory loss function as a possible symptom of COVID-19. *JAMA Otolaryngol Head Neck Surg*. 2020 Apr 8 [Epub ahead of print]. [Full text](#) [Abstract](#)
176. Giacomelli A, Pezzati L, Conti F, et al. Self-reported olfactory and taste disorders in SARS-CoV-2 patients: a cross-sectional study. *Clin Infect Dis*. 2020 Mar 26 [Epub ahead of print]. [Full text](#) [Abstract](#)
177. Lechien JR, Chiesa-Estomba CM, De Siati DR, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. *Eur Arch Otorhinolaryngol*. 2020 Apr 6 [Epub ahead of print]. [Full text](#) [Abstract](#)
178. King's College London. Loss of smell and taste a key symptom for COVID-19 cases. 2020 [internet publication]. [Full text](#)
179. ENT UK. Loss of sense of smell as marker of COVID-19 infection. 2020 [internet publication]. [Full text](#)
180. American Academy of Otolaryngology - Head and Neck Surgery. Coronavirus disease 2019: resources. 2020 [internet publication]. [Full text](#)
181. Wu P, Duan F, Luo C, et al. Characteristics of ocular findings of patients with coronavirus disease 2019 (COVID-19) in Hubei province, China. *JAMA Ophthalmol*. 2020 Mar 31 [Epub ahead of print]. [Full text](#) [Abstract](#)
182. Jin X, Lian JS, Hu JH, et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. *Gut*. 2020 Mar 24 [Epub ahead of print]. [Full text](#) [Abstract](#)
183. Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected by SARS-CoV-2 in Wuhan, China. *Allergy*. 2020 Feb 19 [Epub ahead of print]. [Full text](#) [Abstract](#)
184. Rakel D. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China. *Am J Gastroenterol*. 2020 Mar 28 [Epub ahead of print]. [Full text](#)
185. Pan L, Mu M, Yang P, et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. *Am J Gastroenterol*. 2020 Apr 14 [Epub ahead of print]. [Full text](#) [Abstract](#)
186. Nobel YR, Phipps M, Zucker J, et al. Gastrointestinal symptoms and COVID-19: case-control study from the United States. *Gastroenterology*. 2020 Apr 12 [Epub ahead of print]. [Full text](#) [Abstract](#)

187. Luo S, Zhang X, Xu H. Don't overlook digestive symptoms in patients with 2019 novel coronavirus disease (COVID-19). *Clin Gastroenterol Hepatol*. 2020 Mar 20 [Epub ahead of print]. [Full text](#) [Abstract](#)
188. Guotao L, Xingpeng Z, Zhihui D, et al. SARS-CoV-2 infection presenting with hematochezia. *Med Mal Infect*. 2020 Mar 27 [Epub ahead of print]. [Full text](#) [Abstract](#)
189. Lovato A, de Filippis C. Clinical presentation of COVID-19: a systematic review focusing on upper airway symptoms. *Ear Nose Throat J*. 2020 Apr 13 [Epub ahead of print]. [Full text](#) [Abstract](#)
190. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. *J Eur Acad Dermatol Venereol*. 2020 Mar 26 [Epub ahead of print]. [Full text](#) [Abstract](#)
191. Joob B, Wiwanitkit V. COVID-19 can present with a rash and be mistaken for Dengue. *J Am Acad Dermatol*. 2020 Mar 22 [Epub ahead of print]. [Full text](#) [Abstract](#)
192. Hunt M, Koziatek C. A case of COVID-19 pneumonia in a young male with full body rash as a presenting symptom. *Clin Pract Cases Emerg Med*. 2020 Mar 28 [Epub ahead of print]. [Full text](#) [Abstract](#)
193. Lippi G, Plebani M, Michael Henry B. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. *Clin Chim Acta*. 2020 Mar 13;506:145-8. [Full text](#) [Abstract](#)
194. Tan L, Wang Q, Zhang D, et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. *Signal Transduct Target Ther*. 2020 Mar 27;5:33. [Full text](#) [Abstract](#)
195. Liu Y, Du X, Chen J, et al. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. *J Infect*. 2020 Apr 10 [Epub ahead of print]. [Full text](#) [Abstract](#)
196. Lagunas-Rangel FA. Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis. *J Med Virol*. 2020 Apr 3 [Epub ahead of print]. [Full text](#) [Abstract](#)
197. Tang N, Li D, Wang X, et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. *J Thromb Haemost*. 2020 Apr;18(4):844-7. [Full text](#) [Abstract](#)
198. Tan C, Huang Y, Shi F, et al. C-reactive protein correlates with CT findings and predicts severe COVID-19 early. *J Med Virol*. 2020 Apr 13 [Epub ahead of print]. [Full text](#) [Abstract](#)
199. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet*. 2020 Mar 28;395(10229):1033-4. [Full text](#) [Abstract](#)
200. Han H, Xie L, Liu R, et al. Analysis of heart injury laboratory parameters in 273 COVID-19 patients in one hospital in Wuhan, China. *J Med Virol*. 2020 Mar 31 [Epub ahead of print]. [Full text](#) [Abstract](#)
201. US Food and Drug Administration. Emergency use authorization: coronavirus disease 2019 (COVID-19) EUA information. 2020 [internet publication]. [Full text](#)

202. US Food and Drug Administration. Coronavirus (COVID-19) update: FDA issues first emergency use authorization for point of care diagnostic. 2020 [internet publication]. [Full text](#)
203. World Health Organization. Advice on the use of point-of-care immunodiagnostic tests for COVID-19. 2020 [internet publication]. [Full text](#)
204. Omer SB, Malani P, Del Rio C. The COVID-19 pandemic in the US: a clinical update. JAMA. 2020 Apr 6 [Epub ahead of print]. [Full text](#) [Abstract](#)
205. National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing suspected or confirmed pneumonia in adults in the community. 2020 [internet publication]. [Full text](#)
206. Centre for Evidence-Based Medicine; Heneghan C, Pluddemann A, Mahtani KR. Differentiating viral from bacterial pneumonia. 2020 [internet publication]. [Full text](#)
207. Hani C, Trieu NH, Saab I, et al. COVID-19 pneumonia: a review of typical CT findings and differential diagnosis. Diagn Interv Imaging. 2020 Apr 3 [Epub ahead of print]. [Full text](#) [Abstract](#)
208. National Institute for Health and Care Excellence. COVID-19 rapid guideline: delivery of systemic anticancer treatments. 2020 [internet publication]. [Full text](#)
209. Centers for Disease Control and Prevention. Criteria to guide evaluation and laboratory testing for COVID-19. March 2020 [internet publication]. [Full text](#)
210. Infectious Diseases Society of America. COVID-19 prioritization of diagnostic testing. 2020 [internet publication]. [Full text](#)
211. World Health Organization. Home care for patients with COVID-19 presenting with mild symptoms and management of their contacts. 2020 [internet publication]. [Full text](#)
212. World Health Organization. Updated WHO recommendations for international traffic in relation to COVID-19 outbreak. February 2020 [internet publication]. [Full text](#)
213. Arima Y, Shimada T, Suzuki M, et al. Severe acute respiratory syndrome coronavirus 2 infection among returnees to Japan from Wuhan, China, 2020. Emerg Infect Dis. 2020 Apr 10;26(7). [Full text](#) [Abstract](#)
214. Kwon KT, Ko JH, Shin H, et al. Drive-through screening center for COVID-19: a safe and efficient screening system against massive community outbreak. J Korean Med Sci. 2020 Mar 23;35(11):e123. [Full text](#) [Abstract](#)
215. Emanuel EJ, Persad G, Upshur R, et al. Fair allocation of scarce medical resources in the time of Covid-19. N Engl J Med. 2020 Mar 23 [Epub ahead of print]. [Full text](#) [Abstract](#)
216. Truog RD, Mitchell C, Daley GQ. The toughest triage: allocating ventilators in a pandemic. N Engl J Med. 2020 Mar 23 [Epub ahead of print]. [Full text](#) [Abstract](#)
217. White DB, Lo B. A framework for rationing ventilators and critical care beds during the COVID-19 pandemic. JAMA. 2020 Mar 27 [Epub ahead of print]. [Full text](#) [Abstract](#)

218. Cohen IG, Crespo AM, White DB. Potential legal liability for withdrawing or withholding ventilators during COVID-19: assessing the risks and identifying needed reforms. *JAMA*. 2020 Apr 1 [Epub ahead of print]. [Full text](#) [Abstract](#)
219. British Medical Association. COVID-19: ethical issues. 2020 [internet publication]. [Full text](#)
220. World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19 - 16 March 2020. 2020 [internet publication]. [Full text](#)
221. Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in critically ill patients in the Seattle region: case series. *N Engl J Med*. 2020 Mar 30 [Epub ahead of print]. [Full text](#) [Abstract](#)
222. National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing symptoms (including at the end of life) in the community. 2020 [internet publication]. [Full text](#)
223. National Institute for Health and Care Excellence. COVID-19 rapid guideline: critical care in adults. 2020 [internet publication]. [Full text](#)
224. Alhazzani W, Møller MH, Arabi YM, et al. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with coronavirus Disease 2019 (COVID-19). *Intensive Care Med*. 2020 Mar 28 [Epub ahead of print]. [Full text](#) [Abstract](#)
225. NHS England. Clinical guide for the optimal use of oxygen therapy during the coronavirus pandemic. 2020 [internet publication]. [Full text](#)
226. Centre for Evidence-Based Medicine; Park S, Brassey J, Heneghan C, et al. Managing fever in adults with possible or confirmed COVID-19 in primary care. 2020 [internet publication]. [Full text](#)
227. Day M. Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists. *BMJ*. 2020 Mar 17;368:m1086. [Full text](#) [Abstract](#)
228. European Medicines Agency. EMA gives advice on the use of non-steroidal anti-inflammatories for COVID-19. 2020 [internet publication]. [Full text](#)
229. US Food and Drug Administration. FDA advises patients on use of non-steroidal anti-inflammatory drugs (NSAIDs) for COVID-19. 2020 [internet publication]. [Full text](#)
230. Little P. Non-steroidal anti-inflammatory drugs and covid-19. *BMJ*. 2020 Mar 27;368:m1185. [Full text](#) [Abstract](#)
231. Medicines and Healthcare products Regulatory Agency; Commission on Human Medicines. Commission on Human Medicines advice on ibuprofen and coronavirus (COVID-19). 2020 [internet publication]. [Full text](#)
232. National Institute for Health and Care Excellence. COVID-19 rapid evidence summary: acute use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19. 2020 [internet publication]. [Full text](#)

233. Canelli R, Connor CW, Gonzalez M, et al. Barrier enclosure during endotracheal intubation. *N Engl J Med*. 2020 Apr 3 [Epub ahead of print]. [Full text](#) [Abstract](#)
234. Matava CT, Yu J, Denning S. Clear plastic drapes may be effective at limiting aerosolization and droplet spray during extubation: implications for COVID-19. *Can J Anaesth*. 2020 Apr 3 [Epub ahead of print]. [Full text](#) [Abstract](#)
235. Lucchini A, Giani M, Isgrò S, et al. The "helmet bundle" in COVID-19 patients undergoing non invasive ventilation. *Intensive Crit Care Nurs*. 2020 Apr 2:102859. [Full text](#) [Abstract](#)
236. Matthay MA, Aldrich JM, Gotts JE. Treatment for severe acute respiratory distress syndrome from COVID-19. *Lancet Respir Med*. 2020 Mar 20 [Epub ahead of print]. [Full text](#) [Abstract](#)
237. McEnery T, Gough C, Costello RW. COVID-19: respiratory support outside the intensive care unit. *Lancet Respir Med*. 2020 Apr 9 [Epub ahead of print]. [Full text](#) [Abstract](#)
238. NHS England. Guidance for the role and use of non-invasive respiratory support in adult patients with COVID19 (confirmed or suspected). 2020 [internet publication]. [Full text](#)
239. Wang K, Zhao W, Li J, et al. The experience of high-flow nasal cannula in hospitalized patients with 2019 novel coronavirus-infected pneumonia in two hospitals of Chongqing, China. *Ann Intensive Care*. 2020 Mar 30;10(1):37. [Full text](#) [Abstract](#)
240. Mahase E. Covid-19: most patients require mechanical ventilation in first 24 hours of critical care. *BMJ*. 2020 Mar 24;368:m1201. [Full text](#) [Abstract](#)
241. Gattinoni L, Coppola S, Cressoni M, et al. Covid-19 does not lead to a "typical" acute respiratory distress syndrome. *Am J Respir Crit Care Med*. 2020 Mar 30 [Epub ahead of print]. [Full text](#) [Abstract](#)
242. Gattinoni L, Chiumello D, Caironi P, et al. COVID-19 pneumonia: different respiratory treatments for different phenotypes? *Intensive Care Med*. 2020 Apr 14 [Epub ahead of print]. [Full text](#) [Abstract](#)
243. NHS England. Clinical guide for the management of critical care for adults with COVID-19 during the coronavirus pandemic. 2020 [internet publication]. [Full text](#)
244. American Thoracic Society; Wilson KC, Chotirmall SH, Bai C, et al. COVID-19: interim guidance on management pending empirical evidence. 2020 [internet publication]. [Full text](#)
245. Pan C, Chen L, Lu C, et al. Lung recruitability in SARS-CoV-2 associated acute respiratory distress syndrome: a single-center, observational study. *Am J Respir Crit Care Med*. 2020 Mar 23 [Epub ahead of print]. [Full text](#) [Abstract](#)
246. Ramanathan K, Antognini D, Combes A, et al. Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases. *Lancet Respir Med*. 2020 Mar 20 [Epub ahead of print]. [Full text](#) [Abstract](#)
247. NHS England. Clinical guide for extra corporeal membrane oxygenation (ECMO) for respiratory failure in adults during the coronavirus pandemic. 2020 [internet publication]. [Full text](#)

248. Zeng Y, Cai Z, Xianyu Y, et al. Prognosis when using extracorporeal membrane oxygenation (ECMO) for critically ill COVID-19 patients in China: a retrospective case series. *Crit Care*. 2020 Apr 15;24(1):148. [Full text](#) [Abstract](#)
249. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. *Lancet*. 2020 Feb 15;395(10223):473-5. [Full text](#) [Abstract](#)
250. Zha L, Li S, Pan L, et al. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). *Med J Aust*. 2020 Apr 8 [Epub ahead of print]. [Full text](#) [Abstract](#)
251. Bhimraj A, Morgan RL, Hirsch Shumaker A, et al. Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19 infection. 2020 [internet publication]. [Full text](#)
252. Yang Z, Liu J, Zhou Y, et al. The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis. *J Infect*. 2020 Apr 10 [Epub ahead of print]. [Full text](#) [Abstract](#)
253. Zhou YH, Qin YY, Lu YQ, et al. Effectiveness of glucocorticoid therapy in patients with severe novel coronavirus pneumonia: protocol of a randomized controlled trial. *Chin Med J (Engl)*. 2020 Mar 5 [Epub ahead of print]. [Abstract](#)
254. Dashraath P, Jing Lin Jeslyn W, Mei Xian Karen L, et al. Coronavirus disease 2019 (COVID-19) pandemic and pregnancy. *Am J Obstet Gynecol*. 2020 Mar 23 [Epub ahead of print]. [Full text](#) [Abstract](#)
255. Royal College of Obstetricians and Gynaecologists. Coronavirus (COVID-19) infection in pregnancy: information for healthcare professionals. 2020 [internet publication]. [Full text](#)
256. American College of Obstetricians and Gynecologists. Novel coronavirus 2019 (COVID-19). 2020 [internet publication]. [Full text](#)
257. Favre G, Pomar L, Qi X, et al. Guidelines for pregnant women with suspected SARS-CoV-2 infection. *Lancet Infect Dis*. 2020 Mar 3 [Epub ahead of print]. [Full text](#) [Abstract](#)
258. Chen D, Yang H, Cao Y, et al. Expert consensus for managing pregnant women and neonates born to mothers with suspected or confirmed novel coronavirus (COVID-19) infection. *Int J Gynaecol Obstet*. 2020 Mar 20 [Epub ahead of print]. [Abstract](#)
259. American Academy of Pediatrics; Puopolo KM, Hudak ML, Kimberlin DW, et al. Management of infants born to mothers with COVID-19. 2020 [internet publication]. [Full text](#)
260. Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19): considerations for inpatient obstetric healthcare settings. 2020 [internet publication]. [Full text](#)
261. Extance A. Covid-19 and long term conditions: what if you have cancer, diabetes, or chronic kidney disease? *BMJ*. 2020 Mar 25;368:m1174. [Full text](#) [Abstract](#)

262. Patel AB, Verma A. COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what is the evidence? *JAMA*. 2020 Mar 24 [Epub ahead of print]. [Full text](#) [Abstract](#)
263. Vaduganathan M, Vardeny O, Michel T, et al. Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. *N Engl J Med*. 2020 Mar 30 [Epub ahead of print]. [Full text](#) [Abstract](#)
264. Bavishi C, Maddox TM, Messerli FH. Coronavirus disease 2019 (COVID-19) infection and renin angiotensin system blockers. *JAMA Cardiol*. 2020 Apr 3 [Epub ahead of print]. [Full text](#) [Abstract](#)
265. Meng J, Xiao G, Zhang J, et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. *Emerg Microbes Infect*. 2020 Dec;9(1):757-60. [Full text](#) [Abstract](#)
266. National Institute for Health and Care Excellence. COVID-19 rapid guideline: severe asthma. 2020 [internet publication]. [Full text](#)
267. Centre for Evidence-Based Medicine; Hartmann-Boyce J, Hobbs R. Inhaled steroids in asthma during the COVID-19 outbreak. 2020 [internet publication]. [Full text](#)
268. National Institute for Health and Care Excellence. COVID-19 rapid guideline: delivery of radiotherapy. 2020 [internet publication]. [Full text](#)
269. National Institute for Health and Care Excellence. COVID 19 rapid guideline: haematopoietic stem cell transplantation. 2020 [internet publication]. [Full text](#)
270. Naicker S, Yang CW, Hwang SJ, et al. The novel coronavirus 2019 epidemic and kidneys. *Kidney Int*. 2020 Mar 7 [Epub ahead of print]. [Full text](#) [Abstract](#)
271. National Institute for Health and Care Excellence. COVID-19 rapid guideline: dialysis service delivery. 2020 [internet publication]. [Full text](#)
272. Centers for Disease Control and Prevention. Interim additional guidance for infection prevention and control recommendations for patients with suspected or confirmed COVID-19 in outpatient hemodialysis facilities. 2020 [internet publication]. [Full text](#)
273. Klinger AS, Silberzweig J. Mitigating risk of COVID-19 in dialysis facilities. *Clin J Am Soc Nephrol*. 2020 Mar 20 [Epub ahead of print]. [Full text](#) [Abstract](#)
274. European Renal Association – European Dialysis and Transplant Association. COVID-19 news and information. 2020 [internet publication]. [Full text](#)
275. Mao R, Liang J, Shen J, et al. Implications of COVID-19 for patients with pre-existing digestive diseases. *Lancet Gastroenterol Hepatol*. 2020 May;5(5):426-8. [Full text](#) [Abstract](#)
276. British Society of Gastroenterology. BSG expanded consensus advice for the management of IBD during the COVID-19 pandemic. 2020 [internet publication]. [Full text](#)
277. Danese S, Cecconi M, Spinelli A. Management of IBD during the COVID-19 outbreak: resetting clinical priorities. *Nat Rev Gastroenterol Hepatol*. 2020 Mar 25 [Epub ahead of print]. [Full text](#) [Abstract](#)

278. Zingone F, Savarino EV. Viral screening before initiation of biologics in patients with inflammatory bowel disease during the COVID-19 outbreak. *Lancet Gastroenterol Hepatol*. 2020 Mar 25 [Epub ahead of print]. [Full text](#) [Abstract](#)
279. Quraishi MN, Clooney R, Brookes MJ, et al. An urgent need to institute COVID-19 testing in patients with IBD experiencing flares. *BMJ*. 2020 Mar 27 [Epub ahead of print]. [Full text](#)
280. National Institute for Health and Care Excellence. COVID-19 rapid guideline: rheumatological autoimmune, inflammatory and metabolic bone disorders. 2020 [internet publications]. [Full text](#)
281. McCreary EK, Pogue JM. Coronavirus disease 2019 treatment: a review of early and emerging options. *Open Forum Infect Dis*. 2020 Apr;7(4):ofaa105. [Full text](#) [Abstract](#)
282. Sanders JM, Monogue ML, Jodlowski TZ, et al. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. *JAMA*. 2020 Apr 13 [Epub ahead of print]. [Full text](#) [Abstract](#)
283. Kalil AC. Treating COVID-19: off-label drug use, compassionate use, and randomized clinical trials during pandemics. *JAMA* Mar 24 [Epub ahead of print]. [Full text](#) [Abstract](#)
284. World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19 - 18 March 2020. 2020 [internet publication]. [Full text](#)
285. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. *Cell Res*. 2020 Mar;30(3):269-71. [Full text](#) [Abstract](#)
286. Cortegiani A, Ingoglia G, Ippolito M, et al. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. *J Crit Care*. 2020 Mar 10 [Epub ahead of print]. [Full text](#) [Abstract](#)
287. Chinese Clinical Trial Registry. A prospective, open-label, multiple-center study for the efficacy of chloroquine phosphate in patients with novel coronavirus pneumonia (COVID-19). 2020 [internet publication]. [Full text](#)
288. Chinese Clinical Trial Registry. Therapeutic effect of hydroxychloroquine on novel coronavirus pneumonia (COVID-19). 2020 [internet publication]. [Full text](#)
289. Multicenter Collaboration Group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for Chloroquine in the Treatment of Novel Coronavirus Pneumonia. Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia [in Chinese]. *Zhonghua Jie He He Hu Xi Za Zhi*. 2020 Feb 20;43(0):E019. [Abstract](#)
290. ClinicalTrials.gov. Post-exposure prophylaxis for SARS-coronavirus-2. 2020 [internet publication]. [Full text](#)
291. ClinicalTrials.gov. Chloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting (COPCOV). 2020 [internet publication]. [Full text](#)

292. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. *Int J Antimicrob Agents*. 2020 Mar 20;105949. [Full text](#) [Abstract](#)
293. Kim AHJ, Sparks JA, Liew JW, et al. A rush to judgment? Rapid reporting and dissemination of results and its consequences regarding the use of hydroxychloroquine for COVID-19. *Ann Intern Med*. 2020 Mar 30 [Epub ahead of print]. [Full text](#) [Abstract](#)
294. Molina JM, Delaugerre C, Le Goff J, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. *Med Mal Infect*. 2020 Mar 30 [Epub ahead of print]. [Full text](#)
295. Chen Z, Hu J, Zhang Z, et al; medRxiv. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. 2020 [internet publication]. [Full text](#)
296. Tang W, Cao Z, Han M, et al; medRxiv. Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial. 2020 [internet publication]. [Full text](#)
297. Wong YK, Yang J, He Y. Caution and clarity required in the use of chloroquine for COVID-19. *Lancet Rheum*. 2020 Apr 2 [Epub ahead of print]. [Full text](#)
298. Zhou D, Dai SM, Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. *J Antimicrob Chemother*. 2020 Mar 20 [Epub ahead of print]. [Full text](#) [Abstract](#)
299. Roden DM, Harrington RA, Poppas A, et al. Considerations for drug interactions on QTc in exploratory COVID-19 (coronavirus disease 2019) treatment. *Circulation*. 2020 Apr 8 [Epub ahead of print]. [Full text](#) [Abstract](#)
300. Multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia. Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia [in Chinese]. *Zhonghua Jie He He Hu Xi Za Zhi*. 2020 Mar 12;43(3):185-8. [Abstract](#)
301. European Medicines Agency. COVID-19: chloroquine and hydroxychloroquine only to be used in clinical trials or emergency use programmes. 2020 [internet publication]. [Full text](#)
302. US Food and Drug Administration. Re: request for emergency use authorization for use of chloroquine phosphate or hydroxychloroquine sulfate supplied from the strategic national stockpile for treatment of 2019 coronavirus disease. 2020 [internet publication]. [Full text](#)
303. Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. *N Engl J Med*. 2020 Mar 5;382(10):929-36. [Full text](#) [Abstract](#)
304. ClinicalTrials.gov. Mild/moderate 2019-nCoV remdesivir RCT. 2020 [internet publication]. [Full text](#)
305. ClinicalTrials.gov. Severe 2019-nCoV remdesivir RCT. 2020 [internet publication]. [Full text](#)
306. ClinicalTrials.gov. Adaptive COVID-19 treatment trial. 2020 [internet publication]. [Full text](#)

307. ClinicalTrials.gov. Study to evaluate the safety and antiviral activity of remdesivir (GS-5734™) in participants with severe coronavirus disease (COVID-19). 2020 [internet publication]. [Full text](#)
308. ClinicalTrials.gov. Study to evaluate the safety and antiviral activity of remdesivir (GS-5734™) in participants with moderate coronavirus disease (COVID-19) compared to standard of care treatment. 2020 [internet publication]. [Full text](#)
309. Gilead Sciences. Remdesivir. 2020 [internet publication]. [Full text](#)
310. European Medicines Agency. EMA provides recommendations on compassionate use of remdesivir for COVID-19. 2020 [internet publication]. [Full text](#)
311. Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe Covid-19. *N Engl J Med*. 2020 Apr 10 [Epub ahead of print]. [Full text](#) [Abstract](#)
312. Young BE, Ong SWX, Kalimuddin S, et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. *JAMA*. 2020 Mar 3 [Epub ahead of print]. [Full text](#) [Abstract](#)
313. Cao B, Wang Y, Wen D, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe COVID-19. *N Engl J Med*. 2020 Mar 18 [Epub ahead of print]. [Full text](#) [Abstract](#)
314. Chen L, Xiong J, Bao L, et al. Convalescent plasma as a potential therapy for COVID-19. *Lancet Infect Dis*. 2020 Apr;20(4):398-400. [Full text](#) [Abstract](#)
315. ClinicalTrials.gov. Anti-SARS-CoV-2 inactivated convalescent plasma in the treatment of COVID-19. 2020 [internet publication]. [Full text](#)
316. Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. *JAMA*. 2020 Mar 27 [Epub ahead of print]. [Full text](#) [Abstract](#)
317. Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. *Proc Natl Acad Sci U S A*. 2020 Apr 6 [Epub ahead of print]. [Full text](#) [Abstract](#)
318. US Food and Drug Administration. Investigational COVID-19 convalescent plasma: emergency INDs. 2020 [internet publication]. [Full text](#)
319. US Food and Drug Administration. Investigational COVID-19 convalescent plasma. 2020 [internet publication]. [Full text](#)
320. US Food and Drug Administration. Coronavirus (COVID-19) update: FDA encourages recovered patients to donate plasma for development of blood-related therapies. 2020 [internet publication]. [Full text](#)
321. ClinicalTrials.gov. Mesenchymal stem cell treatment for pneumonia patients infected with 2019 novel coronavirus. 2020 [internet publication]. [Full text](#)
322. Jawhara S. Could intravenous immunoglobulin collected from recovered coronavirus patients protect against COVID-19 and strengthen the immune system of new patients? *Int J Mol Sci*. 2020 Mar 25;21(7). [Full text](#) [Abstract](#)

323. Regeneron. Regeneron announces important advances in novel COVID-19 antibody program. 2020 [internet publication]. [Full text](#)
324. Xie Y, Cao S, Li Q, et al. Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19. *J Infect*. 2020 Apr 10 [Epub ahead of print]. [Full text](#) [Abstract](#)
325. ClinicalTrials.gov. Tocilizumab in COVID-19 pneumonia (TOCOVID-19). 2020 [internet publication]. [Full text](#)
326. ClinicalTrials.gov. Favipiravir combined with tocilizumab in the treatment of corona virus disease 2019. 2020 [internet publication]. [Full text](#)
327. ClinicalTrials.gov. Tocilizumab vs CRRT in management of cytokine release syndrome (CRS) in COVID-19 (TACOS). 2020 [internet publication]. [Full text](#)
328. ClinicalTrials.gov. Tocilizumab for SARS-CoV2 severe pneumonitis. 2020 [internet publication]. [Full text](#)
329. ClinicalTrials.gov. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19. 2020 [internet publication]. [Full text](#)
330. ClinicalTrials.gov. Cohort multiple randomized controlled trials open-label of immune modulatory drugs and other treatments in COVID-19 patients: sarilumab trial - CORIMUNO-19 - SARI (CORIMUNO-SARI). 2020 [internet publication]. [Full text](#)
331. ClinicalTrials.gov. Sarilumab COVID-19. 2020 [internet publication]. [Full text](#)
332. ClinicalTrials.gov. An observational case-control study of the use of siltuximab in ARDS patients diagnosed with COVID-19 infection (SISCO). 2020 [internet publication]. [Full text](#)
333. Ritchie AI, Singanayagam A. Immunosuppression for hyperinflammation in COVID-19: a double-edged sword? *Lancet*. 2020 Apr 4;395(10230):1111. [Full text](#) [Abstract](#)
334. Monteagudo LA, Boothby A, Gertner E. Continuous intravenous anakinra infusion to calm the cytokine storm in macrophage activation syndrome. *ACR Open Rheumatol*. 2020 Apr 8 [Epub ahead of print]. [Full text](#) [Abstract](#)
335. Wu D, Yang XO. TH17 responses in cytokine storm of COVID-19: an emerging target of JAK2 inhibitor Fedratinib. *J Microbiol Immunol Infect*. 2020 Mar 11 [Epub ahead of print]. [Full text](#) [Abstract](#)
336. CytoDyn Inc. Leronlimab used in seven patients with severe COVID-19 demonstrated promise with two intubated patients in ICU, removed from ICU and extubated with reduced pulmonary inflammation. 2020 [internet publication]. [Full text](#)
337. World Health Organization. Bacille Calmette-Guérin (BCG) vaccination and COVID-19. 2020 [internet publication]. [Full text](#)
338. Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. *Drug Dev Res*. 2020 Mar 4 [Epub ahead of print]. [Full text](#) [Abstract](#)

339. ClinicalTrials.gov. Losartan for patients with COVID-19 requiring hospitalization. 2020 [internet publication]. [Full text](#)
340. ClinicalTrials.gov. Losartan for patients with COVID-19 not requiring hospitalization. 2020 [internet publication]. [Full text](#)
341. Chinese Clinical Trial Registry. A randomized, open-label, blank-controlled trial for the efficacy and safety of lopinavir-ritonavir and interferon-alpha 2b in hospitalization patients with 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP). 2020 [internet publication]. [Full text](#)
342. Chinese Clinical Trial Registry. Clinical study for safety and efficacy of favipiravir in the treatment of novel coronavirus pneumonia (COVID-19). 2020 [internet publication]. [Full text](#)
343. Chinese Clinical Trial Registry. Clinical study of arbidol hydrochloride tablets in the treatment of novel coronavirus pneumonia (COVID-19). 2020 [internet publication]. [Full text](#)
344. Chinese Clinical Trial Registry. Randomized, open-label, controlled trial for evaluating of the efficacy and safety of baloxavir marboxil, favipiravir, and lopinavir-ritonavir in the treatment of novel coronavirus pneumonia (COVID-19) patients. 2020 [internet publication]. [Full text](#)
345. Zeng YM, Xu XL, He XQ, et al. Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus pneumonia. *Chin Med J (Engl)*. 2020 Mar 5 [Epub ahead of print]. [Abstract](#)
346. Li H, Wang YM, Xu JY, et al. Potential antiviral therapeutics for 2019 novel coronavirus [in Chinese]. *Zhonghua Jie He He Hu Xi Za Zhi*. 2020 Mar 12;43(3):170-2. [Abstract](#)
347. Deng L, Li C, Zeng Q, et al. Arbidol combined with LPV/r versus LPV/r alone against corona virus disease 2019: a retrospective cohort study. *J Infect*. 2020 Mar 11 [Epub ahead of print]. [Full text](#) [Abstract](#)
348. ClinicalTrials.gov. Efficacy and safety of darunavir and cobicistat for treatment of pneumonia caused by 2019-nCoV (DACO-nCoV). 2020 [internet publication]. [Full text](#)
349. Synairgen. COVID-19. 2020 [internet publication]. [Full text](#)
350. Zhu Z, Lu Z, Xu T, et al. Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19. *J Infect*. 2020 Apr 10 [Epub ahead of print]. [Full text](#) [Abstract](#)
351. ClinicalTrials.gov. Vitamin C infusion for the treatment of severe 2019-nCoV infected pneumonia. 2020 [internet publication]. [Full text](#)
352. Yang Y, Islam MS, Wang J, et al. Traditional Chinese medicine in the treatment of patients infected with 2019-new coronavirus (SARS-CoV-2): a review and perspective. *Int J Biol Sci*. 2020 Mar 15;16(10):1708-17. [Full text](#) [Abstract](#)
353. World Health Organization. Coronavirus disease (COVID-2019) situation reports. 2020 [internet publication]. [Full text](#)

354. Centre for Evidence-Based Medicine; Oke J, Heneghan C. Reconciling COVID-19 death data in the UK. 2020 [internet publication]. [Full text](#)
355. Verity R, Okell LC, Dorigatti I, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. *Lancet Infect Dis*. 2020 Mar 30 [Epub ahead of print]. [Full text](#) [Abstract](#)
356. Wu P, Hao X, Lau EHY, et al. Real-time tentative assessment of the epidemiological characteristics of novel coronavirus infections in Wuhan, China, as at 22 January 2020. *Euro Surveill*. 2020 Jan;25(3). [Full text](#) [Abstract](#)
357. Centre for Evidence-Based Medicine; Oke J, Heneghan C. Global COVID-19 case fatality rates. 2020 [internet publication]. [Full text](#)
358. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. *JAMA*. 2020 Mar 23 [Epub ahead of print]. [Full text](#) [Abstract](#)
359. Rajgor DD, Lee MH, Archuleta S, et al. The many estimates of the COVID-19 case fatality rate. *Lancet Infect Dis*. 2020 Mar 27 [Epub ahead of print]. [Full text](#) [Abstract](#)
360. Mahase E. Coronavirus covid-19 has killed more people than SARS and MERS combined, despite lower case fatality rate. *BMJ*. 2020 Feb 18;368:m641. [Full text](#) [Abstract](#)
361. Guan WJ, Liang WH, Zhao Y, et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: a nationwide analysis. *Eur Respir J*. 2020 Mar 26 [Epub ahead of print]. [Full text](#) [Abstract](#)
362. Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. *JAMA*. 2020 Apr 6 [Epub ahead of print]. [Full text](#) [Abstract](#)
363. Arentz M, Yim E, Klaff L, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. *JAMA*. 2020 Mar 19 [Epub ahead of print]. [Full text](#) [Abstract](#)
364. McMichael TM, Currie DW, Clark S, et al. Epidemiology of Covid-19 in a long-term care facility in King County, Washington. *N Engl J Med*. 2020 Mar 27 [Epub ahead of print]. [Full text](#) [Abstract](#)
365. Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. *Intensive Care Med*. 2020 Mar 3 [Epub ahead of print]. [Full text](#) [Abstract](#)
366. Yang F, Shi S, Zhu J, et al. Analysis of 92 deceased patients with COVID-19. *J Med Virol*. 2020 Apr 15 [Epub ahead of print]. [Full text](#) [Abstract](#)
367. Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. *BMJ*. 2020 Mar 26;368:m1091. [Full text](#) [Abstract](#)
368. Deng Y, Liu W, Liu K, et al. Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 (COVID-19) in Wuhan, China: a retrospective study. *Chin Med J (Engl)*. 2020 Mar 20 [Epub ahead of print]. [Full text](#) [Abstract](#)

369. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Respir Med*. 2020 Feb 24 [Epub ahead of print]. [Full text](#) [Abstract](#)
370. Wang Y, Lu X, Chen H, et al. Clinical course and outcomes of 344 intensive care patients with COVID-19. *Am J Respir Crit Care Med*. 2020 Apr 8 [Epub ahead of print]. [Full text](#) [Abstract](#)
371. Du RH, Liang LR, Yang CQ, et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. *Eur Respir J*. 2020 Apr 8 [Epub ahead of print]. [Full text](#) [Abstract](#)
372. Li X, Xu S, Yu M, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. *J Allergy Clin Immunol*. 2020 Apr 12 [Epub ahead of print]. [Full text](#) [Abstract](#)
373. Mo P, Xing Y, Xiao Y, et al. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. *Clin Infect Dis*. 2020 Mar 16 [Epub ahead of print]. [Full text](#) [Abstract](#)
374. Chen D, Xu W, Lei Z, et al. Recurrence of positive SARS-CoV-2 RNA in COVID-19: a case report. *Int J Infect Dis*. 2020 Mar 5;93:297-9. [Full text](#) [Abstract](#)
375. Xing Y, Mo P, Xiao Y, et al. Post-discharge surveillance and positive virus detection in two medical staff recovered from coronavirus disease 2019 (COVID-19), China, January to February 2020. *Euro Surveill*. 2020 Mar;25(10). [Full text](#) [Abstract](#)
376. Ye G, Pan Z, Pan Y, et al. Clinical characteristics of severe acute respiratory syndrome coronavirus 2 reactivation. *J Infect*. 2020 Mar 11 [Epub ahead of print]. [Full text](#) [Abstract](#)
377. Yuan J, Kou S, Liang Y, et al. PCR assays turned positive in 25 discharged COVID-19 patients. *Clin Infect Dis*. 2020 Apr 8 [Epub ahead of print]. [Full text](#) [Abstract](#)
378. Xiao AT, Tong YX, Zhang S. False-negative of RT-PCR and prolonged nucleic acid conversion in COVID-19: rather than recurrence. *J Med Virol*. 2020 Apr 9 [Epub ahead of print]. [Full text](#) [Abstract](#)
379. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. *JAMA Intern Med*. 2020 Mar 13 [Epub ahead of print]. [Full text](#) [Abstract](#)
380. Chen JY, Qiao K, Liu F, et al. Lung transplantation as therapeutic option in acute respiratory distress syndrome for COVID-19-related pulmonary fibrosis. *Chin Med J (Engl)*. 2020 Apr 1 [Epub ahead of print]. [Full text](#) [Abstract](#)
381. Madjid M, Safavi-Naeini P, Solomon SD, et al. Potential effects of coronaviruses on the cardiovascular system: a review. *JAMA Cardiol*. 2020 Mar 27 [Epub ahead of print]. [Full text](#) [Abstract](#)
382. Sala S, Peretto G, Gramegna M, et al. Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection. *Eur Heart J*. 2020 Apr 8 [Epub ahead of print]. [Full text](#) [Abstract](#)

383. Liu PP, Blet A, Smyth D, et al. The science underlying COVID-19: implications for the cardiovascular system. *Circulation*. 2020 Apr 15 [Epub ahead of print]. [Full text](#) [Abstract](#)
384. Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. *JAMA Cardiol*. 2020 Mar 25 [Epub ahead of print]. [Full text](#) [Abstract](#)
385. He XW, Lai JS, Cheng J, et al. Impact of complicated myocardial injury on the clinical outcome of severe or critically ill COVID-19 patients [in Chinese]. *Zhonghua Xin Xue Guan Bing Za Zhi*. 2020 Mar 15;48(0):E011. [Abstract](#)
386. Clerkin KJ, Fried JA, Raikhelkar J, et al. Coronavirus disease 2019 (COVID-19) and cardiovascular disease. *Circulation*. 2020 Mar 21 [Epub ahead of print]. [Full text](#) [Abstract](#)
387. Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). *JAMA Cardiol*. 2020 Mar 27 [Epub ahead of print]. [Full text](#) [Abstract](#)
388. Zeng JH, Liu YX, Yuan J, et al. First case of COVID-19 complicated with fulminant myocarditis: a case report and insights. *Infection*. 2020 Apr 10 [Epub ahead of print]. [Full text](#) [Abstract](#)
389. Hu H, Ma F, Wei X, et al. Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin. *Eur Heart J*. 2020 Mar 16 [Epub ahead of print]. [Full text](#) [Abstract](#)
390. Inciardi RM, Lupi L, Zacccone G, et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). *JAMA Cardiol*. 2020 Mar 27 [Epub ahead of print]. [Full text](#) [Abstract](#)
391. Hua A, O'Gallagher K, Sado D, et al. Life-threatening cardiac tamponade complicating myo-pericarditis in COVID-19. *Eur Heart J*. 2020 Mar 30 [Epub ahead of print]. [Full text](#) [Abstract](#)
392. Meyer P, Degrauwe S, Delden CV, et al. Typical takotsubo syndrome triggered by SARS-CoV-2 infection. *Eur Heart J*. 2020 Apr 14 [Epub ahead of print]. [Full text](#) [Abstract](#)
393. Xiong TY, Redwood S, Prendergast B, et al. Coronaviruses and the cardiovascular system: acute and long-term implications. *Eur Heart J*. 2020 Mar 18 [Epub ahead of print]. [Full text](#) [Abstract](#)
394. Xu L, Liu J, Lu M, et al. Liver injury during highly pathogenic human coronavirus infections. *Liver Int*. 2020 Mar 14 [Epub ahead of print]. [Full text](#) [Abstract](#)
395. Bangash MN, Patel J, Parekh D. COVID-19 and the liver: little cause for concern. *Lancet Gastroenterol Hepatol*. 2020 Mar 20 [Epub ahead of print]. [Full text](#) [Abstract](#)
396. Ye Q, Wang B, Mao J. Cytokine storm in COVID-19 and treatment. *J Infect*. 2020 Apr 10 [Epub ahead of print]. [Full text](#) [Abstract](#)
397. Wang Z, Yang B, Li Q, et al. Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China. *Clin Infect Dis*. 2020 Mar 16 [Epub ahead of print]. [Full text](#) [Abstract](#)
398. Pedersen SF, Ho YC. SARS-CoV-2: a storm is raging. *J Clin Invest*. 2020 Mar 27 [Epub ahead of print]. [Full text](#) [Abstract](#)

399. Zhang W, Zhao Y, Zhang F, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the experience of clinical immunologists from China. *Clin Immunol*. 2020 Mar 25;;108393. [Full text](#) [Abstract](#)
400. Tang N, Bai H, Chen X, et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. *J Thromb Haemost*. 2020 Mar 27 [Epub ahead of print]. [Full text](#) [Abstract](#)
401. Cheng Y, Luo R, Wang K, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. *Kidney Int*. 2020 Mar 2020 Mar 20 [Epub ahead of print]. [Full text](#) [Abstract](#)
402. Wang L, Li X, Chen H, et al. Coronavirus disease 19 infection does not result in acute kidney injury: an analysis of 116 hospitalized patients from Wuhan, China. *Am J Nephrol*. 2020 Mar 31;;1-6. [Full text](#) [Abstract](#)
403. Wang F, Wang H, Fan J, et al. Pancreatic injury patterns in patients with COVID-19 pneumonia. *Gastroenterology*. 2020 Apr 1 [Epub ahead of print]. [Full text](#) [Abstract](#)
404. Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. *JAMA Neurol*. 2020 Apr 10 [Epub ahead of print]. [Full text](#) [Abstract](#)
405. Mao L, Wang M, Chen S, et al. Neurological manifestations of hospitalized patients with COVID-19 in Wuhan, China: a retrospective case series study. 2020 [internet publication]. [Full text](#)
406. AHA/ASA Stroke Council Leadership. Temporary emergency guidance to US stroke centers during the COVID-19 pandemic. *Stroke*. 2020 Apr 1 [Epub ahead of print]. [Full text](#) [Abstract](#)
407. Jin H, Hong C, Chen S, et al. Consensus for prevention and management of coronavirus disease 2019 (COVID-19) for neurologists. *Stroke Vasc Neurol*. 2020 Apr 1 [Epub ahead of print]. [Full text](#)
408. Poyiadji N, Shahin G, Noujaim D, et al. COVID-19–associated acute hemorrhagic necrotizing encephalopathy: CT and MRI features. *Radiology*. 2020 Mar 31:201187. [Full text](#) [Abstract](#)
409. Filatov A, Sharma P, Hindi F, et al. Neurological complications of coronavirus disease (COVID-19): encephalopathy. *Cureus*. 2020 Mar 21 [Epub ahead of print]. [Full text](#)
410. Moriguchi T, Harii N, Goto J, et al. A first case of meningitis/encephalitis associated with SARS-coronavirus-2. *Int J Infect Dis*. 2020 Apr 3 [Epub ahead of print]. [Full text](#) [Abstract](#)
411. Zhao H, Shen D, Zhou H, et al. Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? *Lancet Neurol*. 2020 Apr 1 [Epub ahead of print]. [Full text](#) [Abstract](#)
412. Cui S, Chen S, Li X, et al. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. *J Thromb Haemost*. 2020 Apr 9 [Epub ahead of print]. [Full text](#) [Abstract](#)
413. Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. *Thromb Res*. 2020 Apr 10 [Epub ahead of print]. [Full text](#) [Abstract](#)

414. Wang T, Chen R, Liu C, et al. Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19. *Lancet Haematol*. 2020 Apr 9 [Epub ahead of print]. [Full text](#) [Abstract](#)
415. American Society Of Hematology. COVID-19 and VTE/anticoagulation: frequently asked questions. 2020 [internet publication]. [Full text](#)
416. Jin M, Tong Q. Rhabdomyolysis as potential late complication associated with COVID-19. *Emerg Infect Dis*. 2020 Mar 20;26(7). [Full text](#) [Abstract](#)
417. Liu D, Li L, Wu X, et al. Pregnancy and perinatal outcomes of women with coronavirus disease (COVID-19) pneumonia: a preliminary analysis. *AJR Am J Roentgenol*. 2020 Mar 18:1-6. [Full text](#) [Abstract](#)
418. Di Mascio D, Khalil A, Saccone G, et al. Outcome of coronavirus spectrum infections (SARS, MERS, COVID 1 -19) during pregnancy: a systematic review and meta-analysis. *Am J Obstet Gynecol MFM*. 2020 Mar 25;:100107. [Full text](#) [Abstract](#)
419. Centre for Evidence-Based Medicine; Greenhalgh T, Treadwell J, Burrow R, et al. NEWS (or NEWS2) score when assessing possible COVID-19 patients in primary care? 2020 [internet publication]. [Full text](#)
420. Ji D, Zhang D, Xu J, et al. Prediction for progression risk in patients with COVID-19 pneumonia: the CALL score. *Clin Infect Dis*. 2020 Apr 9 [Epub ahead of print]. [Full text](#) [Abstract](#)
421. Centre for Evidence-Based Medicine; Green K, Allen AJ, Suklan J, et al. What is the role of imaging and biomarkers within the current testing strategy for the diagnosis of Covid-19? 2020 [internet publication]. [Full text](#)
422. Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19): if you have animals. 2020 [internet publication]. [Full text](#)
423. IDEXX Laboratories. Leading veterinary diagnostic company sees no COVID-19 cases in pets. 2020 [internet publication]. [Full text](#)
424. Shi J, Wen Z, Zhong G, et al. Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2. *Science*. 2020 Apr 8 [Epub ahead of print]. [Full text](#) [Abstract](#)

Images




Figure 1: Illustration revealing ultrastructural morphology exhibited by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) when viewed with electron microscopically

Centers for Disease Control and Prevention




Figure 2: Transverse CT scans from a 32-year-old man, showing ground-glass opacity and consolidation of lower lobe of right lung near the pleura on day 1 after symptom onset (top panel), and bilateral ground-glass opacity and consolidation on day 7 after symptom onset

Xu XW et al. BMJ. 2020;368:m606

Disclaimer

This content is meant for medical professionals situated outside of the United States and Canada. The BMJ Publishing Group Ltd ("BMJ Group") tries to ensure that the information provided is accurate and up-to-date, but we do not warrant that it is nor do our licensors who supply certain content linked to or otherwise accessible from our content. The BMJ Group does not advocate or endorse the use of any drug or therapy contained within nor does it diagnose patients. Medical professionals should use their own professional judgement in using this information and caring for their patients and the information herein should not be considered a substitute for that.

This information is not intended to cover all possible diagnosis methods, treatments, follow up, drugs and any contraindications or side effects. In addition such standards and practices in medicine change as new data become available, and you should consult a variety of sources. We strongly recommend that users independently verify specified diagnosis, treatments and follow up and ensure it is appropriate for your patient within your region. In addition, with respect to prescription medication, you are advised to check the product information sheet accompanying each drug to verify conditions of use and identify any changes in dosage schedule or contraindications, particularly if the agent to be administered is new, infrequently used, or has a narrow therapeutic range. You must always check that drugs referenced are licensed for the specified use and at the specified doses in your region. This information is provided on an "as is" basis and to the fullest extent permitted by law the BMJ Group and its licensors assume no responsibility for any aspect of healthcare administered with the aid of this information or any other use of this information.

View our full [Website Terms and Conditions](#).

Contact us

+ 44 (0) 207 111 1105
support@bmj.com

BMJ
BMA House
Tavistock Square
London
WC1H 9JR
UK

DISCLAIMER

BMJ Best Practice

Contributors:

// Authors:

Nicholas J. Beeching, MA, BM BCh, FRCP, FRACP, FFTM RCPS (Glasg), FESCMID, DCH, DTM&H

Consultant and Honorary Senior Lecturer in Infectious Diseases

Royal Liverpool University Hospital and Liverpool School of Tropical Medicine, Liverpool, UK

DISCLOSURES: NJB is partially supported by the National Institute of Health Research Health Protection Unit (NIHR HPRU) in Emerging and Zoonotic Infections at University of Liverpool in partnership with Public Health England (PHE), in collaboration with Liverpool School of Tropical Medicine. He is affiliated with Liverpool School of Tropical Medicine. The views expressed are those of the author and not necessarily those of the NHS, the NIHR, the Department of Health, or PHE.

Tom E. Fletcher, MBE, PhD, MBChB, MRCP, DTM&H

Senior Clinical Lecturer and Defence Consultant in Infectious Diseases

Royal Liverpool University Hospital and Liverpool School of Tropical Medicine, Liverpool, UK

DISCLOSURES: TEF is a consultant/expert panel member to the World Health Organization, and is funded by the UK Surgeon General, the NHS, and Liverpool School of Tropical Medicine. TEF is partially supported by the National Institute of Health Research Health Protection Unit (NIHR HPRU) in Emerging and Zoonotic Infections at University of Liverpool in partnership with Public Health England (PHE), in collaboration with Liverpool School of Tropical Medicine. He is affiliated with Liverpool School of Tropical Medicine. He has received research grants from the Wellcome Trust, Medical Research Council, and the UK Public Health Rapid Support Team (UK-PHRST). The views expressed are those of the author and not necessarily those of the NHS, the NIHR, the Department of Health, or PHE.

Robert Fowler, MDCM, MS (Epi), FRCP(C)

H. Barrie Fairley Professor of Critical Care

University Health Network and Interdepartmental Division of Critical Care Medicine, Director, Clinical Epidemiology and Health Care Research, Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Chief, Tory Trauma Program, Sunnybrook Hospital, Toronto, Canada

DISCLOSURES: RF declares that he has no competing interests.

// Peer Reviewers:

William A. Petri, Jr., MD, PhD

Professor

Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA

DISCLOSURES: WAP declares that he has no competing interests.

Xin Zhang, MD, PhD

Attending Physician

The Fifth Medical Center of PLA General Hospital, Clinical Division and Research Center of Infectious Disease, Beijing, China

DISCLOSURES: XZ declares that he has no competing interests.

Ran Nir-Paz, MD

Associate Professor in Medicine

Department of Clinical Microbiology and Infectious Diseases, Hadassah Hebrew University Medical Center, Jerusalem, Israel

DISCLOSURES: RNP has received research grants from US-Israel Binational Science Foundation, Hebrew University, Rosetrees Trust, and Speedx. He is chair of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Mycoplasma and Chlamydia Infections (ESGMAC). RNP is a consultant for and has stocks in eDAS Healthcare. He is also chairperson of the Israeli Society for Infectious Diseases guidelines committee.